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1 Introduction 
Diabetes mellitus is one of the most common human diseases worldwide with a still 
increasing prevalence. Today there are more than 300 million people suffering from 
diabetes and its accompanying diseases. It is expected, that the number of diabetic 
patients will reach close to 500 million within 20 years, if nothing is done to slow 
down the epidemic (International Diabetes Federation 2009).  
Animal models, particularly mouse models, play an essential role for studying the 
pathogenesis of diabetes mellitus and its complications. Transgenic and knock-out 
mouse models used to be a common and powerful tool to explore the pathogenesis 
of diabetes mellitus. In recent years, more and more mutant mouse models, 
especially with point mutations in a diabetes relevant gene, have additionally been 
established. Due to the fact that such mutations are also found in human patients, 
these mutant mouse models are of great value in prospective diabetes research. 
The Munich Ins2C95S mutant mouse and the Akita mutant mouse are two mouse 
models, which possess point mutations in the Ins2 gene. These mutations lead to the 
loss of the interchain and the intrachain disulfide bond of insulin 2, respectively 
(Herbach et al. 2007, Wang et al. 1999). Extensive studies could demonstrate that 
misfolded (pro-)insulin accumulates in β-cells of Akita mice, what leads to 
endoplasmic reticulum (ER)-stress and β-cell dysfunction (Izumi et al. 2003,      
Nozaki et al. 2004, Zuber et al. 2004). Moreover it could be shown that misfolded and 
accumulated proteins can also induce β-cell apoptosis                                  
(Scheuner and Kaufman 2008, Xu et al. 2005).  
The disease pattern of both Ins2 mutant models is similar. It is characterized by a 
progressive diabetic phenotype with severe hyperglycaemia, disturbed insulin 
secretion, insulin resistance and profound β-cell loss of male mutant mice, and a 
much milder disease-form with preserved β-cell mass of female mutant mice. This 
considerable difference is probably based on several protective effects attributed to 
estrogen, such as antioxidative effects (Katalinic et al. 2005, Le May et al. 2006), 
enhancement of insulin sensitivity (Gonzalez et al. 2001, Lee et al. 1999), insulin 
secretion (Balhuizen et al. 2010, Ropero et al. 1999) and diminution of ER-stress 
(Kozlov et al. 2010).  
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The aim of the present study was to investigate the impact of 17βEstradiol on the 
survival of β-cells in female Munich Ins2C95S mutant mice. To exclude effects of other 
ovarian hormones, one group of ovariectomized female mutant mice was 
supplemented with 17βEstradiol long-term pellets. Sham-operated placebo-treated 
mutant and wild-type mice served as controls.  
Besides various clinical tests to determine β-cell function and insulin sensitivity, 
isolated pancreatic islets were analysed with respect to ER-stress, islet-cell apoptosis 
and cell proliferation, and further oxidative stress was investigated in serum samples. 
Additionally, the effects of ovariectomy and estradiol supplementation on the 
endocrine pancreas were determined, using qualitative histological as well as 
quantitative stereological methods. 
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2 Literature review 
2.1 Diabetes mellitus 
2.1.1 Definition and description 
Diabetes mellitus is recognized as a group of metabolic diseases characterized by 
chronic hyperglycaemia and glucose intolerance resulting from insulin deficiency, 
impaired effectiveness of insulin or both. Various organs, particularly eyes, nerves, 
heart, and blood vessels, can be affected by long-term consequences of sustained 
hyperglycaemia, appearing in organ dysfunction culminating in organ failure 
(American Diabetes Association 2009).  
The development of diabetes is a complex interaction of several pathogenic 
processes. Three important factors are involved in the pathogenesis of diabetes 
mellitus: genetic predisposition, peripheral insulin resistance as well as β-cell 
dysfunction and failure, resulting in inadequate insulin secretion                    
(Lehmann and Spinas 2005). The genetic predispositions comprise monogenetic 
defects leading to β-cell dysfunction, including mutations in genes encoding for 
transcription factors or mutations in the glucokinase gene (maturity onset diabetes of 
the young, MODY 1-6), as well as genetic defects in insulin action which are based 
on various mutations of the insulin receptor (American Diabates Association 2009).  
Additionally, a cellular mediated autoimmune destruction of the β-cells within the 
pancreas can occur, leading to complete insulin deficiency (Type 1 diabetes). Key 
contributors to the susceptibility of Type 1 diabetes include genetic but also 
environmental factors like virus infections or chemicals that can lead to an induction 
of the disease (Kukreja and Maclaren 1999).  
The most common symptoms of diabetic patients are polyuria and polydipsia, blurred 
vision and sometimes weight loss combined with polyphagia, retarded growth of 
children and susceptibility to distinct infections (American Diabetes Association 
2009).  
Chronic elevation of blood glucose levels along with the impact of increased blood 
pressure, abnormal lipid levels and abnormalities of small blood vessels can lead to 
long-term complications such as cardiovascular disease (CVD), nephropathy, 
2  Literature review 4 
 
retinopathy, autonomic neuropathy causing gastrointestinal, genitourinary and 
cardiovascular symptoms and sexual dysfunction as well as peripheral neuropathy 
with risk of foot ulcers, amputations and Charcot joints. Moreover, the incidence of 
atherosclerotic cardiovascular, peripheral arterial and cerebrovascular disease is 
increased (American Diabetes Association 2009). 
Uncontrolled hyperglycaemia can lead to the two most serious acute and life-
threatening complications, diabetic ketoacidosis (DKA) and the hyperglycaemic 
hyperosmolar syndrome (HHS), which are both still associated with excess mortality 
(American Diabetes Association 2009, Chiasson et al. 2003). 
2.1.2 Classification and diagnosis criteria in human beings 
2.1.2.1 Classification 
In the last decades, the classification for diabetes mellitus was revised several times, 
due to the considerable new knowledge about the aetiology of different forms of 
diabetes and better information about the validity of blood glucose concentrations 
with regard to diabetic complications (Alberti and Zimmet 1998). The first systematic 
classification was published in 1979 by the National Diabetes Data Group (NDDG) 
and was mainly based on the pharmacological treatment. This classification 
differentiated between insulin-dependent (IDDM, type 1 diabetes), non-insulin-
dependent (NIDDM, type 2 diabetes), gestational diabetes and a fourth group named 
diabetes associated with other conditions and syndromes (Harris 1988). Expert 
groups of the World Health Organisation (WHO) revised this classification in 1980 
and 1985, defining 5 classification groups which also considered pathogenic aspects 
and were named IDDM, NIDDM, gestational diabetes, malnutrition-related diabetes 
and other types.  
In May 1995, an International Expert Committee, working under the sponsorship of 
the American Diabetes Association (ADA), was established to review scientific 
literature since 1979 and to decide if changes to the classification and diagnosis of 
diabetes were warranted. They revised the NDDG/WHO classification in 1997 in 
order to establish a classification, reflecting the aetiology and pathogenesis of 
diabetes mellitus. The main features of the changes were deletion of the terms 
IDDM, NIDDM and malnutrition-dependent diabetes, while the terms type 1 and type 
2 as well as gestational diabetes, were retained. Type 2 diabetes includes all forms 
2  Literature review 5 
 
of diabetes which result from insulin resistance with an insulin secretory defect 
(American Diabetes Association 2003). According to the recommendations of the 
ADA and the WHO, human diabetes mellitus is classified into four main groups: 
 
I.  Type 1 diabetes  
 Immune mediated or idiopathic β-cell destruction with usually total insulin 
deficiency 
II. Type 2 diabetes  
 May range from predominantly insulin resistance with relative insulin deficiency 
to a predominantly secretory defect with insulin resistance  
III. Other specific types  
- Genetic defects resulting in β-cell dysfunction or disturbed insulin action 
- Diseases of the endocrine pancreas 
- Endocrinopathies 
- Drug- or chemical-induced 
- Infections 
- Uncommon forms of immune-mediated diabetes 
- Other genetic syndromes sometimes associated with diabetes 
IV. Gestational diabetes mellitus (GDM) 
Defined as any degree of glucose intolerance with onset or first recognition 
during pregnancy, regardless of whether insulin is used for treatment or the 
condition persists after pregnancy (Metzger et al. 2007). 
 
2.1.2.2 Diagnosis criteria 
The diagnosis of diabetes mellitus and the assignment to one type of diabetes is 
sometimes difficult due to the particular circumstances present at the time of 
diagnosis and the lack of an identified unique qualitative biological marker that 
separates diabetic from non-diabetic people (American Diabetes Association 2009, 
Genuth et al. 2003). In 1997, the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus re-examined the till then generally accepted 
diagnosis criteria, which relied on distributions of glucose levels, rather than on the 
relationship of glucose levels with complications. The committee made two seminal 
contributions: First they refocused attention on the relationship between glucose 
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levels and the presence of long-term complications. Second, they recommend that 
the fasting plasma glucose (FPG) level, rather than the plasma glucose 2 hours after 
oral glucose challenge (2HPG), be the preferred test for diagnosis, based on the fact 
that it is more convenient for the patients and less costly as well as less time 
consuming and, moreover, the reproducibility of the repeat-test is superior  
(American Diabetes Association 2003). The WHO adopted most of these 
recommendations in a consultation. However, for the WHO the 2HPG remained the 
“gold standard” for diagnosis of diabetes mellitus, especially for individuals with 
impaired fasting glucose (IFG) (Gillett 2009). According to the Expert Committee, 
three possibilities for the diagnosis of diabetes exist. Prerequisite for the diagnosis is 
the presence of at least one point listed in Table 2.1. If no explicit hyperglycaemia is 
detectable, each test has to be confirmed on a subsequent day by any of the three 
methods (American Diabetes Association 2009). This requirement is necessary 
particularly for people without diabetic symptoms, because several impacts like 
severe infections, trauma or even stress can lead to transient hyperglycaemia in non-
diabetic individuals (Lehmann and Spinas 2005).  
 
Table 2.1 Criteria for the diagnosis of diabetes 
  
1) Fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no 
caloric intake for at least 8 hours* 
 
2)  Symptoms of hyperglycaemia and a casual plasma glucose ≥200 mg/dl       
(11.1 mmol/l). Casual is defined as any time of day without regard to time since 
last meal. The classic symptoms of hyperglycaemia include polyuria, polydipsia, 
and unexplained weight loss. 
 
3) 2-h plasma glucose (2HPG) ≥200 mg/dl (11.1 mmol/l) during an oral glucose 
tolerance test (OGTT). The test should be performed as described by the WHO, 
using a glucose load containing the equivalent of 75 g anhydrous glucose 
dissolved in water.* 
 
*In the absence of unequivocal hyperglycaemia, these criteria should be confirmed by 
repeat testing on a different day. 
 
Some individuals feature slightly elevated plasma glucose levels, which are too low 
to meet criteria for diabetes. The Committee therefore introduced the term “impaired 
fasting glucose” (IFG) to differentiate the intermediate metabolic state from a 
2  Literature review 7 
 
physiologic state (FPG < 100 mg/dl or 5.6 mmol/dl) and diabetes (FPG ≥ 126 mg/dl 
or ≥ 7.0 mmol/l) by using the FPG test. If an OGTT is used for the diagnosis, the 
intermediate glycaemic state (2HPG between 140 and 200 mg/dl or between 7.8 and 
11.1 mg/dl) is called “impaired glucose tolerance” (IGT) as in the NDDG report from 
1979 (Genuth et al. 2003). 
Due to the perception that chronic hyperglycaemia, which is sufficient to cause 
diabetic long-term complications, is the hallmark of diabetes, laboratory measures 
which capture long-term glycaemic exposure are better markers for the presence and 
severity of the disease than single measures of glucose concentration             
(Nathan 2009). The glycated haemoglobin A1C (HbA1C) assay (A1C-test) captures the 
degree of glucose exposure over the previous 8-12 weeks and correlates well with 
the risk of diabetic complications. The concentration of HbA1C, which is formed 
through non-enzymatic attachment of glucose to haemoglobin, is commonly 
considered to reflect the integrated mean glucose level (Nathan et al. 2007). The 
HbA1C assay is the test of choice for the management of chronic diabetes and 
therefore is recommended since July 2010 by the International Expert Committee for 
the diagnosis of diabetes. Therefore diabetes should be diagnosed when the HbA1C 
level is ≥ 6.5%, and the result should be confirmed with a repeat A1C-test. 
Confirmation is not necessary in persons with plasma glucose levels > 200mg/dl 
(>11.1 mmol/l). Individuals with an A1C level ≥ 6% but < 6.5% are likely at the 
highest risk for progression to diabetes, but this range should not be considered an 
absolute threshold at which preventative measures are initiated. People with HbA1C 
levels below 6.0% may still be at risk and, particularly when other diabetic risk factors 
are present, they should also benefit from prevention efforts (Nathan 2009). If it is not 
possible to obtain a standardised or an affordable A1C-test, the previously 
recommended diagnostic methods (fasting and post-challenge glucose) remain 
acceptable (American Diabetes Association 2009, Fonseca et al. 2009). 
2.1.3 Global and economical burden 
2.1.3.1 Global burden of diabetes mellitus 
The International Diabetes Federation (IDF) reports 2009, that the prevalence of 
diabetes mellitus has reached globally epidemic levels. It is estimated that 285 million 
adults are suffering from diabetes in the seven regions of the IDF 2010, implying an 
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increase by 39 million compared to 2007 and by 255 million in the last 35 years. 
Moreover, the IDF expects an ongoing increase to almost 439 million people in the 
next 20 years which relates to an annual growth of 2.2%, nearly twice the annual 
growth of the total world adult population (Egede and Ellis 2010, International 
Diabetes Federation 2009). From this anticipated absolute global increase by 154 
million people, 36% is projected to occur in India and China alone. The main reason 
for this huge increase is likely population growth, ageing of populations, and 
urbanization with associated lifestyle change, resulting in reduced physical activity 
and increased obesity. There are marked differences between developed and 
developing countries: In developing countries, numbers of diabetic adults are likely to 
increase by 69% from 2010 to 2030, compared to 20% for developed countries, 
whereas total adult populations are expected to increase by 36% and 2%, 
respectively (Shaw et al. 2010). One reason for the great increase of (mainly type 2) 
diabetes prevalence in developing countries could be the growing urbanization that is 
associated with a more sedentary lifestyle (Ramachandran et al. 1999). Specific 
lifestyle intervention programs have been shown to be efficacious in reducing 
diabetes incidence (Pan et al. 1997). Currently, the greatest number of people 
worldwide suffering from diabetes is in the 40- to 59-year-old age-group, but a 
tendency to older age-groups during the next 20 years is expected. The highest 
regional prevalence for 2010 can be stated for North America (10.2%), followed by 
the EMME (Eastern Mediterranean and Middle-East) (9.3%) and South Asia (7.6%). 
The African region is expected to have the largest proportional increase of the 
number of diabetic adults by 2030 (98.1%), followed by the EMME (93.9%), but North 
America will continue to have the world’s highest prevalence (12.1%)                 
(Shaw et al. 2010).  
2.1.3.2 Economical burden 
The treatment and prevention of diabetes mellitus and its accompanying diseases 
requires huge amounts of money every year. It is expected to reach 11.6% of the 
total healthcare expenditure in the world for the year 2010 (at least 376 billion US 
Dollar). Due to the increasing prevalence of the disease, the projections for the year 
2030 are expecting 490 billion US Dollar for global healthcare expenditure to treat 
and prevent diabetes mellitus. In the year 2010, approximately 75% of the global 
expenditure on care for diabetic patients will be spent for individuals between 50 and 
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80 years of age. The disparity between regions and countries is also alarming. In 
regions where 70% of people with diabetes live, namely low- and middle-income 
countries, less than 20% of the estimated global expenditures are spent, whereas the 
remaining 80% are spent in the world’s economically richest countries, first of all the 
United States of America, with an expected 52.7% of global expenditure in 2010. 
Additionally, indirect costs of diabetes based on loss of production caused by 
disability as well as mortality are estimated to be even higher than the direct 
healthcare costs (International Diabetes Federation 2009). 
2.2 Animal models in diabetic research 
2.2.1 The role of animal models for human diseases 
Animal models are used for studying the genetics and pathogenesis of diabetes and 
its accompanying complications, to develop new treatment strategies, including islet 
cell transplantation, and to find preventative strategies (Rees and Alcolado 2005). 
Animal models, especially rodents like rats and mice play an essential role in the 
investigation of human diseases. Due to their small size, short generation time of 
about 10 weeks, easy availability, possibility of breeding under standardised 
conditions as well as economic considerations, rodents are mostly preferred to other 
animal models like pigs or dogs (Silver 1995, Srinivasan and Ramarao 2007). 
Moreover, large regions of synteny between the mouse and human genome exist, 
thus linkages can be easily translated between the two genomes                 
(Waterston et al. 2002). 
Mainly two conceptually different approaches exist for the generation of animal 
models for human diseases. The disease-driven directed genetic approach is based 
on identifying human disease genes and the characterization of the nature of the 
underlying mutation. Afterwards, the aim is to detect the corresponding gene in the 
murine genome and to create either the exact copy of the mutation observed in 
humans or to alter the genome, creating a physiologically similar situation. The 
second possibility is the mutagenesis-driven, non directed approach with the idea to 
create a mutation by radiation or chemical substances (e.g. N-ethyl-N-nitrosourea, 
ENU) and then identify the disease caused by the mutation as well as the underlying 
mutation. This random mutagenesis-driven approach has become a feasible way to 
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identify disease genes and is a rich source of novel disease genes and new animal 
models (Hardouin and Nagy 2000). 
2.2.2 Animal models for diabetes mellitus 
Various diabetic animal models have been created in recent years and it is a still 
ongoing process. Most experiments are carried out on rodents, although some 
studies are performed on larger animals. Several methods are available to induce 
diabetes in animal models (Rees and Alcolado 2005, Srinivasan and Ramarao 2007): 
- Toxins like streptozotocin and alloxan induce hyperglycaemia by toxic β-cell 
destruction 
- Diabetogenic diets (e.g. high fat diet) 
- Surgical manipulations (e.g. partial pancreatectomy) 
- Selective inbreeding has already produced several diabetic strains that are 
useful models for Type 1 and Type 2 diabetes as well as related phenotypes 
such as obesity and insulin resistance.  
- Gene targeting for the generation of e.g. transgenic animals, constitutive or 
conditional knock-out mice 
Furthermore, genetic polymorphisms linked to different plasma glucose phenotypes 
of already existing mouse strains are examined in a genome-wide search for 
causative loci. The mapping of these so called quantitative trait loci (QTL) was 
carried out in independent as well as combined crosses of inbred mouse strains 
(Aigner et al. 2008, Clee and Attie 2007). 
2.2.3 ENU mutagenesis 
The alkylating agent N-ethyl-N-nitrosourea (ENU) is a chemical compound which is 
known for a long time to be one of the most effective mutagens for the induction of 
specific-locus-mutations in murine premeiotic spermatogonial stem cells          
(Russell et al. 1979). Its great advantage over other mutagens is the potential of 
creating primarily point mutations. Therefore, most of the observed abnormal 
phenotypes are based on a single gene effect (Nolan et al. 2002). Moreover, ENU 
mutagenesis creates not only recessively acting null alleles but also dominant 
hypermorphic, hypomorphic and antimorphic alleles. This is a very important aspect 
in view of the fact that approximately 51% of human disease alleles do not act in a 
recessive way. In addition, the potential of ENU to create an allelic series for any 
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gene may provide useful informations for mapping of functional domains        
(Barbaric and Dear 2007). 
Due to the fact that ENU not only possesses mutagenic but also toxic potential, the 
optimal dose must be found out, so that the highest mutation rate can be induced 
without rendering the animal infertile. It was determined that a repeated dosing 
regimen can achieve a higher mutation frequency (Hitotsumachi et al. 1985). 
Optimised treatment protocols can reach mutation frequencies of one mutation in 
0.1-2.5 Mb (Beier 2000, Concepcion et al. 2004, Sakuraba et al. 2005). Numerous 
phenotype-driven ENU mouse mutagenesis projects were established world-wide 
during the last 12 years and provide the opportunity for the systematic, genome-wide, 
large-scale production and analysis of mouse mutants which can serve as models for 
inherited human diseases. The projects facilitate the identification as well as the 
functional characterization of genes that are relevant for the prevention, diagnosis 
and therapy of diseases (Aigner et al. 2008). 
2.2.3.1 Munich ENU Mouse Mutagenesis Project 
In the Munich ENU mouse mutagenesis project, mutations in single genes and their 
effects on the animal organism are investigated. Standardised procedures to 
characterize mutant phenotypes have been developed and include screens for 
dysmorphological malformations and alterations in clinical chemistry, biochemistry, 
immunology, allergy and behaviour (Balling 2001, Soewarto et al. 2000). The project 
is carried out on the inbred C3HeB/FeJ (C3H) genetic background, known as a highly 
glucose-tolerant strain with a robust insulin secretory response (Clee and Attie 2007, 
Kaku et al. 1988). Starting at an age of ten weeks, male C3H mice receive three 
intraperitoneal ENU injections in weekly intervals. After a period of infertility, these 
treated male mice are mated to female C3H wild-type mice. The offspring (G1 
animals) are screened for dominant mutations. Afterwards, different back- and     
side-crosses are performed to determine the inheritance of the mutation as well as to 
reveal recessive mutations (Aigner et al. 2008). Backcrossing phenotypic mutant 
mice for several generations to C3H wild-type mice will reduce the amount of non-
causative mutations. Due to the fact that every backcross will decrease the number 
of mutations on average by 50 %, after 5 backcrosses a mouse will harbour 
approximately only one mutation and mutations on other chromosomes are 
eliminated (Aigner et al. 2008, Keays et al. 2006). 
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To determine the chromosomal position of the causative mutation, linkage analysis is 
carried out. For this purpose, heterozygous phenotypic mutant mice on the C3H 
inbred genetic background are bred to wild-type mice of a second inbred strain 
(C57Bl/6J). The male hybrid offspring (G1) are screened for the aberrant phenotype. 
Mice displaying the abnormal phenotype are then backcrossed to wild-type female 
mice of the second inbred strain (to screen for dominant mutations) or intercrossed 
(to detect recessive mutations). The resulting progenies (G2) are also screened and 
then separated into phenotypic mutant and phenotypic wild-type mice. The 
chromosomal location of the causative mutation is determined by analysing DNA 
samples of phenotypic G2 mutant mice and wild-type littermates via genome-wide 
linkage analysis, using a panel of DNA markers (single-nucleotide polymorphisms 
(SNPs) or microsatellites (Xing et al. 2005)) which are polymorphic for the two inbred 
strains used. Further linkage analysis and candidate gene sequencing are carried out 
to reveal the exact position of the mutation within the identified chromosomal section 
(Aigner et al. 2008). 
2.2.3.2 ENU-induced hyperglycaemia models  
Several hyperglycaemic mouse strains with identified dominant causative mutations 
have already been generated in ENU mouse mutagenesis projects. Most of the 
identified mutations are related to the glucokinase gene (Gck) (Aigner et al. 2008). 
About 600 heterozygous mutations in the human glucokinase gene are already 
known to cause maturity-onset diabetes of the young type 2 (MODY 2), whereas 
homozygous mutations are reported to cause permanent neonatal diabetes mellitus 
(PNDM) (Osbak et al. 2009). A total number of 15 ENU-induced glucokinase mutant 
mouse strains have been generated in various ENU-driven mutagenesis projects 
(Fenner et al. 2009, Inoue et al. 2004, Toye et al. 2004) 
(http://www.informatics.jax.org/). Five of the identified mutations could also be found 
in humans with MODY 2 or PNDM (Inoue et al. 2004). Recently, a new mouse model 
for MODY 2 generated in the large-scale Munich ENU mouse mutagenesis project 
could be identified. The so-called Munich GckM210R mutant mouse exhibits a T to G 
transversion mutation at nt 629 in Gck which leads to a reduction of the hepatic 
glucokinase enzyme activity (van Burck et al. 2010). 
Another hyperglycaemic strain derived from the Munich ENU mouse mutagenesis 
screen, the Munich Ins2C95S mutant mouse, exhibits a missense mutation in the 
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insulin 2 gene (Ins2) (Herbach et al. 2007). Insulin gene mutations in human beings 
are also known to be associated with PNDM (Støy et al. 2007) (see below). 
2.3 Insulin gene mutations 
2.3.1 Mutations in humans 
More than 20 mutations in the insulin gene have recently been described as a new 
monogenic cause of neonatal diabetes (Colombo et al. 2008, Edghill et al. 2008, 
Støy et al. 2007). The clinical manifestation of these new mutations is more severe 
like that of most previously described INS mutations and diabetes-onset already 
occurs at a mean age of 11 weeks (Støy et al. 2007). Mutations reported earlier, 
primarily affected the biological activity of the altered (pro)insulin molecules but did 
not impair their biosynthesis significantly, thereby leading to impaired (pro)insulin 
clearance with hyperinsulinaemia and hyperproinsulinaemia. Therefore, in these 
patients, diabetes only occurred in the presence of insulin resistance and in adults 
but most of the carriers were asymptomatic (Nanjo et al. 1986, Støy et al. 2007). New 
studies could demonstrate that mutations in the INS gene are the second most 
common cause of permanent neonatal diabetes mellitus (PNDM). One study 
demonstrated that out of 141 patients with PNDM which was diagnosed in the first 6 
months of life, 33 (23%) exhibited missense mutations in the INS gene. From 86 
cases of diabetes diagnosed between 6 and 12 months only 2% were caused by INS 
gene mutations. From 263 cases of MODY 2 and 463 cases of type 2 diabetes 
occurring in young patients, only one case each could be attributed to mutations in 
the insulin gene. Sixteen different heterozygous INS mutations could be determined 
in the 35 patients with diabetes diagnosed during infancy (the first 12 months of life). 
The three most common (46%) mutations were A24D, F48C and R89C, representing 
amino acid exchanges at different positions in the preproinsulin molecule          
(Edghill et al. 2008). Moreover, one mutation (C96Y) was found in three patients and 
was already identified in the Akita mouse (Støy et al. 2007, Wang et al. 1999). Most 
of the observed mutations result in addition or removal of a cysteine, which leads to 
an odd number of potential disulfide pairing sites, resulting in an imbalance that is 
thought to cause misfolding and aggregation of mutant (pro)insulin (Weiss 2009). 
Dominant inheritance was only observed in 20% of the identified INS gene mutations, 
whereas the majority results from sporadic de novo mutations (Edghill et al. 2008). 
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Recently, studies could also identify some novel INS gene mutations as a cause for 
MODY (Boesgaard et al. 2010, Molven et al. 2008). The relatively mild phenotype in 
most of these cases suggests, that a spectrum of phenotypes may exist in patients 
with INS mutations, ranging from mild diabetes and hyperinsulinaemia in patients 
with mutations that cause reduced biological activity of the insulin molecule (i.e., 
B24Ser, B25Leu, and A3Leu) to MODY in patients with mutations that are predicted 
to reduce the structural stability of the insulin molecule (i.e., R46Q). Finally, neonatal 
diabetes can occur in patients with mutations that cause severe defects in the 
biosynthesis of the insulin molecule (for example B8Ser and B19Gly) with the 
consequence of presumably unfolded protein response (UPR), ER-stress and β-cell 
apoptosis (Molven et al. 2008, Støy et al. 2007). The severity of the phenotype is 
likely depending on the perturbation grade of disulfide pairing in nascent proinsulin, 
on the site of the mutation and the properties of the substituted side chain. It is still 
unclear, why expression of the wild-type allele is not sufficient to maintain glucose 
homeostasis. It is suggested, that the misfolded protein variant also perturbs 
synthesis of wild-type insulin (Weiss 2009). In one study on isolated pancreatic islets 
of Akita mice it could be shown, that the mutant C(A7)Y proinsulin forms high-
molecular-weight protein complexes, and that the intermolecular protein complexes 
also include wild-type endogenous proinsulin, involving covalent as well as possible 
hydrophobic interactions. Liu et al. (2007) also suggested that the retention of mutant 
proinsulin in the ER leads to impaired transport of non-mutant proinsulin and to ER-
associated protein degradation of the mutant- and non-mutant proinsulin complexes. 
This thesis is affirmed by the observation of a decrease in steady-state levels of non-
mutant proinsulin and insulin, induced by dominant negative effects of the C(A7)Y 
mutant (Liu et al. 2007).  
The misfolding of insulin, and consequently defective trafficking to secretory 
granules, has been recognized as the likely underlying cause of β-cell dysfunction 
and death in several rodent models of non-immune diabetes like in the Akita mouse 
and the Munich Ins2C95S mutant mouse (Meur et al. 2010).  
Unlike in Akita and Munich Ins2 mutant mice, the phenotype of male and female 
human patients harbouring INS mutations does not differ, however, the birth weight 
of male patients in some cases was lower compared to that of newborn female 
mutation carriers (Edghill et al. 2008). 
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Due to the fact that a spectrum of phenotypes exists in INS mutation carriers, 
screening for INS mutations was suggested not only in neonatal diabetes, but also in 
MODY and in selected cases of type 1 diabetes (Molven et al. 2008). 
2.3.2 The Munich Ins2C95S mutant mouse 
The nonobese diabetic mouse model Munich Ins2C95S was generated in the Munich 
ENU Mouse Mutagenesis Project on the genetic background of the inbred strain 
C3HeB/FeJ (C3H). The hyperglycaemic phenotype is caused by an autosomal 
dominant mutation at nucleotide position 1903 in exon 3 of the Ins2 gene with the 
consequence of an amino acid exchange from cysteine to serine at position 95 of 
preproinsulin (C95S), corresponding to amino acid 6 on the A chain of proinsulin 
(A6). This in turn, inhibits the formation of the A6 - A11 intrachain disulfide bond 
(Herbach et al. 2007).  
2.3.2.1 Heterozygous Munich Ins2C95S mutant mice 
Heterozygous mutant mice showed significantly elevated blood glucose 
concentrations both 15-hours fasted and 1.5-hours postprandially at 1, 3 and 6 
months of age as compared to sex- and age-matched littermate controls. At an age 
of 3 weeks, blood glucose levels did not differ yet between mutant and wild-type 
mice. 
Blood glucose levels of male mutant mice increased steadily between 1 and 6 
months of age, whereas female mutant mice only featured a mild diabetic phenotype 
with almost stable blood glucose concentrations. 
Mutant mice of both genders also showed significantly higher blood glucose 
concentrations versus wild-type mice during oral glucose tolerance tests (OGTT). 
Three- and 6-month-old male mutant mice demonstrated significantly elevated blood 
glucose concentrations during OGTT as compared to female mutant mice at all time 
points investigated. 
Fasting and 1.5-h postprandial serum insulin levels of male and female mutant mice 
were similar to those of sex-matched controls. The serum insulin levels 10 minutes 
after glucose stimulation however, were significantly reduced in male and female 
mutant mice as compared to controls, irrespective of the age at sampling. Serum 
insulin levels of male and female mutant mice were equal, despite much lower blood 
glucose levels in female vs. male mutants. 
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The homeostasis model assessment (HOMA) of β-cell function index of mutant 
versus wild-type mice was largely reduced in both genders at 1, 3 and 6 months of 
age. The HOMA of insulin resistance index at an age of 3 and 6 months was 
significantly higher in male mutant mice as compared to controls, whereas female 
mutant mice exhibited almost similar insulin sensitivity as the accordant wild-type 
mice.  
At an age of 3 and 6 months, the insulin content in the pancreas was significantly 
reduced in both male and female mutant mice as compared to sex-matched wild-type 
mice. In female mutant mice, the insulin content at an age of 6 months was still about 
half of the amount of wild-type mice, whereas in male mutant mice almost no insulin 
was detectable. 
Immunohistochemical investigations of the endocrine pancreas for insulin and 
glucagon of 6-month-old mutant mice showed a disturbed islet structure: The amount 
of insulin positive β-cells was reduced, whereas the amount of glucagon producing α-
cells was increased and α-cells were distributed all over the islet. In contrast, islets of 
wild-type mice demonstrated a typical murine islet structure, with a core of insulin-
expressing cells, surrounded by a few non-β-cells. Moreover, the staining intensity of 
insulin-positive cells in mutants was much weaker as compared to that of wild-type 
mice (Herbach et al. 2007). All the described alterations were less distinct in female 
mutant mice compared to male mutants (Herbach et al. personal communication). 
Quantitative stereological investigations showed no difference concerning total 
pancreas volume between 6-month-old mutant and wild-type mice.  
The total islet volume, the total β-cell volume as well as the volume density of β-cells 
in the islets were significantly reduced in male but not in female mutant mice 
compared to sex-matched wild-type mice. 
Both, male and female mutant mice demonstrated a significantly increased volume 
density of α-cells in the islets compared to wild-type mice, whereas the total volume 
of α-cells was only significantly increased in female mutants compared to wild-type 
mice.  
Only male mutant mice exhibited a significantly higher volume density and total 
volume of somatostatin producing δ-cells as well as of pancreatic polypeptide 
producing PP-cells as compared to male wild-type mice. 
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Electron microscopically, the β-cells of 6-month-old male mutant mice featured a 
variety of ultrastructural alterations compared to male wild-type mice, such as 
prominent disorganization of the rough endoplasmic reticulum (rER) with dilated 
cisternae, mitochondrial swelling with largely destroyed crests and apparent myelin 
figures. Moreover, in male mutant mice only few small immature insulin granules 
were found, in contrast to the high numbers of granules apparent in male wild-type 
mice (Herbach et al. 2007). In female mutants, these ultrastructural alterations were 
less distinct compared to male mutants, however, female mutant mice also 
demonstrated less secretory granules than female wild-type mice                   
(Herbach et al. personal communication). 
No signs of apoptosis, including chromatin condensation or apoptotic bodies could be 
found in islets of male mutants (Herbach et al. 2007).  
 
These results demonstrate that male and female heterozygous Munich Ins2C95S 
mutant mice both develop diabetes mellitus. Male mutants show a progressive 
diabetic phenotype with massive hyperglycaemia, insulin resistance and profound 
decrease of β-cell mass. In contrast, female mutant mice demonstrate a much milder 
and stable diabetic phenotype with no signs of insulin resistance and an almost 
unaltered β-cell mass (Herbach et al. 2007). 
2.3.2.2 Homozygous Munich Ins2C95S mutant mice 
Homozygous mutant mice demonstrated no diabetic phenotype until 18 days 
postnatally. At 21 days of life, mutant mice of both genders already showed severe 
hyperglycaemia, reaching blood glucose levels of almost 400 mg/dl. At an age of 28 
days, the body weight of both male and female mutant mice was reduced compared 
to wild-type mice and further decreased until time of death. Homozygous male and 
female mutants died at a mean age of 46 and 52 days, respectively (Herbach et al. 
2007). 
2.3.3 Akita mouse 
The Akita mouse is a nonobese diabetic mouse model that arose from a female 
C57BL/6 mouse harbouring a spontaneous point mutation in Ins2. A stable mouse 
line was established by breeding male heterozygous mutant mice with female 
C57BL/6 (B6) wild-type mice (Yoshioka et al. 1997). The mutation is characterized by 
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a GA transversion at nucleotide position 1907 in exon 3 of Ins2, leading to a 
substitution of cysteine on position 96 of the A chain of preproinsulin 2 by tyrosine 
(C96Y). As a consequence, the mutation prevents formation of the A7-B7 interchain 
disulfide bond of insulin 2, resulting in a reduced processing of proinsulin and a 
severe reduction of mature insulin. The mutation is inherited in an autosomal 
dominant way (Clee and Attie 2007, Wang et al. 1999).  
The identical mutation (C96Y) in the Ins2 gene could be identified in humans with 
PNDM (2.3.1 Mutations in humans). 
2.3.3.1 Heterozygous Akita mutant mice 
Soon after weaning, heterozygous Akita mutant mice exhibit a diabetic phenotype, 
including symptoms like hyperglycaemia, polydipsia and polyuria. Male mice develop 
a progressive diabetic phenotype, whereas female mutant mice only show mild 
diabetic symptoms.  
From the age of 18 weeks, male mutant mice did not gain further weight and 
moreover, weight loss was apparent by 30 weeks of age, whereas female mutant 
mice demonstrated growth rates comparable to female wild-type mice up to an age of 
43 weeks. The 50% survival rate of male mutant mice was less than half that of male 
wild-type mice, whereas female mutant mice showed a similar life expectancy as the 
accordant controls. 
From an age of 4 weeks onwards, randomly fed blood glucose concentrations of both 
male and female Akita mutant mice were significantly higher as compared to sex- 
and age-matched wild-type mice. Male mutants showed a constant increase of blood 
glucose levels up to an age of 9 weeks, afterwards blood glucose remained relatively 
stable (approximately 550-600mg/dl). In contrast, female mutant mice demonstrated 
blood glucose concentrations below 330mg/dl. At 7 weeks of age, randomly fed 
plasma insulin levels were significantly lower in mutant mice of both genders as 
compared to sex- and age-matched wild-type mice (Yoshioka et al. 1997).  
The insulin content in the pancreas of pooled male and female mutant Akita mice at 
an age of 2 weeks was about half that of wild-type mice (Kayo and Koizumi 1998). At 
an age of 8 weeks, the pancreatic insulin content of male and female mutant mice 
was approximately 25 and 50% that of wild-type mice, respectively              
(Oyadomari et al. 2002). The loss of only mutant insulin 2 cannot explain such a 
drastic reduction of proinsulin and insulin protein levels (Izumi et al. 2003). 
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Heterozygous Akita mutant mice should also have native insulin molecules derived 
from 3 wild-type alleles (two Ins1 and one Ins2). Ins1 transcripts represent 
approximately 25% of the total insulin transcripts in mutant as well as in wild-type 
mice and transcripts of Ins2 were also similar in mutants and wild-type mice, 
representing 75% of the total insulin transcripts. Mutant and the wild-type Ins2 alleles 
in heterozygous mutant mice were also transcribed in similar amounts                
(Wang et al. 1999). If the native insulin molecules were secreted efficiently, severe 
glucose intolerance and insulin deficiency should not occur in Akita mice             
(Izumi et al. 2003).  
Morphologic studies of islets on pancreas sections immunostained for insulin and 
glucagon of 4-, 10- , 20- and 30-week-old-mice revealed that irrespective of sex and 
age, the relative areas (%) of islets in diabetic mice were not significantly different 
from those of wild-type mice. At the age of 4 weeks, mutant mice of both genders 
demonstrated a significantly lower proportion of insulin-positive cells in the islets than 
sex-matched wild-type mice. At the age of 30 weeks, the proportion of insulin positive 
islet cells decreased further in male mutant mice, whereas the proportion in female 
mutant and wild-type mice remained stable (Yoshioka et al. 1997).  
The staining intensity for insulin in age-matched 8-12 week-old male mutant mice 
was weaker as compared to sex-and age-matched wild-type mice. Since the insulin-
autoantibody only detects the wild-type and not the mutated insulin, the weak 
staining intensity indicates a dramatic decrease in wild-type insulin. The 
immunoreactivity of C-peptide was also much weaker in β-cells of mutant mice as 
compared to wild-type mice, strongly suggesting that the amount of proinsulin from 
both mutant and wild-type alleles was decreased (Wang et al. 1999). 
Electron microscopic analysis of β-cells from 4- to 18-week-old male Akita mutant 
mice revealed that the lumina of ER-like organelles were markedly enlarged and had 
a more electron-dense appearance, suggesting that misfolded proinsulin 2 is trapped 
and accumulated. Mitochondria of older mice were markedly swollen and denatured 
without distinct cristae (Izumi et al. 2003). The average volume and the volume 
density of secretory granules of 8- to 12-week-old mutant mice were severely 
reduced versus age-matched wild-type mice, however the number of secretory 
granules (numerical density per unit volume) was not altered from that of control mice 
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Moreover, immunogold labelling suggested, that proinsulin accumulates in the pre-
Golgi intermediates of Akita mutant mice (Zuber et al. 2004). 
In recent studies it could be demonstrated that islets of mutant Akita mice contain 
more apoptotic cells than islets of wild-type mice. Moreover, disruption of the     
C/EBP homologous protein (CHOP)/growth arrest and DNA damage (Gadd)153 
gene resulted in an ameliorated diabetic phenotype, indicating that apoptosis was 
induced by ER-stress (Oyadomari et al. 2002). 
2.3.3.2 Homozygous Akita mutant mice 
One-day-old homozygous mutant Akita mice showed reduced body weight but only 
slightly elevated blood glucose levels as compared to heterozygous mutant and wild-
type mice, whereas 14-day-old homozygous mutant mice demonstrated much higher 
blood glucose levels than the other two genotypes, reaching approximately           
450 mg/dl. Gender differences in blood glucose levels or other cytometric parameters 
could not be observed until 14 days of age. The relative area (%) of islets in 
pancreas sections of sex-matched homozygous mutant mice at an age of 1 and      
14 days was less than half that of the two other genotypes. At the same age, 
immunohistochemical examinations revealed a markedly lower proportion of insulin 
positive β-cells as compared to heterozygous mutant as well as wild-type mice, 
whereas the proportion of glucagon positive α-cells was largely increased. 
Electron microscopy of pancreas sections from 14-day-old homozygous mutant mice 
showed a decreased density of secretory granules, increased amount of ER and 
swollen mitochondria (Kayo and Koizumi 1998). 
2.3.3.3 ER-stress in the Akita mouse 
Proinsulin from mutant Akita mice is more hydrophobic and less stable than wild-type 
proinsulin. As a result of hydrophobic interactions between the molecules, it is likely 
that mutant proinsulin aggregates more easily than wild-type proinsulin. Mutant 
proinsulin is mainly found as a tetramer, wild-type as a dimer, but it is also possible 
that the wild-type insulin is incorporated into aggregates of the mutant insulin 
(Yoshinaga et al. 2005). Liu et al. (2007) could directly show that the intermolecular 
mutant proinsulin complexes also include wild-type proinsulin, involving covalent as 
well as possible hydrophobic interactions (Liu et al. 2007). Aggregation of 
hydrophobic mutant proinsulin can lead to ER-stress by mobilizing the ER-stress 
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chaperone binding Ig protein (BiP), also called glucose regulated protein 78 (GRP78) 
(Yoshinaga et al. 2005). This protein was overexpressed in pancreatic islets of 8- to 
12-week-old Akita mutant mice, probably forming complexes with proinsulin       
(Wang et al. 1999). In response to the accumulation of unfolded proteins in the ER, 
eukaryotic cells activate an intracellular signalling pathway from the ER to the 
nucleus known as the unfolded protein response (UPR). This response consists 
mainly of three components that counteract ER-stress: First, up-regulation of genes 
encoding ER chaperone proteins such as BiP/GRP78 to increase the protein folding 
capacity in the ER, second, translational attenuation to reduce the load of new 
protein synthesis and prevent further accumulation of unfolded proteins, and third, 
transcriptional induction of components of the ER-associated protein degradation 
system (ERAD) to eliminate misfolded proteins by the ubiquitin-proteasome system 
(Mori 2000, Oyadomari and Mori 2004) (Figure 2.1). 
 
       
 
Figure 2.1: ER-stress response pathway 
Accumulation of unfolded proteins in the ER activates four distinct cellular responses. (A) 
Transcriptional induction of ER chaperones increases protein folding activity and prevents protein 
aggregation. (B) Translational attenuation reduces the load of new protein synthesis and prevents 
further accumulation of unfolded proteins. (C) The ER-associated degradation (ERAD) pathway 
eliminates misfolded proteins by the ubiquitin-proteasome system (UPS). (D) When functions of the 
ER are severely impaired, apoptosis is induced to destroy the cell (Araki et al. 2003). 
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Inositol-requiring protein-1 (IRE1), double-stranded RNA-dependent protein kinase-
related ER kinase (PERK) and activating transcription factor-6 (ATF6) are the 
proximal sensors of unfolded protein accumulation in the ER. These sensors control 
the load of nascent polypeptides entering the ER lumen as well as the concentration 
of chaperones and catalysts participating in disulfide bond formation and the 
machinery for degradation of misfolded protein (Scheuner and Kaufman 2008).         
It could be demonstrated, that BiP as well as the ERAD components HMG-CoA 
reductase degradation protein 1 (HRD-1) and protein sel-1 homolog 1 (Sel1L) were 
up-regulated in the islets of mutant Akita mice. Moreover, X-box binding protein 1 
(XBP-1) splicing levels were elevated as compared to wild-type mice. Due to these 
results, it is supposed that misfolded (pro)insulin is degraded by a HRD-1 mediated 
pathway (Allen et al. 2004). When the functions of the ER are severely impaired and 
cell protective changes mediated by the UPR fail to restore folding capacity, 
apoptosis can occur as a fourth component of the UPR, to protect the organism by 
eliminating the damaged cells (Lai et al. 2007, Oyadomari and Mori 2004). One of the 
components of the ER-stress-mediated apoptosis pathway is C/EBP homologous 
protein (CHOP), also known as growth arrest- and DNA damage-inducible gene 153 
(GADD153) (Oyadomari and Mori 2004). It is one of the most highly up-regulated 
genes during prolonged ER-stress and encodes a transcription factor that promotes 
programmed cell death (Lai et al. 2007, Ron 2002). All three UPR signalling 
pathways are involved in inducing CHOP transcription, although the PERK pathway 
is essential (Lai et al. 2007) (Figure 2.2). 
In 8-week-old heterozygous mutant Akita mice with an additional Chop knockout 
(Chop-/-), the onset of diabetes began 8 – 10 weeks later as compared to Akita mice 
without intact Chop (Chop+/+). The pancreatic insulin content of both male and female 
heterozygous Chop-/- Akita mutant mice was significantly higher as compared to 
accordant sex- and age- matched Chop+/+ mice. It was also shown, that pancreatic 
islets of 4-week-old heterozygous Chop-/- Akita mutant mice exhibited significantly 
less apoptotic cells as compared to Chop+/+ Akita mutants (Oyadomari et al. 2002). 
All these findings show that the activation of CHOP in heterozygous Akita mutant 
mice leads to β-cell apoptosis and therefore enhances the progression of diabetes 
mellitus. 
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Figure 2.2: ER-stress signalling 
IRE1, ATF6 and PERK are the three main ER-stress transducers. They are inactive due to binding to 
the ER chaperone BiP, which is a key regulator of the ER-stress response. When proteins misfold in 
the ER lumen, BiP dissociates from the ER-stress transducers, leading to their activation. The IRE1 
endoribonuclease splices XBP1 mRNA, allowing its translation. XBP1s is a transcription factor 
regulating expression of ER genes involved in protein folding and export as well as ERAD (ER-
associated protein degradation). IRE1 also activates JNK. ATF6 induces ER chaperones, such as BiP. 
PERK phosphorylates eIF2α, thereby inhibiting translation initiation and reducing the arrival of newly 
synthesized proteins in the ER. Translation of some proteins such as ATF4 is facilitated. ATF4 
induces expression of the pro-apoptotic transcription factor CHOP. In the case of prolonged and 
excessive ER-stress, apoptosis will be triggered. Apoptosis is caused through JNK, CHOP and the 
ER-specific caspase 12 (modified according to Cnop et al. 2008). 
 
 
2.3.4 Ins1 and Ins2 null mutant mice 
For the creation of insulin deficient double homozygous null mutant mice (Ins1-/-, 
Ins2-/-) as well as single homozygous null mutant mice (Ins1-/-, Ins2+/+ or Ins1+/+,    
Ins2-/-), the particular insulin genes (Ins1 and/or Ins2) were disrupted by means of 
gene targeting (Duvillie et al. 1997). Further, single heterozygous null mutant mouse 
models were created harbouring only one single copy of one Ins gene (Ins1+/-, Ins2-/- 
or Ins1-/-, Ins2+/-) (Babaya et al. 2006). 
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2.3.4.1 Double homozygous Ins1 and Ins2 null mutant mice 
In double homozygous Ins null mutant mice, the absence of embryonic insulin had no 
impact on embryonic lethality. Intrauterine growth retardation, with a 15 - 20% 
reduction in body weight as compared to control mice was observed at day 18.5 of 
fetal life. The relative organ weights of homozygous Ins null mutants remained 
unaltered and no differences in blood glucose concentrations were observed. As 
soon as the mutant mice started to suckle, glucosuria was detected, followed by 
ketonuria developing within a day, and homozygous null mutants finally died on 
average within 48 h (Duvillie et al. 1997). 
The mean islet area was higher in double homozygous null mutant mice than in wild-
type controls as well as in heterozygous single null mutant mice (Ins1-/-, Ins2+/-) at 
embryonic day 18.5 and also in the newborn (Duvillie et al. 1997, Duvillie et al. 2002). 
The individual β-cell size in insulin deficient mice was similar to controls, suggesting 
that islets were enlarged due to a higher replication rate of established endocrine 
islet-cells within existing islets. Additionally, insulin deficient mutant mice 
demonstrated a significantly lower incidence of apoptotic islet cells, which may be 
related to a 2-fold increased vascularisation of the pancreas. Morphometric analysis 
demonstrated that the area fraction of β-cells in the islets of Ins1-/-, Ins2-/- and Ins1-/-, 
Ins2+/- mutant mice at embryonic day 18.5 was about 76 % and that of α-cells about 
17 %. Due to the fact that the proportional contribution of α- and β-cells in Ins1-/-, 
Ins2-/- mutant mice was similar to that of Ins1-/-, Ins2+/- mutant as well as to that of 
wild-type mice, the increased mean islet area of double homozygous null mutant 
mice seems to be caused by an increase of both, the total estimated β-cell and α-cell 
mass. It was therefore suggested that insulin may act as a negative regulator of islet 
size in utero (Duvillie et al. 2002). 
2.3.4.2 Single homozygous Ins1 and Ins2 null mutant mice 
Single homozygous Ins1-/- as well as Ins2-/- mutant mice did not show major metabolic 
disorders and were both viable and fertile. Both mutants as well as wild-type mice 
exhibited similar plasma insulin levels at an age of 2 – 4 months and the pancreatic 
insulin content was also comparable to wild-type mice. RT-PCR revealed that Ins2 
transcripts of Ins1-/- mutant mice were comparable to wild-type mice, whereas in  
Ins2-/- mutant mice a dramatic increase of Ins1 transcripts was observed. This finding 
led to the conclusion that in Ins2-/- mutants, the absence of Ins2, which represents the 
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majority of total insulin transcripts in wild-type mice, is being compensated by up-
regulation of Ins1 transcription. This compensation first occurred during late gestation 
or postnatally and explains the similar pancreatic insulin content of mutant and wild-
type mice as well as the prevention from developing diabetes mellitus. 
From one week of age onwards, blood glucose concentrations of both Ins1-/- and 
Ins2-/- mutant mice were similar to those of wild-type mice. Moreover, 4- to 6-month-
old Ins2-/- mutants showed similar intraperitoneal glucose tolerance tests as 
compared to wild-type mice.  
Immunocytochemical staining of pancreas sections from 2-to 4-month-old male Ins1-/- 
and Ins2-/- mutant mice indicated normal distribution of β-, α-, δ- and PP-cells in the 
islets and therefore, the overall islet morphology as well as the distribution of the 
different endocrine islet cell types were not altered compared to wild-type mice. 
Morphometric analyses were accomplished on pancreas sections of 7- to               
11-week-old male Ins1-/- and Ins2-/- mutant mice immunostained with anti-insulin 
antibody. These investigations revealed an almost 3-fold increased β-cell mass in 
Ins2-/- mutant mice and a less than 2-fold increased β-cell mass in Ins1-/- mutant mice 
as compared to wild-type mice, whereas the mean individual β-cell size was similar. 
It is suggested, that the lack of insulin or low insulin production may lead to β-cell 
hyperplasia (Leroux et al. 2001).  
The compensatory increase of Ins1 transcription in Ins2 deficient β-cells was 
confirmed in in vitro studies using a β-cell line (βIns2-/-lacZ) derived from Ins2-/- mice 
that carry the lacZ reporter gene under control of the Ins2 promoter. Ins1 gene 
expression was largely increased in βIns2-/-lacZ cells, which was interpreted as a 
compensatory effect due to the absence of Ins2 transcripts and explains the similar 
total insulin content compared to other murine β-cell lines, in which both Ins genes 
were functional. When βIns2-/-lacZ cells were incubated for 2 hours in glucose 
supplemented Krebs-Ringer secretion buffer, the amount of insulin released from the 
βIns2-/-lacZ cells increased with increasing glucose concentrations (Leroux et al. 2003).  
2.3.4.3 Single heterozygous Ins1 and Ins2 null mutant mice 
Babaya et al. (2006) described a novel insulin-deficient mouse model on a nonobese 
diabetic (NOD) background with a single copy of the gene encoding insulin 1 (Ins1) 
and no gene encoding insulin 2 (Ins2) (NODIns1+/-,Ins2-/-). In addition they established 3 
other lines with different knock-outs (NODIns1-/-,Ins2+/-, NODIns1+/+,Ins2-/-, NODIns1-/-,Ins2+/+). 
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By 10 weeks of age, all male NODIns1+/-,Ins2-/- mice developed diabetes, whereas no 
male mouse with only a single Ins2 gene (NODIns1-/-,Ins2+/-) as well as mice with single 
homozygous knock-outs (NODIns1+/+,Ins2-/-, NODIns1-/-,Ins2+/+) developed diabetes by this 
age and in addition, none of the female knock-outs showed a diabetic phenotype, 
irrespective of the number of genes encoding for insulin. After 10 weeks of age, 
female NODIns1+/+,Ins2−/− and NODIns1+/−,Ins2−/− mice showed a high prevalence of 
diabetes and severe insulitis. Both male and female homozygous Ins1 knock-out 
mice (NODIns1-/-,Ins2+/+) and mice with only a single Ins2 gene (NODIns1-/-,Ins2+/-) did not 
develop diabetes until 36 weeks of age.  
The pancreatic insulin content in 4- to 5-week-old male and female NODIns1+/-,Ins2-/- 
mice was extremely low compared to all other genotypes including wild-type mice but 
no difference between male and female NODIns1+/-,Ins2-/- mice was detected, 
prefiguring a higher insulin-resistance of male NOD mice. During intraperitoneal 
insulin tolerance tests (ipITTs) at an age of 10 weeks, male NODIns1+/−,Ins2−/− mice 
showed significantly higher fasted blood glucose levels as compared to female 
NODIns1+/−,Ins2−/− mice and the blood glucose concentrations 15 and 30 minutes after 
an intraperitoneally insulin injection also were significantly higher in male mutants as 
compared to female mutants, substantiating the suspicion of increased insulin-
resistance in male mice.  
All these results demonstrate that existing sex differences between male and female 
NODIns1+/−,Ins2−/− mice lead to a milder diabetic phenotype in female mice and 
suggested less insulin resistance as compared to male mice (Babaya et al. 2006). 
2.4 Estrogen 
2.4.1 Estrogen production and action 
Estrogens belong to the group of sex steroid hormones (SSH) comprising also 
progestagens (pregnenolone, progesterone) and androgens (testosterone, 
dihydrotestosterone, dehydroepiandrosterone, androstenedione) (Bulun and Adashi 
2008). 
The naturally occurring estrogens estradiol (E2), estrone (E1), and estriol (E3) are 
C18 steroids derived from cholesterol. Aromatization is the last step in estrogen 
formation, catalyzed by the P450 aromatase monooxygenase enzyme complex that 
is present in the smooth endoplasmic reticulum. In three consecutive hydroxylating 
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reactions, estrone and estradiol are formed from their obligatory precursors 
androstenedione and testosterone, respectively (Gruber et al. 2002). The primary 
sources of estrogen in premenopausal women are the theca and granulosa cells of 
the ovaries. According to the “two-cell” theory of estrogen synthesis, the theca cells 
secrete androgens that diffuse to the granulosa cells to be aromatized to estrogens 
(Hillier et al. 1994). The principal sites of aromatase expression in pregnant women 
are the placental syncytiotrophoblast, and in the postmenopausal woman the adipose 
tissue and skin fibroblasts (Simpson et al. 1994). Both in men and postmenopausal 
women, aromatization of C19 steroids in peripheral tissues (adipose tissue and skin) 
is the primary mechanism for estrogen formation (Grodin et al. 1973).  
Estradiol (E2) is the predominant form in non pregnant females and is produced in at 
least 3 major sites (Figure 2.3). Estrone arises primarily from peripheral aromatisation 
of androstendione and, in part, from ovarian secretion. It is not a potent estrogen, but 
can be viewed as a precursor that must be converted to estradiol to exert full 
estrogenic action (Bulun et al. 1999). Estriol is the predominant estrogen during 
pregnancy (Mucci et al. 2003). 
             
 
Figure 2.3: Estrogen biosynthesis in women  
The biologically active estrogen estradiol (E2) is produced in at least three major sites: First by direct 
secretion from the ovary in reproductive-age women; second by conversion of circulating 
androstenedione (A) of adrenal or ovarian origins, or both, to estrone (E1) in peripheral tissues; and 
third by conversion of A to E1 in estrogen target tissues. In the latter two instances, estrogenically 
weak E1 is further converted to E2 within the same tissue. The presence of the enzyme aromatase 
and 17β-hydroxysteroid dehydrogenase (17β-HSD) is critical for E2 formation at these sites (modified 
according to Bulun and Adashi 2008). 
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While estrogens are present in both men and women, they are usually present at 
significantly higher levels in women of reproductive age and responsible for the 
development of secondary sexual characteristics, regulation of gonadotropin 
secretion for ovulation, preparation of tissues for progesterone response, 
maintenance of bone mass, regulation of lipoprotein synthesis, prevention of 
urogenital atrophy, regulation of insulin responsiveness, and maintenance of 
cognitive function (Nelson and Bulun 2001). Unlike ovulating women, in whom most 
of the circulating estrogen is derived from the ovaries, in males 85% of circulating 
estradiol and more than 95% of circulating estron is derived from extragonadal 
conversion of testosterone and androstendione, mostly in fat and skin             
(Hemsell et al. 1974, Simpson et al. 1994). It regulates certain functions of the 
reproductive system such as the maturation of sperm (Fisher et al. 1998) and it is 
important for the fusion of epiphyses and maintenance of bone mass in young adult 
men (Carani et al. 1997). 
2.4.2 Estrogen receptors 
During the last 40 years, several different estrogen receptors (ER) have been 
identified. The classical genomic estrogen action is known for the longest time and 
involves the diffusion of estrogen across the plasma membrane and the activation of 
specific intracellular receptors (Nadal et al. 1998). Until 1995, it was assumed that 
there was only one estrogen receptor responsible for all of the physiological and 
pharmacological effects of natural and synthetic estrogens as well as antiestrogens, 
namely the ERα. In 1996, an additional estrogen receptor was cloned from rat 
prostate. This novel receptor was designated ERβ. In the following years, several ER 
subtypes, isoforms and products of mRNA splice variants have been identified 
(Katzenellenbogen and Katzenellenbogen 1996, Nilsson et al. 2001). Both, the 
concentration of these receptors and the relative ratio of subtypes and isoforms vary 
in different target tissues and at different stages of development     
(Katzenellenbogen and Katzenellenbogen 1996). In the last three decades, 
increasing evidence for rapid, non-classical steroid effects through a membrane-
associated ER has been demonstrated for virtually all groups of steroids. In contrast 
to the delayed genomic steroid actions, non-genomic steroid effects are principally 
characterized by their insensitivity to inhibitors of transcription and protein synthesis, 
and by their rapid onset of action (within seconds to minutes)                     
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(Falkenstein et al. 2000). In addition, recent studies discovered an orphan G protein-
coupled receptor (GPR30) that seems to be involved in several non-genomic rapid 
estrogen actions (Thomas et al. 2005) as well as other non-classical membrane 
estrogen receptors (ncmER), like the so-called γ-adrenergic receptor                  
(Nadal et al. 2000).  
2.4.2.1 Classical genomic estrogen receptors (ERα and ERβ) 
Classical estrogen receptors are located in the cytoplasm and act as intracellular 
transcription factors whose principal target is in the nucleus where they exert positive 
or negative effects on the expression of target genes (Beato et al. 1996, 
Katzenellenbogen and Katzenellenbogen 1996). The classical ERs belong to the 
steroid/thyroid hormone superfamily of nuclear receptors, which members share a 
common structural architecture (Evans 1988, Katzenellenbogen and 
Katzenellenbogen 1996). These receptors are composed of a ligand binding domain, 
a DNA-binding domain and several transactivating functions distributed along the 
molecule (Beato 1989). Ligand binding to the ER regulates gene expression by 
recognizing palindromic estrogen response elements (ERE) of the DNA after homo- 
or heterodimerization of the ligand-receptor complex. Together with different 
coactivators, repressors and transcription regulators, the basal transcription complex 
binds with high affinity to specific EREs in the regulatory regions of target genes to 
either activate or repress gene expression. The expression of steroid-induced genes 
is modulated at the protein level some hours after stimulation with the steroid 
(Falkenstein et al. 2000).  
ERα and ERβ are products of distinct genes on different chromosomes and are 
widely distributed throughout the body, exhibiting various tissue- and cell-type 
specific expression patterns. ERα is expressed primarily in the uterus, liver, kidney, 
and heart, whereas ERβ basically is expressed in the ovary, prostate, lung, 
gastrointestinal tract, bladder, as well as the hematopoietic and central nervous 
system. In studies with mice lacking ERα (αERKO) or ERβ (βERKO) or both 
(αβERKO) it could be demonstrated that both receptor subtypes have overlapping as 
well as unique roles in estrogen-dependent action (Matthews and Gustafsson 2003). 
In a number of tissues, including for example the mammary gland, thyroid, adrenal, 
bone and certain brain regions, the two receptors are coexpressed and form 
functional heterodimers in which ERβ can oppose the actions of ERα in many 
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instances (Liu et al. 2002, Matthews and Gustafsson 2003). In addition, the synthetic 
antiestrogens tamoxifen and raloxifene can exhibit distinctive responses and can be 
for example partial agonists for ERα whereas they act as pure antagonists for ERβ 
(Barkhem et al. 1998). Moreover, several isoforms of ERα and ERβ exist, also 
altering estrogen-mediated gene expression (Shupnik et al. 1998). Specific 
pharmacologic targeting of ERα or ERβ would open up novel therapeutic 
opportunities, stratifying hormonal treatment, thereby reducing undesired side effects 
(Zhao et al. 2008). Moreover it was recognized that 17βEstradiol (E2) actions were 
mediated by at least two more other “non-classical” ER pathways: first, ligand-
independent ER signalling, in which gene activation occurs through second-
messenger pathways that alter intracellular kinase and phosphatase activity, 
resulting in changed phosphorylation of the ER (Weigel and Zhang 1998). Second, 
genotropic, estrogen response element (ERE)-independent signalling, in which ER 
regulates genes independent of direct DNA binding via protein-protein interaction 
with other transcription factors, such as c-Fos/c-Jun B (AP-1), Sp1, and nuclear 
factor kappa B (NF-κB) (Jakacka et al. 2002, Marino et al. 2006). This ER-indirect 
DNA association transcribes roughly 35% of the categorized human primary          
E2-responsive genes (O'Lone et al. 2004). 
2.4.2.2 Rapid estrogen signalling 
Various studies could demonstrate that classic estrogen receptors may be involved 
not only in classical steroid action, but also in rapid non-genomic steroid effects. 
Such a receptor is most often localized to the plasma membrane and is structurally 
similar to the classic intracellular estrogen receptors mentioned above       
(Falkenstein et al. 2000, Hammes and Levin 2007). The rapid signalling can be 
inhibited by classic ER antagonists like tamoxifen or ICI-182,780                       
(Lantin-Hermoso et al. 1997). 
Clarke et al. (2000) could supply evidence for the existence of ERα in close proximity 
to the plasma membrane in isolated fetal rat hippocampal neurons                    
(Clarke et al. 2000). Other studies demonstrated that these receptors can be located 
in the cell membrane with epitopes exposed on the outer surface                    
(Pappas et al. 1995). Whether ERs span the plasma membrane or contain an 
extracellular ligand binding region is still controversial (Levin 2005). Alternatively, 
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evidence exists for ERβ within isolated caveolae vesicles shorn from the plasma 
membrane of cultured endothelial cells (Chambliss et al. 2002). 
Binding of 17βEstradiol (E2) activates various rapid signalling pathways which could 
be classified into four main signalling cascades, presenting numerous interactions 
with several other pathways (Marino et al. 2006): 
1) Phospholipase C/protein kinase C 
2) Ras/Raf/MAPK 
3) Phosphatidyl inositol 3 kinase (PI3K)/AKT 
4) cAMP/protein kinase A 
These signals subsequently mediate the posttranslational modification of many 
proteins, leading to rapid enzyme induction and modulation of cell functions, mainly 
by phosphorylation (Levin 2005). The activation of these signalling pathways by E2 is 
cell type-specific and depends on a number of conditions such as the set of signal 
transduction molecules and downstream targets in the target cell, thus the responses 
are likely to be diverse (Marino et al. 2006). The fact that estrogen effects are 
triggered outside the nucleus does not mean that gene expression is not affected. 
Actually, the rapid activation of signalling cascades such as those involving 
MAPKinase, as well as the generation of second messengers such as cAMP, cGMP 
and intracellular Ca2+, regulates the activation of transcription factors such as cAMP 
response element-binding protein (CREB) and nuclear factor of activated T-cells 
(NFAT), thereby regulating gene expression (Ropero et al. 2006). This implies that 
the regulation of gene expression by estrogen has both genomic and non-genomic 
inputs, and that the balance of these inputs may vary in a cell- and gene-specific 
manner (Madak-Erdogan et al. 2008). It seems like ERα is the main endogenous 
mediator of rapid estrogen actions and less is known about the role of ERβ in rapid 
non-genomic mechanisms although several studies indicate that ERβ could also 
originate cell-specific signal transduction cascade (Geraldes et al. 2003,           
Marino et al. 2006). 
2.4.2.3 Non-classical estrogen receptors 
In the last years, other estrogenic effects have been described through membrane 
receptors other than ERα and ERβ and therefore were named “non-classical 
membrane estrogen receptors” (ncmER). Some of them have been molecularly 
characterized and defined as new membrane estrogen receptors, such as the orphan 
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G protein-coupled seven-transmembrane receptor 30 (GPR30) (Ropero et al. 2006) 
which is suggested to work as a cell surface receptor, activating G proteins after 
stimulation through E2 (Filardo and Thomas 2005). It is assumed that GPR30 is 
redistributed from the plasma membrane to cathrin-coated vesicles after stimulation 
with E2 (Filardo et al. 2007). Moreover, it is reported that GPR30, additionally to its 
appearance in the plasma membrane, localizes in both the endoplasmic reticulum 
and Golgi apparatus (Revankar et al. 2005). But this fact needs to be evaluated 
carefully because expression of exogenous genes often leads to an accumulation in 
the endoplasmic reticulum. Additionally, the use of insufficiently specific antibodies 
might be the reason for confusion concerning the localization of GPR30. The 
biological functions of GPR30 are mainly attributed to the immunological and 
circulatory system as well as to glucose homeostasis and colon functions     
(Mizukami 2010). The official new acronym is G-protein coupled estrogen receptor 1 
(GPER), due to its action as an estrogen receptor (Maggiolini and Picard 2010). The 
high concentrations of E2 needed for the activation of GPR30 raise the question, 
whether these concentrations are physiological in living animals, or whether another 
physiological ligand is present in cells (Mizukami 2010). The current knowledge 
about this receptor in terms of its contributions to physiological as well as 
pathological estrogen responses is yet very little and needs to be further investigated 
(Maggiolini and Picard 2010). 
2.4.3 Role of estrogen in glucose homeostasis 
Estrogens were known to be involved in energy balance and glucose metabolism for 
a long time and several studies have reported on the potential relationship between 
E2 and glucose metabolism in physiological and pathological states with variability in 
E2 levels, such as menstrual cycle, gestation, gestational diabetes mellitus and 
polycystic ovarian syndrome (PCOS) (Barros et al. 2006a). In aromatase knock-out 
mice (ArKO), estrogen cannot be produced and as a consequence, both male and 
female ArKO mice show reduced glucose oxidation accompanied by obesity and 
increased insulin levels, eventually leading to diabetes mellitus (Heine et al. 2000, 
Jones et al. 2000). Moreover, it could be demonstrated that the lack of estrogen in 
male ArKO mice after 12 weeks of age, can lead to glucose intolerance and insulin 
resistance, accompanied by an increase of body weight. These effects can be 
reversed by estrogen treatment (Takeda et al. 2003). In humans, all patients with 
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aromatase deficiency, based on a point mutation in the aromatase gene, show an 
impairment of glucose metabolism and insulin resistance (Zirilli et al. 2008). On the 
other hand, high concentrations of E2, such as in oral contraceptives or estrogen 
replacement therapy, are related to insulin resistance and the development of 
diabetes mellitus (Godsland 2005). 
With the development of ERα (αERKO) and ERβ (βERKO) knockout mice, it could be 
demonstrated that ERα and ERβ both participate in the regulation of many processes 
related to the control of energy homeostasis. Nevertheless, evidence points to ERα 
as the main mediator (Ropero et al. 2008b). ERα is involved in glucose metabolism in 
different tissues, including skeletal muscle, adipose tissue, liver, brain and endocrine 
pancreas (Barros et al. 2009). Both female and male αERKO mice exhibit profound 
insulin resistance, impaired glucose tolerance and adipocyte hyperplasia as well as 
hypertrophy (Bryzgalova et al. 2006, Heine et al. 2000). To understand the role of 
ERβ in glucose homeostasis, αERKO mice were ovariectomized to remove the action 
of E2 on ERβ. Such mice showed improved glucose and insulin metabolism, 
indicating that ERβ activation might have a diabetogenic effect and therefore ERβ 
may oppose the action of ERα (Naaz et al. 2002). 
2.4.4 Effects of estrogen on pancreas 
In pancreatic tissue there exist different expression profiles of receptors for the three 
different types of sex steroid hormones (estrogens, progestagens and androgens). 
Moreover, specific enzymes involved in the synthesis of sex steroid hormones are 
present (Robles-Diaz and Duarte-Rojo 2001).  
It could be demonstrated that both ERα and ERβ are existent in pancreatic β-cells.  
Long-term exposure to 17β-estradiol (E2) in physiological concentrations can lead to 
an increase of β-cell insulin content, insulin gene expression and insulin release, yet 
pancreatic β-cell mass is unaltered. Studies, using synthetic selective estrogen 
receptor modulators (SERMs) such as propyl-pyrazole-triol (PPT) for ERα and 
diarylpropionitrile (DPN) for ERβ as well as studies in αERKO and βERKO mice 
suggest that ERα is the estrogen receptor responsible for these effects            
(Alonso-Magdalena et al. 2008).  
Further, the existence of an estrogen membrane receptor in pancreatic β-cells was 
demonstrated, which is responsible for the rapid insulinotropic effect of E2 when it is 
applied in physiological concentrations (Alonso-Magdalena et al. 2006,                
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Nadal et al. 1998). This non-classical membrane estrogen receptor (ncmER) has a 
completely different pharmacological profile as compared to ERα and ERβ. It does 
not bind the antiestrogen ICI182,780, but binds catecholamines with a similar profile 
to the so-called gamma-adrenergic receptor (Nadal et al. 2000). By binding to this 
receptor, estrogen can increase insulin secretion from pancreatic β-cells              
(Nadal et al. 1998).  
2.4.4.1 Impact of estrogen on pancreatic insulin content 
Estrogen is known to influence β-cell function by an increase of pancreatic insulin 
production, leading to a release of higher amounts of insulin granules after glucose 
stimulus (Alonso-Magdalena et al. 2006, Marban et al. 1989). 
Effects of 17βEstradiol on blood glucose homeostasis can be imitated by the 
widespread environmental contaminant Bisphenol-A (BPA) that acts through both a 
rapid non-classical pathway and a classical estrogen receptor pathway           
(Alonso-Magdalena et al. 2006). BPA is a plasticizer, mainly used to manufacture 
polycarbonate plastic and as an additive in other widely used plastics such as 
polyvinylchlorid (PVC) and polyethylenterephthalat (PET) (Ropero et al. 2008a). The 
exposure of adult mice to a single dose of either E2 or BPA rapidly increases plasma 
insulin, leading to a decrease of blood glucose concentration through a non-classical 
pathway. This is unaffected by the antiestrogen ICI and is most likely initiated by the 
ncmER. Longer exposure to BPA and E2 increases β-cell insulin content, an effect 
that is completely blocked by ICI and therefore likely involves the classical ER 
pathway (Alonso-Magdalena et al. 2006). It could also be demonstrated that this 
long-term action is mediated by the estrogen receptor ERα. It is unlikely that ERα 
operates via estrogen response elements (ERE), because ERE has not been 
described in the promoters of mouse insulin genes (Alonso-Magdalena et al. 2008). 
E2 can also work via alternative pathways, triggered outside the nucleus, likely 
through other transcription factors binding to their respective response elements, 
involving phosphatidylinositol 3-kinase (PI3K) or extracellular-regulated kinases 
(ERK) activation (Nadal et al. 2005, Ropero et al. 2006). It is documented that insulin 
gene transcription is regulated by ERK1/2 which are essential in glucose-stimulated 
insulin gene transcription by phosphorylating the transcription factors Neuro-D1 and 
pancreatic and duodenal homeobox 1 (PDX-1), which directly activate the insulin 
promoter (Khoo et al. 2003). ERα rapidly associates with the tyrosine kinase Src in  
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β-cells, then activating ERK1/2. E2-induced insulin expression occurs predominantly 
at physiological stimulatory glucose concentrations, suggesting that E2 amplifies the 
glucose signal (Wong et al. 2010) (Figure 2.4). 
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Figure 2.4: Proposed mechanism of E2 amplification of insulin gene transcription 
ERα-induced insulin transcription involves NeuroD1 binding to the insulin promotor through 
phosphorylation of ERK1/2 (modified according to Wong et al. 2010). 
 
 
The E2-induced increase in insulin content and secretion would be beneficial when it 
occurs during an appropriate period of time and at doses within the physiological 
range like it may happen during pregnancy. However, if this estrogenic action occurs 
at an inappropriate time, or at doses out of the physiological levels, it may cause 
adverse effects. Longer E2-exposure can generate chronic hyperinsulinaemia in the 
fed state and peripheral insulin resistance as indicated by altered glucose and insulin 
tolerance tests. However, the extent of insulin resistance induced by E2-treatment is 
not enough to induce hyperglycaemia in the fasted state                         
(Alonso-Magdalena et al. 2006). It is also known in humans that the persistence of 
chronic physiologic euglycaemic hyperinsulinaemia for 3–5 days can induce severe 
insulin resistance in healthy subjects with normal glucose tolerance                       
(Del Prato et al. 1994). Whether insulin resistance precedes hyperinsulinaemia or 
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hyperinsulinaemia precedes insulin resistance in the development of type 2 diabetes 
is controversial. The only clear conclusion is that both seem to walk hand in hand 
(Prentki et al. 2002). 
Beside this, the direct effect of Bisphenol A on peripheral tissue (e.g. down-regulation 
of GLUT4 transporters in adipose tissue as well as the favoured conversion of 
fibroblasts to adipocytes with an enhanced risk for obesity) might also be of 
importance to developing insulin resistance (Alonso-Magdalena et al. 2006). 
2.4.4.2 Enhancement of insulin secretion by estrogen 
Beta-cells are electrically excitable and electrical activity consists of oscillations in the 
membrane potential. Glucose metabolism increases the intracellular ATP/ADP ratio, 
leading to the closure of ATP-regulated K+ (KATP) channels (Rorsman et al. 2000), 
thereby inducing membrane depolarisation, opening of voltage-operated              
Ca2+ channels and Ca2+ influx (Valdeolmillos et al. 1992). As a consequence, a 
[Ca2+]i oscillatory pattern is originated triggering a pulsatile insulin secretion        
(Gilon et al. 1993, Nadal et al. 1999).  
By binding to a gamma-adrenergic membrane receptor, E2 can trigger the synthesis 
of cGMP, which in turn activates protein kinase G (PKG). PKG can induce the 
closure of ATP-dependent potassium channels (KATP) by a phosphorylation-
dependent process, leading to plasma membrane depolarisation                     
(Ropero et al. 1999). The maximum effect is reached 3 to 7 minutes after estradiol 
application and the effect is transient, returning to normal levels 30 minutes later 
(Alonso-Magdalena et al. 2010). Plasma membrane depolarisation increases the 
frequency of [Ca2+] oscillations and due to this, an enhanced insulin secretion (rapid 
insulinotropic effect) occurs when estradiol is applied along with a stimulatory 
glucose concentration. A minor participation of cAMP as a second messenger in 
addition to cGMP in this process cannot be completely ruled out (Ropero et al. 1999). 
Moreover, latest studies could demonstrate that GPR30-specific ligand G-1 
stimulated insulin release and inhibited glucagon and somatostatin release in a 
manner almost identical to 17βEstradiol, inducing an increase of cAMP content in 
parallel with an amplified insulin release, but the intracellular signalling following the 
activation of GPR30 in the different islet cells is far from being elucidated      
(Balhuizen et al. 2010) (Figure 2.4). 
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Worth to mention is the fact that such an ncmER not only exists in pancreatic β-cells, 
but in α-cells as well. When E2 acts through this receptor in α-cells, it inhibits [Ca2+]i 
oscillations induced at low glucose concentrations and therefore abolishes glucagon 
release (Ropero et al. 2002). 
An additional rapid effect of BPA and E2 on isolated islet cells is the increased 
activation of the ubiquitous transcription factor CREB (Quesada et al. 2002). This 
effect may be of great importance for the β-cell physiology, since CREB activation 
induces insulin gene expression and is implicated in β-cell survival                      
(Jhala et al. 2003).  
 
                           
Figure 2.5: Proposed model for the action of 17βEstradiol and bisphenol-A (BPA) in β-
cells 
In synergy with a stimulatory glucose concentration, binding of BPA or 17βEstradiol to a membrane 
ER activates a guanylyl cyclase (GC) and as a consequence a protein kinase G (PKG), whose action 
involves the closing of KATP channels. The subsequent depolarization opens L-type calcium channels; 
inducing Ca
2+
 influx and potentiating insulin release. At the same time the activation of ERα by either 
E2 or BPA in the presence of stimulatory glucose levels rapidly activates ERK1/2 that regulates insulin 
gene expression through a still unknown pathway (modified according to Nadal et al. 2009). 
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2.4.5 Effects of estrogen on skeletal muscle, adipose tissue and liver 
2.4.5.1 Insulin sensitivity and insulin resistance 
Insulin action in insulin dependent tissues like skeletal muscle, adipose tissue and 
liver involves the tyrosine phosphorylation of intracellular substrates, thereby 
transmitting the insulin signal (White and Kahn 1994). Insulin receptor substrate 1 
(IRS-1) is considered the major substrate for the insulin receptor (Sun et al. 1992). 
The level of tyrosine kinase activity reflects the serum concentration of insulin and 
appears to mediate the insulin response (DeFronzo et al. 1992). It could be shown 
that estrogen can induce the expression of the downstream signalling molecules  
IRS-1 and IRS-2 (Lee et al. 1999). Moreover, it is known that IRS-1 promoter does 
have four consensus half-estrogen response elements (Kato et al. 1992). 
When plasma concentration of 17βEstradiol is low, like it is seen in early pregnancy, 
IRS-1 is up-regulated by a transcriptional mechanism and insulin sensitivity increases 
in peripheral tissues. However, when the concentration of E2 is high, like it is found in 
late pregnancy, the binding of many complexes of ER-estradiol to the IRS-1 promoter 
could induce a decrease in IRS-1 expression, probably by displacement of other 
transcription factors linked to the IRS-1, leading to diminished insulin sensitivity in 
peripheral tissues (Gonzalez et al. 2001). IRS-1 knockout mice develop insulin 
resistance due to impaired insulin signalling in skeletal muscle and adipose tissues, 
but they do not develop diabetes mellitus due to islet hyperplasia and 
hyperinsulinaemia. In contrast, IRS-2 knockout mice are unable to increase their      
β-cell mass sufficiently to fulfill the increased insulin requirement, and they develop 
severe diabetes mellitus (Withers et al. 1998). Further, it is suggested that E2 
treatment employs a common mechanism (such as induction of IRS-2 expression 
through the activation of CREB (Jhala et al. 2003)) that improves β-cell function and 
subsequently reverses insulin resistance. Elevated levels of IRS-2 can potentiate an 
insulin signalling cascade, leading to increased β-cell proliferation and decreased 
apoptosis (Choi et al. 2005).  
Moreover, estrogens have been shown to increase hepatic insulin sensitivity by 
decreasing gluconeogenesis and glycogenolysis in ovariectomized mice         
(Ahmed-Sorour and Bailey 1981). It is proposed that hepatic insulin resistance 
results from the upregulation of lipogenic genes via the suppression of Leptin 
receptor expression (Bryzgalova et al. 2006). 
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2.4.5.2 Modulation of GLUT4 expression by estrogen 
ERα and ERβ are expressed in all tissues involved in glucose homeostasis but have 
different roles in its regulation. In skeletal muscle as well as in adipose tissue, insulin 
stimulates glucose uptake by inducing the expression of GLUT4 (glucose transporter 
4) (Gould and Holman 1993). GLUT4 belongs to a family of glucose transporters that 
include 12 members from which only GLUT4 responds to insulin                        
(Wood and Trayhurn 2003). The uptake of glucose in muscle cells is responsible for 
75% of the whole-body glucose uptake (Bjornholm and Zierath 2005). Estrogen 
receptor α and β are co-expressed in skeletal muscle where they have opposing 
effects on modulation of GLUT4 expression. ERα is a positive regulator of GLUT4 
expression while ERβ has a suppressive role. Therefore the effect of estrogen 
depends on the balance between the two receptor isoforms (Barros et al. 2006b). 
Tamoxifen (Tam) is a non steroidal selective ER modulator (SERM) that binds to 
both ERs with high affinity, causing agonist or antagonist actions in a tissue-specific 
way (Jensen et al. 2003). In skeletal muscle, ERβ is predominant and blocking of 
ERβ by tamoxifen (Tam) in αERKO mice increased GLUT4 expression, whereas 
blocking of ERα by Tam in βERKO mice had very small effects on GLUT4 
expression. In white adipose tissue, ERα is predominant and may regulate GLUT4 
expression through peroxisome proliferator-activated receptor gamma 2 (PPARγ2). 
The loss of ERα as well as treatment of βERKO mice with TAM decreased GLUT4 
expression and diminished glucose uptake. In the liver, ERα is predominant and has 
an important role in the regulation of genes involved in glucose metabolism      
(Barros et al. 2009).  
2.4.6 Positive effects of estrogen on oxidative stress and apoptosis 
Disregarding the causal events, in type 1 and the late stages of type 2 diabetes, 
proinflammatory cytokines and/or chronic elevation of blood glucose (glucotoxicity) 
generate oxidative stress in pancreatic islets, which ultimately provokes β-cell death 
by apoptosis (Mathis et al. 2001, Robertson et al. 2003). Estrogen deficient ArKO 
mice are vulnerable to β-cell apoptosis and prone to insulin-deficient diabetes 
mellitus after exposure to streptozotocin (STZ), which augments the generation of 
reactive oxygen species in pancreatic islets, leading to acute oxidative stress         
(Le May et al. 2006). E2 protects β-cells through ERα and ERβ via                      
ERE-independent, extra-nuclear mechanisms, but ERβ plays a minor cytoprotective 
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role compared to ERα. In αβERKO−/− mice and their isolated pancreatic islets, E2 
partially prevents apoptosis, suggesting that an alternative pathway compensates for 
ERα/ERβ deficiency. This pathway seems to be G-protein coupled estrogen receptor 
1 (GPER)-dependent, due to the fact that a selective GPER agonist can improve islet 
survival, and GPERKO−/− mice are susceptible to streptozotocin-induced insulin 
deficiency. It could also be shown that cytoprotection by E2 is impaired in            
ERα-deficient islets and can be compensated, only partially, by GPER or ERβ. Thus, 
ERα is the major E2 receptor to favour islet survival in mice (Liu et al. 2009). 
Moreover it could be shown that estrogens do have antioxidant effects by both up-
regulation of the expression of the superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) gene. This is mediated by interaction with classical estrogen 
receptors α and/or β, located at the plasma membrane, but a direct genomic effect of 
estradiol is unlikely because neither superoxide dismutase nor glutathione 
peroxidase have estrogen responsive elements in their promoter region. The action 
of estradiol is suggested to be mediated via intracellular signalling cascades: After 
binding of estrogen to its membrane receptor, mitogen activated protein kinases 
(MAPK) are activated by phosphorylation, which in turn activates nuclear factor 
kappa B (NF-κB). As a consequence, NF-κB up-regulates the expression of the SOD 
and GPx genes, whose promoters contain putative NF-κB-binding motifs              
(Viña et al. 2005). 
Recent studies could demonstrate, that 17βEstradiol can modulate apoptosis in 
pancreatic β-cells dependent on expression of sulfonylurea receptor 1 (SUR1), which 
obviously can act as a “non-classical” estrogen receptor (Ackermann et al. 2009). 
SURs are known to be regulatory subunits of ATP-sensitive potassium channels 
(KATP channels) (Ashcroft 2007). The isoform SUR1 is the regulatory subunit of 
pancreatic ATP-sensitive K+-channels and E2 treatment can modulate β-cell 
apoptosis under specific involvement of SUR1. Moreover, an age-dependent 
difference in apoptotic and anti-apoptotic effects of E2 could be demonstrated.           
A clear apoptotic effect is likewise found in elderly mice (20-32 week-old), whereas 
clear anti-apoptotic effects were observed in young mice (5-7 week-old)    
(Ackermann et al. 2009).  
Furthermore it is suggested that activation of c-Jun N-terminal kinase (JNK) is the 
signal transducer for oxidative stress as well as for toxicity of proinflammatory 
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cytokines (PICs) to β-cells (Ammendrup et al. 2000). PICs, such as tumor necrosis 
factor-α (TNF-α), interleukin-1β (IL-1β), and interferon-γ (IFN-γ), cause islet 
dysfunction, apoptosis, and induce the expression of the cytokine inducible            
NO synthase, which results in intracellular NO synthesis in β-cells                      
(Eizirik and Mandrup-Poulsen 2001). A number of transcription factors regulated by 
JNK, including c-Jun, c-Fos, c-myc and activating transcription factor 2 (ATF-2), have 
been implicated with the onset of apoptosis (Eckhoff et al. 2003). It could be 
demonstrated that estrogen reduces the production and effects of PICs by blocking 
JNK activity and the resulting phosphorylation of c-Jun and JunD. The consequent 
decrease in the nuclear levels of c-Jun and JunD leads to diminished binding of       
c-Jun/c-Fos and JunD/c-Fos heterodimers to the activator protein 1 (AP-1) 
consensus sequence in the TNF promoter and, thus, to decreased transactivation of 
the TNF gene (Srivastava et al. 1999). 
2.4.7 Role of estrogen in endoplasmic reticulum stress 
ER-stress triggers the initially protective unfolded protein response (UPR), an 
adaptive endoplasmic reticulum signalling pathway that allows cells to survive the 
accumulation of unfolded proteins in the endoplasmic reticulum lumen              
(Zhang and Kaufman 2006). Although the UPR is initially a compensatory 
mechanism by which cells can reset normal endoplasmic reticulum function, 
prolonged UPR will induce cell death (Gomez et al. 2007). Induced by cellular 
stressors, UPR can be initiated by each of three molecular sensors, i.e., insulin-
response-element 1 (IRE1), activating transcription factor 6 (ATF6), and PKR-like 
endoplasmic reticulum kinase (PERK) (Araki et al. 2003). Splicing of X-box binding 
protein 1 (XBP-1) by IRE1 is an obligate component in both IRE1- and ATF6-induced 
UPR. XBP-1 mRNA has been shown to be unconventionally spliced by IRE1 in 
response to endoplasmic reticulum stress, resulting in production of a highly active 
transcription factor (XBP-1(S)) that can activate the mammalian unfolded protein 
response (Yoshida et al. 2001). Trauma-hemorrhage (T-H) and resuscitation have 
been shown to induce ER-stress (Jian et al. 2008). In an experiment with 6- to         
8-week-old rats it could be demonstrated that XBP1(S) is increased at the end of the 
shock phase in trauma-hemorrhage, two hours after removal of 62% of the circulating 
blood volume. Administration of 17βEstradiol after T-H decreased the level of         
XBP-1(S) in shock animals. A similar picture was observed for C/EBP homologous 
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protein (CHOP) expression at mRNA level, showing a significantly elevated 
expression in the T-H group but not in the T-H + E2 group. It must be mentioned that 
all of these effects appeared to be liver-specific and were not observed in the kidney 
(Kozlov et al. 2010). 
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3 Research design and methods 
3.1 Research design 
The study consisted of two subsequent parts. The first part (Group 1) was designed 
to find out, if ovariectomy has any effects on glucose homeostasis, histological as 
well as quantitative stereological parameters of the pancreas. For this purpose,        
11 female Munich Ins2C95S mutant mice were ovariectomized and 10 mutant and      
11 wild-type females were sham-operated.  
The second part (Group 2) was accomplished to study the effects of estradiol-
replacement therapy in ovariectomized mutant mice. This second test group included 
placebo-treated ovariectomized, placebo-treated sham-operated and estradiol-
treated ovariectomized female Munich Ins2C95S mutant mice as well as placebo-
treated sham-operated wild-type mice (n=9 per group). 
For most of the accomplished tests, non-treated (nt) mice of Group 1 and the 
accordant placebo-treated (p) mice of Group 2 were pooled (nt/p). 
3.2 Materials and methods 
3.2.1 Animals 
Munich Ins2C95S mutant mice were generated within the Munich N-ethyl-N-nitrosurea 
(ENU) mouse mutagenesis project. Male heterozygous mutants were bred onto a 
C3HeB/FeJ genetic background. 
Animals received standard rodent diet (Altromin C1324, Germany) and tap water ad 
libitum. They were housed in a temperature- and light-controlled room (21 - 23°C,   
55 ± 3 % relative humidity, 12 hours light : 12 hours dark cycle). At the age of          
21 days, mice were weaned, separated depending on sex, and marked by ear 
perforation. Tail tip biopsies for genotyping were taken, and blood glucose 
concentrations were measured. 
At the age of 30 days 29 female heterozygous mutant mice were ovariectomized (mt-
ovx-nt/p), 19 female heterozygous mutant mice (mt-sham-nt/p) and 20 wild-type mice 
(wt-sham-nt/p) were sham-operated. Nine ovariectomized female mutants (mt-ovx-
E2) of Group 2 received 17βEstradiol supplementation by implanting a subcutaneous 
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17βEstradiol long-term pellet subsequent to ovariectomy still under anaesthesia and 
the remaining 27 mice of Group 2 received a placebo-pellet. Serum was collected at 
intervals of at least 50 days starting at the age of 65 days to examine serum estradiol 
levels. Regular clinical examinations were carried out, starting with 20 non-/placebo-
treated sham-operated wild-type, 20 non-/placebo-treated ovariectomized mutant,   
19 non-/placebo-treated sham-operated mutant and 9 estradiol-supplemented 
ovariectomized mutant mice. At the age of 25, 50, 90 and 180 days, oral glucose 
tolerance tests (OGTTs) were carried out and serum insulin levels were determined 
before and 10 minutes after glucose challenge. Intraperitoneal insulin tolerance tests 
(ipITTs) were performed at the age of 60, 100 and 187 days. At the age of 190 days, 
35 animals (11 wt-sham-nt/p, 10 mt-ovx-nt/p, 10 mt-sham-nt/p and 4 mt-ovx-E2) were 
exsanguinated under general anaesthesia and finally killed by cervical dislocation for 
qualitative histological and quantitative stereological analyses of the pancreas. The 
remaining 31 animals (9 wt-sham-nt/p, 10 mt-ovx-nt/p, 9 mt-sham-nt/p and 3 mt-ovx-
E2) were also exsanguinated under general anaesthesia at the age of 210 days and 
finally killed by cervical dislocation. The islets were isolated and assayed in respect 
of ER-stress via Western blot analyses. From both groups the collected serum was 
assayed in order to examine serum estrogen concentrations as well as serum 
oxidative stress markers (TBARS levels). The number of animals used in the distinct 
examinations is stated in table 3.1. All experiments were performed under the 
approval and in accordance with the guidelines of the responsible animal welfare 
authority (AZ 55.2-1-54-2531-94-07). Further information about companies, from 
whom chemicals and other materials were purchased, is listed below (Companies 
and materials). 
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Table 3.1: Number of animals investigated in distinct tests 
Group 1 Group 2 
Investigations after 
weaning mt ovx 
nt 
mt sham 
nt 
wt sham 
nt 
mt ovx  
p 
mt sham 
p 
mt  ovx 
E2 
wt sham 
p 
genotyping 11 10 11 9 9 9 9 
body weight 11 10 11 9 9 9 9 
blood glucose 11 10 11 9 9 9 9 
OGTT                               
50 d                                  
90 d                                
180 d 
              
8            
8            
8 
              
7             
7             
7 
              
9          
10         
10 
              
7           
7            
7 
              
7            
7            
7 
              
7            
7            
5 
              
6            
6            
6 
Insulin, serum                           
50 d                                   
90 d                                 
180 d 
              
3            
8            
8 
              
3             
6             
7 
              
6            
9          
10 
              
3            
7            
7 
              
2             
6             
7 
              
2            
5            
5 
              
6            
6            
6 
ipITT                                 
50 d                                   
90 d                                 
180 d   
              
8            
8            
8 
              
7             
7           
7 
              
10          
10         
10         
Estradiol, serum               
65 d                                
110 d                               
160 d                               
190 d 
              
2            
2            
5            
2 
              
0            
3            
4            
1 
              
6            
4            
6            
4 
              
8            
8            
9            
5 
              
8            
9            
9            
4 
              
9            
9           
7            
4 
              
8            
9            
6            
5 
TBARS, serum                 
190 d                             5 5 5 5 5 4 5 
Pancreas (LM, IHC)  
190 d 5 5 6 5 5 4 5 
Pancreas (LM and TEM) 
190 d        3 3  2  3  
ER-stress, Apoptosis and 
Cell proliferation, islets               
210 d 6 5 5 4 4 3 4 
wt: wild-type mice; mt: mutant mice; ovx: ovariectomized mice; sham: sham-operated mice; nt: non-
treated mice; p: placebo-treated mice; E2: 17βEstradiol supplemented mice;  
d: days of age; OGTT: oral glucose tolerance test; ipITT: intra peritoneal insulin tolerance test; 
TBARS: thiobarbituric acid reactive substances; ER: endoplasmic reticulum; LM: light microscopy; 
IHC: immunohistochemistry; TEM: transmission electron microscopy 
 
3.2.2 Genotyping 
The genotype of mice was determined by a restriction fragment length polymorphism 
(RFLP) based method as previously described (Herbach et al. 2007). The missense 
mutation in Ins2 creates a new Hpy 188I restriction site which is used for the allelic 
differentiation of Ins2. After DNA amplification with the primers Ins2_5for and 
Ins2_6rev, which are specific for insulin2, and digestion of the 529 bp PCR 
amplificates, wild-type mice show a 521 bp fragment, heterozygous Munich Ins2C95S 
mutant mice show both the 473 bp and the 521 bp fragment, and homozygous 
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mutants demonstrate the 473 bp fragment (Fig. 3.1). Tail tip biopsies of 
approximately 0.3 cm length were taken at weaning and stored at 
-80°C until assayed. For DNA extraction, the tail tip was incubated in 400 µl master 
mix over night in a heating block at 55°C over night. Thereafter, undigested 
components were separated by centrifugation for two minutes at 15,000 rpm. The 
supernatant was poured into an Eppendorf cup. To precipitate DNA, 400 µl 
isopropanol (neoLab, Germany) were added. The DNA pellet was washed three 
times with 400 µl 70% EtOH (Merck, Germany), the liquid phase was discarded and 
the DNA pellet was dried at room temperature. DNA was suspended in 30 - 150 µl 
1*TE buffer, according to the size of the DNA pellet. To make sure that the DNA was 
dissolved completely, it was stored at 4°C for at least 24h before proceeding with the 
PCR. 19 µl of the PCR master mix and 1 µl of the suspended DNA were mixed 
carefully in PCR analysis cups (Eppendorf, Germany), before starting the PCR-
program in a Mastergradient thermocycler (Eppendorf, Germany). PCR-H2O served 
as quality control. If needed, PCR samples were stored at -20°C until further use. 
Enzymatic digestion took place in a thermocycler (Eppendorf; 37°C, 30 minutes), 
using 9 µl of the amplified DNA sample, and 11 µl of restriction enzyme master mix. 
After enzymatic digestion, 4 µl of loading dye was added to each sample before 
being transferred into the sample wells of a 2 % agarose gel. The gel was positioned 
in an Easy Cast™ gel chamber (PeqLab, Germany) and filled with 1*TAE running 
buffer. At the beginning of the row 12 µl pUC Mix Marker 8 (MBI Fermentas, 
Germany) was placed in a well in order to allow estimation of amplified fragment size. 
Electrophoresis was run at 65 volt for the first 15 minutes, afterwards at 110 volt for 
about 100 minutes (PowerPac 300, Bio-Rad, USA). The gel was stained in an 
ethidium bromide solution (Roth, Germany) for 20 minutes. The amplified products 
were visualised (Universal Hood, Bio-Rad, USA) under UV light (306 nm), and a 
digital picture was taken to document the result. 
Materials 
Master Mix for DNA isolation 
 Cutting Buffer 375 µl 
 20% SDS (Roth, Germany)  20 µl 
 Proteinase K (20 mg/ml)  5 µl 
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Cutting buffer 
 1 M Tris/HCl, pH 7.5 (Roth, Germany) 2.5 ml 
 0.5 M EDTA, pH 8.0 (Sigma, Germany) 5.0 ml 
 5 M NaCl (AppliChem, Germany) 1.0 ml 
 1 M DTT (Roth, Germany) 250 µl 
 Spermidine (500 mg/ml, Sigma, Germany) 127 µl 
 ad 50 ml aqua bidest;  stored at 4°C 
 
TE buffer 
 10 mM Tris/HCl, pH 8.0 (Roth, Germany) 
 1 mM EDTA (Sigma, Germany) 
 
PCR master mix: Taq PCR Master Mix Kit (Quiagen, Germany) 
  10x Buffer: 2 µl 
  MgCl2: 1.25 µl 
  Q-solution: 4 µl 
  Taq polymerase: 0.1 µl 
  Redistilled water: 8.65 µl 
  dNTP 1 mM (Eppendorf, Germany):  1 µl 
  Primer sense (Ins2_5for): 1 µl 
  Primer antisense (Ins2_6rev): 1 µl 
  Primer concentration 2 µM each 
  (Genzentrum/DNSynthese, Germany; primer sequences: 
  Ins2_5for: 5’-TGA CCT TCA GAC CTT GGC AC-3’ 
  Ins2_6rev: 5’-TAG CTG CCA TCA CCC ATG CC-3’) 
  all reagents stored at -20°C 
 
Restriction enzyme master mix: 
 Restriction enzyme Hpy 188I (New England BioLabs, UK): 0.8 µl 
 NEBuffer 4 (New England BioLabs, UK): 2.0 µl 
 Redistilled water: 8.2 µl 
 stored at -20°C 
 
Loading dye 6x: 
 Glycerine (Merck, Germany): 3 ml 
 Bromphenol blue (Merck, Germany): spatula tip  
 Redistilled water: 7 ml 
 
Agarose gel, 2%:  
 Agarose (Roth, Germany)  2g 
 dissolved in boiling TAE buffer: 100 ml 
 
Marker:  
 100 bp DNA Ladder (New England BioLabs, UK): 25 µl 
 Loadind dye x6: 25 µl 
 Redistilled water: 100 µl 
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Ethidium bromide solution: 
 Ethidium bromide 1% (Roth, Germany): 100 µl 
 TAE: 1,000 ml 
 
EDTA 0.5 M pH 8.0, stock solution: 
 EDTA (Roth, Germany): 14.89 g 
 Distilled water 80 ml 
 adjust to pH 8.0 with NaOH 5 M (Merck, Germany) 
 
TRIS 1M:  
 Tris base (Roth, Germany): 6.057 g 
 ad 50 ml distilled water;  
 adjust to pH 8.0 with 37% HCl (Merck, Germany) 
 
TAE x 50:  
 Tris base (Roth, Germany):  242 g 
 Glacial acetic acid (Merck, Germany) 57.1 ml 
 EDTA 0.5 M, pH 8.0: 100 ml 
  ad 1,000 ml distilled water 
 
Program for DNA amplification: 
 
1. 94°C, 5 minutes (denaturation, initiation)   
2. 94°C, 45 seconds (denaturation)                           
3. 62°C, 45 seconds (primer annealing)                     
4. 72°C, 90 seconds (elongation) 
34 cycles 
5. 72°C, 10 minutes (final extension)   
hold on 4°C   
 
 
 
 
Figure 3.1: Genotyping via 
polymerase chain reaction (PCR) 
and restriction fragment length 
polymorphism (RFLP) 
After PCR and RFLP analysis, wild-
type mice (2, 7, 10) present DNA 
fragments of 521 base pairs (bp), 
heterozygous mutant mice (1, 3, 4, 5, 
6, 7, 9) exhibit fragments of 473 bp and 
521 bp, homozygous mutants (not 
shown) possess fragments of 473 bp; 
M: marker 
 
M 1 2 3 4 5 6 7 8 9 10 
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3.2.3 Ovariectomy and pellet implantation 
One hour before surgical intervention, each mouse received 10 µl of Metacam® 
solution (15 mg/ml Meloxicam, Boehringer, Germany) per os, using a pipette. 
Analgesia was repeated once a day for at least 5 days. An anaesthetic mixture of 
Medetomidine (0.5 mg/kg body weight, Domitor®, Pfizer, Germany), Midazolam        
(5 mg/kg body weight, Midazolam-Ratiopharm®, Ratiopharm, Germany) and Fentanyl 
(0.05 mg/kg body weight, Fentanyl DeltaSelect®, Delta Select, Germany) was 
injected intraperitoneally with a 30-gauge needle. A dexpanthenol containing 
ointment (Bepanthen®, Roche, Germany) was applied into both eyes. Approximately 
15 minutes after the injection, an area of 2 cm2 was shaved caudal the costal arch on 
either lateral sides of the mouse using an electric shaver. Subsequently the mice 
were placed laterally on a warm base. Once the anaesthesia was in the stage of 
surgical tolerance, shaved skin was disinfected (Softasept®N, Braun, Germany). 
Approximately 1 cm behind the costal arch a cut of about 1 cm length was made 
through the skin with a surgical pair of scissors. After that, the peritoneum was held 
up with a forceps and the abdominal cavity was opened with a cut of about 5 mm 
length. A forceps was inserted into the abdominal cavity, the forceps was closed and 
the ovary was gently retracted. After ligation of the vessels (Monosyn® metric2, 
Braun, Germany), the ovary was removed and fixed in 4% neutral buffered 
formaldehyde solution (SAV LP, Germany). The peritoneum was closed by a 
continuous monofilament absorbable suture (Syneture metric 1.5, Tyco Healthcare, 
UK). Finally, the skin was closed, using 2 or 3 suture clips (Heiland, Gemany). After 
moving the mouse to the other side, the other ovary was removed the same way. 
When the operation was finished, the narcosis was antagonized, by intraperitoneal 
injection of a mixture of Atipamezol (2.5 mg/kg body weight, Antisedan®, Pfizer, 
Germany), Flumazenil (0.5 mg/kg body weight, Anexate®, Roche, Germany) and 
Naloxon (1.2 mg/kg body weight, Naloxon DeltaSelect®, DeltaSelect, Germany). The 
animals were kept under an infrared lamp until complete recovery. Sham-operation 
followed the same procedure as described for the ovariectomized mice, with the 
exception, that the ovaries were retracted, manipulated and placed back into 
physiological position. Directly after ovariectomy/sham-operation, mice of Group 2 
additionally received either a 17βEstradiol longterm pellet (containing 0.18mg E2) or 
a placebo pellet (Innovative Research of America, USA). Therefore an area of about 
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1 cm2 in the mid dorsal region of the mouse was shaved, using an electric shaver 
and the skin was disinfected (Softasept®N, Braun, Germany). A cut of about 0.3cm 
length was made through the shaved and disinfected skin with a surgical pair of 
scissors. Afterwards, a 16-gauge trocar containing the pellet was pushed through the 
skin orifice and the pellet was placed under the skin. Finally skin was closed with one 
suture clip (Heiland, Gemany). 
3.2.4 Body weight 
Body weights of randomly fed mice were determined at least every 4 weeks during 
the investigation period to the nearest 0.1 g, using a precision balance (KERN, 
Germany). 
3.2.5 Blood glucose concentration 
3.2.5.1 Randomly fed mice 
Starting at the age of weaning (21 days), blood glucose levels were measured in     
4-week intervals. Blood samples were taken from the nicked tail tip with a 10 µl open-
end capillary (HITADO, Germany) by softly massaging the tail. The capillary was 
placed into a tube filled with 500 µl haemolysis solution (Glucapil®, HITADO, 
Germany), and blood glucose concentration was determined, using the blood 
glucose analyser SUPER GL® (HITADO, Germany). Blood glucose levels during oral 
glucose tolerance tests and intraperitoneal insulin tolerance tests were evaluated in 
an analogue way. Additionally, the glucose concentration in blood collected from the 
retroorbital plexus of 190- and 210-day-old mice was determined as described 
above. 
3.2.5.2 Fasted mice 
Starting at the age of 50 days, fasting blood glucose levels (fasting from 7 pm until    
9 am) were measured at least every 4 weeks as described above. 
3.2.6 Oral glucose tolerance test (OGTT) 
Glucose tolerance tests were performed at an age of 50, 90 and 180 days. The mice 
were fasted over night for 14 hours, starting at 7 pm. The next morning at 9 am, each 
mouse was placed into an individual cage with tap water access ad libitum. The tail 
tip was nicked, and blood samples were collected to analyse basal blood glucose 
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and serum insulin concentrations. The mice received 11.1 µl of a 1 M glucose 
solution per gram body weight (α-D-Glucose, Sigma, Germany; diluted in tap water) 
into the stomach via gavage tube. Ten minutes after glucose administration, further 
blood samples for determination of blood glucose and serum insulin levels were 
taken. At 20, 30, 60, 90 and 120 minutes, samples for analysing the blood glucose 
concentrations were collected. Blood glucose levels were measured immediately as 
described above (3.2.5). The area under the glucose curve was calculated using the 
program GraphPad Prism 3.0 (GraphPad Software, USA). 
For serum insulin determination, about 100 - 120 µl blood was collected from the tail 
tip, using a 75 µl capillary tube (Hirschmann, Germany). After centrifugation (1K15, 
Sigma, Germany; 10 minutes, 10,000 rpm), serum was removed and stored at -80°C 
until assayed. The area under the blood glucose curve was calculated, using 
GraphPad Prism 3.0. (GraphPad Software, USA). The β-cell function indices 
homeostasis model assessment of baseline insulin secretion (HOMA B) and insulin 
resistance (HOMA IR), were calculated by means of fasting blood glucose and serum 
insulin concentrations according to the following equation (Wallace et al. 2004): 
 
 
 
FSI = Fasting serum insulin (mU/L) 
FBG = Fasting blood glucose (mmol/L) 
 
The quantitative insulin-sensitivity check index (Quicki) (Katz et al. 2000) and the 
fasting glucose-to-insulin ratio (FGIR) (Legro et al. 1998), both useful methods for 
assessing insulin sensitivity, were also calculated by means of fasting blood glucose 
and serum insulin concentrations according to the following equation: 
 
 
 
 
HOMA B = (20 × FSI) / (FBG – 3.5) 
HOMA IR = (FSI × FBG) / 22.5 
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FSI = Fasting serum insulin (mU/L) 
FBG = Fasting blood glucose (mg/dl) 
 
3.2.7 Intraperitoneal insulin tolerance test 
Insulin tolerance tests were performed at an age of 60, 100 and 187 days with mice 
of Group 1. At 2 pm, each mouse was placed into an individual cage with tap water 
access ad libitum. Blood samples were collected from the nicked tail tip to determine 
basal blood glucose levels. Straight after that, 0.75 I.U. insulin per kilogram body 
weight (40 U/ml, Insuman® Rapid, Aventis, Germany; diluted 1:247 in 0.9 % NaCl; 
120 µl injection volume) were injected intraperitoneally, using a 30G x ½” needle. 
Ten, 20, 30, 60 and 90 minutes after insulin application, further blood samples were 
taken for determination of blood glucose concentrations as described above        
(3.2.5 Blood glucose concentration)  
3.2.8 Serum insulin concentration 
The serum insulin concentrations were determined from samples, which were 
collected during OGTT (3.2.6 Oral glucose tolerance test) at the age of 50, 90 and 
180 days. A rat insulin radioimmunoassay kit (Linco Research, USA), which fully 
cross-reacts with murine insulin, was used for the detection. Due to small sample 
volumes (55 - 70 µl serum), the assay was performed using the half amount of 
sample and assay reagents as denoted in the instruction sheet. The assay was 
performed according to the manufacturer’s protocol. Additionally, the difference 
between the insulin levels 10 minutes after glucose application and basal values      
(0 minutes) was calculated. 
3.2.9 Serum estradiol concentration 
The serum 17βEstradiol concentration of 65-, 105-, 160-, 190- and 210-day-old mice 
was determined using an Estradiol ELISA KIT (DRG Instruments GmbH, Germany). 
The assay was performed according to the manufacturer’s protocol. Blood samples 
Quicki = 1 / (log FSI + log FBG 
FGIR = (FBG / FSI)  
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were obtained from the nicked tail tip (65-, 110- and 160-day-old) or the retroorbital 
plexus (190- and 210-day-old) and serum was separated as described above       
(3.2.6 Oral glucose tolerance test). Additional blood glucose determinations were 
performed at the same time points (3.2.5 Blood glucose concentration). 
3.2.10 Serum lipid peroxidation 
Lipid peroxidation in the serum of 190- and 210-day-old mice was examined, using a 
TBARS Assay Kit® (Cayman, USA), according to the manufacturer’s protocol. Mice 
were anaesthetised by intraperitoneal injection of 200 µl of a ketamine/xylazine 
mixture, exsanguinated from the retroorbital plexus and finally killed by cervical 
dislocation. The serum was separated from cellular components via centrifugation 
(1K15, Sigma, Germany; 10 minutes, 10,000 rpm) and stored at -80°C until assayed. 
Serum samples were diluted 1:2 (mt-sham-nt/p, mt-ovx-E2 and wt-sham-nt/p mice) or 
1:4 (mt-ovx-nt/p mice) in HPCL grade water (Applichem, Germany). Blood glucose 
concentrations were measured at the same time points (see 3.2.5 Blood glucose 
concentration). 
Materials 
Narcotics: 
 Ketamine 10% (Selectavet, Germany): 1 ml 
 Xylazine 2% (Rompun 2%, Bayer, Germany): 0.25 ml 
 NaCl 0.9%: 5 ml 
 
3.2.11 Western blot analyses of isolated islets 
For analysis of endoplasmic reticulum stress, islets of 210-day-old mice were isolated 
and examined with regard to the endoplasmic reticulum stress markers BiP/Grp78 
(Binding Ig protein/Glucose regulated protein 78), PeIF2α (phosphorylated eukaryotic 
initiation factor 2α), GADD153/CHOP-10 (Growth arrest and DNA damage 
153/C/EBP-homologous protein 10). For detection of apoptosis and cell proliferation, 
the isolated islets were investigated with regard to the apoptosis marker caspase-3 
and the cell proliferation marker PCNA. Actin was used as loading control. The 
optical density of BiP, PeIF2α, CHOP and PCNA was determined, using ImageJ 
1.41o  and divided by the optical density of actin. 
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3.2.11.1 Islet isolation 
Sixteen mice of Group 1 were euthanized by intraperitoneal injection of 200 µl 
ketamine/xylazine mixture and cervical dislocation. After abdominal incision, the 
bowel was retracted and placed on the right side of the mouse in order to expose the 
pancreas and the bile duct. The small intestine was clamped 1 cm left and right of the 
bile duct orifice with two arterial clamps to exclude collagenase solution efflux into the 
intestine. The bile duct was ligated as close as possible to the liver with a thin string. 
Using a winged infusion set (Venofix®, B.Braun, Germany), the bile duct was 
cannulated via the small intestine, and 2 ml collagenase solution (Sigma, Germany) 
was injected into the pancreas. The pancreas was carefully separated from adjacent 
tissue, and transferred immediately into a 15 ml screw-cap tube, filled with 3.5 ml 
perfusion solution and 1.5 ml collagenase solution. Fifteen mice of Group 2 were 
euthanized the same way as mice of Group 1, but were additionally perfused through 
the left heart ventricle with body warm filtered 0.02% neutral red in 0.9% NaCl at      
60 mmHg, using a perfusion device developed by Dr. Andreas Blutke (German utility 
patent no. DE 202006001542 U1, Figure 3.2). Neutral red selectively stains 
pancreatic islets, exocrine pancreas remains unstained. After opening the chest by a 
pair of scissors, the needle was placed into the left heart ventricle. An incision in the 
inferior vena cava, cranial of the diaphragm provided outflow of the perfusate. After 
neutral red perfusion, collagenase solution was injected into the pancreas as 
described above. Pancreatic tissue was digested for at least 20 minutes up to at 
most one hour in a water bath (GFL, Germany; 37°C) under occasional gently 
agitation. Digested tissue fragments were transferred into a petri dish filled with ice 
cold HANK`s with 0.3% BSA to stop digestion. All reagents and tissues were kept on 
ice during the ongoing procedure steps. Islets were hand picked with an Eppendorf 
pipette under a stereomicroscope (Stemi DV4, Zeiss, Germany; magnification x32) 
and transferred into a 1.5 ml Eppendorf tube. After centrifugation for 1 minute at 
1,000 rpm (1K15, Sigma, Germany), the supernatant was discarded and the islets 
were resuspended in 20-50 µl (1µl/6 islets) of protein extraction buffer.                    
Cell membranes were destroyed by freezing at -80°C, thawing on ice for 30 minutes, 
followed by sonication (7 strokes <1 s each by a Branson sonifier cell disruptor B15 
(Branson Ultrasonic Corporation, USA)), and lysing on ice for another 30 minutes. 
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After centrifugation (5 minutes, 5,000 rpm), the supernatant was separated, and 
stored at -80°C until assayed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Device used for perfusion (A) and Perfusion technique (B). 
A: Perfusion can be performed under adjustable pressure conditions. 
B: Perfusion was performed at a pressure of 60 mm Hg via the left heart ventricle. An incision in the 
vena cava caudalis (indicated) provided outflow of the perfusate (Courtesy of A. Blutke). 
 
Materials 
Anaesthetics 
        desrcibed above (3.2.9) 
0.02% Neutral red solution 
 Neutral red 200mg 
 NaCl 0.9% 1000ml 
 
4x Hank’s solution  
 NaCl (AppliChem, Germany) 16.0 g 
 HEPES (Sigma, Germany) 4.76 g 
 KCl (Roth, Germany) 0.80 g 
 NaHCO3 (Merck, Germany) 0.70 g 
 KH2PO4 (Roth, Germany) 0.12 g 
 Na2HPO4 (Merck, Germany) 0.12 g 
 MgSO4 (Merck, Germany) 0.40 g 
 CaCl2 (Merck, Germany) 0.37 g 
50 ml Falcon  
tube 
14 
gauge          
needle 
60 ml perfusor 
manometer 
air 
tube 
© Blutke 2005 
V. cava 
0.02% neutral 
red in 0.9%  
NaCl 
----- 
----- 
------- 
----    
A B 
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 distilled water 500 ml 
 stored at 4°C 
 
1x Hank’s solution 
 Hank’s 4x 375 ml 
 α-D-Glucose (Sigma, Germany) 0.60 g  
 adjust to pH 7.25 and keep on ice 
1x Hank’s with 0.3% BSA 
 Hank’s 1x 500 ml  
 BSA (Sigma, Germany) 1.5 g 
 
Perfusion solution 
 Hank’s 1x 20 ml 
 CaCl2 1 M (Merck, Germany) 47 µl 
 Hepes 1 M (Sigma, Germany) 500 µl 
 kept on ice 
 
Collagenase solution 
 Perfusion solution 10 ml 
 Collagenase type 1 (#C0130, Sigma, Germany) 20 mg 
 kept on ice  
 
Protein extraction buffer 
 200 mM NaCl/Tris pH 7.6 100 µl 
 Ipegal CA 630 (ICN Biomedicals GmbH, Germany) 5 µl 
 300 mM EDTA 10 µl 
 300 mM EGTA 10 µl 
 100 mM PMSF 10 µl 
 200 mM NaOV 10 µl 
 1M DTT 1 µl 
 25x Complete 40 µl 
 Aqua bidest 814 µl 
 
Stock solutions 
200 mM NaCl/Tris pH 7.6: 
 Tris base(Roth, Germany) 1.58 g 
 NaCl (AppliChem, Germany) 7.31 g 
 dissolved in 30 ml aqua bidest and adjusted to pH 7.6;  
 ad 50 ml aqua bidest 
 
300 mM EDTA: 1.12 g EDTA (Sigma, Germany); ad 10 ml aqua bidest 
300 mM EGTA: 1.41 g EDTA (Sigma, Germany); ad 10 ml aqua bidest 
100 mM PMSF: 17.4 mg PMSF (Sigma, Germany)  
 dissolved in 1 ml isopropanol (Merck, Germany) and stored at -20°C.  
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200 mM NaOV: 0.92 g NaOV (ICN Biomedicals GmbH, Germany)  
dissolved in 20 ml distilled water and adjusted to pH 10 until the solution turns 
yellow. Solutions were reiterated boiled and cooled down on ice until remaining 
clear and of stable pH. After addition of 22.5 ml aqua bidest, the solution was 
aliquoted and stored at -20°C. Prior to use, solutions were boiled for 10 minutes 
on a heating block (Biometra TB1 Thermoblock, Whatman, Germany) to 
remove crystallisation. 
 
1 M DTT: 77.0 mg DTT (Roth, Germany); ad 500 µl aqua bidest 
25x Complete: Complete Protease Inhibitor Cocktail Tablets (Roche, Germany)  
 dissolved according to manufacturer’s instructions 
 
3.2.11.2 Islet protein content 
To evaluate the protein content of islet samples, the Bradford method was applied. A 
protein standard was created by dissolving 10 mg of bovine serum albumin (BSA, 
Sigma, Germany) in 1 ml phosphate buffered saline (PBS). From this initial solution, 
standard concentrations of 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39 and 0.195 µg     
BSA/ml were produced in duplicate by 1:2 dilution in a NUNC™ 96-well Optical 
Bottom Plate (Thermo Fisher Scientific (Nunc GmbH & Co. KG), Germany).           
Two µl sample were added to 198 µl PBS in the first well, and diluted 1:2 in PBS in 
the adjacent 4 wells ending in a 1:16 dilution. The reaction was initiated by addition of 
100 µl 40% Bradford reagent (Bio-Rad, Germany) to each well. After incubation for at 
least 5 minutes, absorbance was determined spectrophotometrically at a wavelength 
of 595 nm using a plate reader (SUNRISE, Tecan, Germany) and the corresponding 
software (Magellan 2, Tecan, Germany). 
Materials 
Phosphate buffered saline (PBS) 
 NaCl (AppliChem, Germany) 7.95 g 
 Na2HPO4 (Roth, Germany) 1.15 g 
 KCl (Merck, Germany) 0.20 g 
 KH2PO4 (AppliChem, Germany)  0.20 g 
 ad 1,000 ml distilled water 
 
Bradford reagent:  
 Bio-Rad Protein Assay 100% (Bio-Rad, Germany): 2 ml 
 Distilled water: 5 ml 
 protected from light and stored at 4°C 
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3.2.11.3 SDS-PAGE 
Islet proteins were separated by SDS-PAGE, using a 10% separating SDS gel (ER-
Stress markers and replication-marker) or a 12% separating SDS gel (apoptosis 
marker). The separating gel solutions were poured into the intercept of 2 glass 
plates, clamped in a Mini-Protean III® gel casting chamber (Bio-Rad, Germany) and 
were immediately covered with isopropanol. After a polymerization period of about  
45 min, the isopropanol was drained and the stacking gel was casted onto the 
separation gel and a 10-well-comb was inserted into the still fluid stacking gel in 
order to create sample wells. After polymerization of the stacking gel, the comb was 
carefully removed, and the gel was placed into an electrophoresis cell (Protean III®, 
Bio-Rad, Germany). The inner cell of the chamber was then filled to the top with 
running buffer and the outer cell was filled up to about 3 cm from the bottom. The 
islet sonicates were diluted creating a protein concentration of 20 µg/20 µl, but at 
least with equal volumes of sample buffer, whereas the maximum final volume did 
not exceed 25 µl. After denaturation of proteins in a thermoblock (TB1, Biometra, 
Germany; 10 minutes, 100°C) samples were loaded into the wells. Furthermore,       
a molecular weight standard (Precision Plus ProteinTM, Bio-Rad, Germany) was 
pipetted  into the first well of the gel and then electrophoresis was run at 200V 
(Biorad PowerPac 300, Bio-Rad, USA) for about 50 minutes.   
Materials 
Reducing sample buffer: 
 Sample buffer, stock solution: 475 µl  
 ß-mercaptoethanol (Sigma, Germany): 25 µl 
 
Sample buffer, stock solution: 
 Tris/HCl 0.5 M, pH 6.8: 1.2 ml 
 SDS 10% (Sigma, Germany): 2 ml 
 Glycerol (Merck, Germany): 1 ml 
 Bromphenol blue 0.05% (Merck, Germany): 0.6 ml  
 Distilled water: 4.8 ml 
 
10%-SDS polyacrylamide gel: 
 Distilled water 2.085 ml 
 Tris/HCl 1.5 M, pH 8.8: 1.25 ml 
 SDS 10% (Sigma, Germany): 50 µl 
 Acrylamide 30% (Roti Phenol®, Roth, Germany): 1.665 ml 
 Ammonium persulfate (APS) 10% (Bio-Rad, Germany): 25 µl 
 Tetraethylethylenediamine (TEMED) (Roth, Germany): 5 µl 
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12%-SDS polyacrylamide gel: 
 Distilled water 1.75 ml 
 Tris/HCl 1.5 M, pH 8.8: 1.25 ml 
 SDS 10% (Sigma, Germany): 50 µl 
 Acrylamide 30% (Roti Phenol®, Roth, Germany): 2 ml 
 Ammonium persulfate (APS) 10% (Bio-Rad, Germany): 25 µl 
 Tetraethylethylenediamine (TEMED) (Roth, Germany): 5 µl 
 
Stacking gel (5%-SDS polyacrylamid gel): 
 Distilled water 1.525 ml 
 Tris/HCl 0.5 M, pH 6.8: 0.625 ml 
 SDS 10%, (Sigma, Germany): 25 µl 
 Acrylamide 30% (Roti Phenol®, Roth, Germany) 0.325 ml 
 Ammonium Persulfate (APS) 10% (Bio-Rad, Germany) 25 µl 
 Tetraethylethylenediamine (TEMED) (Roth, Germany) 5 µl 
 
Tris/HCl 0.5 M, pH 6.8: 
 Tris base (Roth, Germany): 6.057 g 
 ad 100 ml distilled water 
 adjust to pH 6.8 with HCl 37% (Merck, Germany) 
 
Tris/HCl 1.5 M, pH 8.8: 
 Tris base (Roth, Germany): 18.5 g 
 ad 100 ml distilled water 
 adjust to pH 8.8 with HCl 37% (Merck, Germany) 
 
Running buffer, ready to use: 
 Stock solution: 40 ml 
 SDS 10% (Sigma, Germany): 4 ml 
 ad 400 ml distilled water 
 
Running buffer, stock solution: 
 Tris base (Roth, Germany): 30.3 g 
 Glycine (Merck, Germany): 144 g 
 ad 1,000 ml distilled water 
 
3.2.11.4 Western blot 
Following electrophoresis, the gels were covered with a nitrocellulose membrane 
(Schleicher & Schuell, Germany), which had been moistened in Towbin buffer and 
placed between 3 layers of absorbent paper and a fibre pad (both humidified with 
Towbin buffer) each side in a gel holder cassette. Two cassettes were inserted into 
the electrode module which was positioned in the buffer tank (Mini Trans-Blot Cell, 
Biorad, Germany) filled with ice cold Towbin buffer, and contained a frozen cooling 
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unit, and a magnetic stir bar. The whole tank was additionally cooled in a box with 
crushed ice while running the transfer for 90 minutes at 100 volt on a magnetic stirrer 
(IKA, Germany). Subsequently, the membrane was washed in Tris buffered saline-
Tween (TBS-T) for 10 minutes. Finally, silver staining of the gel was done to 
demonstrate blotting success (3.2.11.5 Silver staining and drying). 
Materials 
Towbin buffer 
 Tris base (Roth, Germany) 3.03 g  
 Glycine (Merck, Germany) 14.4 g 
 Methanol (neoLab, Germany) 200 ml 
 Distilled water 800 ml 
 stored at 4°C 
 
Tris buffered saline (TBS), ready to use: 
 TBS, stock solution: 500 ml 
 Distilled water: 4,500ml 
 
Tris buffered saline (TBS), stock solution x10: 
 Tris base (Roth, Germany): 60.6 g 
 NaCl (AppliChem, Germany): 87.6 g 
 ad 1,000 ml distilled water 
 adjust to pH 7.4 with HCl 37% (Merck, Germany) 
 
TBS-T:  
 TBS, stock solution x10: 50 ml 
 Distilled water: 450 ml 
 Tween 20 (Merck, Germany): 250 µl 
 
3.2.11.5 Silver staining and drying 
The SDS gel was incubated for at least 30 minutes in fixation solution and afterwards 
washed 3 times for 20 minutes with 50% ethanol (Merck, Germany). Then it was 
pretreated in sodium thiosulfate solution for one minute before being rinsed with 
distilled water (3 x 20 seconds). Thereafter, it was impregnated for 20 minutes and 
washed (2 x 20 seconds) with distilled water. The gel then was developed under 
visual control until bands appeared. Afterwards it was rinsed for 20 seconds in 
distilled water and then the reaction was stopped with EDTA solution. After 3 times 
washing for 2 minutes in distilled water, the gel was incubated over night (4°C) in 
drying solution on a tumbling shaker. The next day, the first part of the DryEase gel 
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drying frame, (Novex, Germany) was brought into position on a dryer base 
(DryEaseMini-Gel Drying Base, Novex, Germany) and covered with a cellophane 
sheet (DryEase Mini Cellophane, Novex, Germany) which was moistened in drying 
solution for 30 seconds. Then the gel was placed in the centre of the film and another 
moistened cellophane sheet was used to cover the gel. Air blisters and wrinkles were 
carefully removed before closing the gel/cellophane sandwich with the second part of 
the frame with 5 plastic clips. The gel was dried in an upright position for 36 hours in 
a draft-protected place, removed from the frame and placed under a heavy book for 
straightening. 
Materials 
Fixation solution:  
 Ethanol 100% (Merck, Germany): 500 ml 
 Glacial acetic acid (Merck, Germany): 120 ml 
 Formaldehyde 37% (SAV-LP, Germany): 0.5 ml 
 ad 1,000 ml distilled water 
 
Pre-treating solution: 
 (Na2S2O3 ) x 5 H2O (Merck, Germany) 50 mg 
 Distilled water: 50 ml 
 
Impregnation solution: 
 AgNO3 (AppliChem, Germany): 50 mg 
 Distilled water: 50 ml
 Formaldehyde 37% (SAV-LP, Germany): 35 µl 
 
Development solution: 
 Na2CO3 (Merck, Germany): 1.5 g 
 (Na2S2O3 ) x 5 H2O (Merck, Germany): 0.1 g 
 Distilled water: 100 ml 
 Formaldehyde 37% (SAV-LP, Germany): 50 µl 
 
Stop solution:  
 EDTA 0.1 M, pH 8.0 (Sigma, Germany): 14.8 g 
 Distilled water: 400 ml 
 
Drying solution:  
 Methanol 15% 
 Glycerol 3% 
 diluted in distilled water 
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3.2.11.6 Western blot analysis 
Detection of specific antigens was performed by Western blot analysis. Washing and 
incubation procedures were accomplished under consequent agitation of the 
membranes on a tumbling shaker (Heidolph, Germany) to allow consistent 
moistening of the membranes. Washing was carried out 3 times for 10 minutes with 
TBS-Tween (TBS-T) if not stated differently. All reaction steps were carried out at 
room temperature unless stated otherwise. 
 
ER-stress markers 
The membrane was blocked in 1% bovine serum albumin (BSA) in TBS for one hour 
at room temperature to avoid non-specific binding of the antibodies used. Antibodies 
were diluted in 10 ml of 1% BSA in TBS. After washing, the membrane was 
simultaneously incubated in polyclonal rabbit anti-Grp78 (Stressgen, Canada; 
1:10,000), monoclonal rabbit anti-PeIF2α (Cell Signalling, USA; 1:1,000), and 
polyclonal rabbit anti-GADD153 (Santa Cruz Biotechnology, USA; 1:500) antibodies 
over night at 4°C. The next day, the membrane was washed and then incubated for 
one hour with a horseradish peroxidase conjugated anti-rabbit antibody (Cell 
signalling, USA; 1:10,000), followed by another washing step. Afterwards, the 
membrane was covered with Luminol Reagent (Santa Cruz Biotechnology, USA) for 
1 minute, before being placed into a film cassette (Ortho Fine, AGFA, Germany). To 
avoid dehydratation, the membrane was covered with a plastic transparency. An 
Amersham Hyperfilm ECL (GE Healthcare, Germany) was laid upon the covered 
membrane in a dark room. After an exposition time of about 2 minutes, the film was 
developed (Kodak professional developer, Kodak, USA), shortly rinsed in a          
12% acetic acid solution, fixed (Kodak professional fixer, Kodak, USA), rinsed 
thoroughly with tap water, and dried. Afterwards, the membrane was removed from 
the cassette, washed for 5 minutes in TBS-T, incubated for 10 minutes in stripping 
buffer, washed for 2 x 10 minutes in PBS and for 2 x 5 minutes in TBS-T (mild 
stripping protocol according to Abcam, UK). Subsequently the membrane was 
blocked for one hour in 1% BSA in TBS, washed and then incubated with a 
monoclonal mouse anti-actin antibody (Chemicon international, Germany; 1:10,000, 
over night, 4°C). After another washing step, a horseradish peroxidase rabbit anti-
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mouse antibody was added (DAKO, Germany; 1:10,000) and detection of 
immunoreactivity was performed as described. 
 
Apoptosis markers 
The membrane was blocked for 1 hour at room temperature in Blotto A (5% non fat 
dry milk (Roth, Germany) in 0.05% TBS-T) to avoid non-specific binding of the 
antibody used. After washing, the membrane was incubated over night at 4°C with 
polyclonal rabbit anti-Caspase-3 antibody (Cell Signalling, USA; 1:1,000), which was 
diluted in 10ml Blotto A. The next day, the membrane was washed and then 
incubated for one hour at room temperature with a horseradish peroxidase 
conjugated anti-rabbit antibody (Cell Signalling, USA; 1:2,000) diluted in 10 ml Blotto 
A, followed by another washing step. Detection of immunoreactivity then was 
performed as described above, but exposing the film for 12 minutes. 
 
Cell proliferation markers 
After blocking in 3% BSA in TBS for one hour at room temperature to avoid non 
specific binding of the antibody used, the membrane was washed and then incubated 
with a mouse monoclonal anti-PCNA antibody (Abcam, USA; 1:2,500) diluted in       
10 ml 1% BSA in TBS at 4°C over night.  The next day, the membrane was first 
washed and then incubated for one hour at room temperature with a horseradish 
peroxidase conjugated rabbit anti-mouse antibody (DAKO®, Germany; 1:10,000), 
followed by another washing step. Detection of immunoreactivity then was performed 
as described above, exposing the film for 2 minutes. 
Materials 
TBS and TBS-T:   described above (3.2.11.4) 
 
Luminol Reagent (Santa Cruz Biotechnology, USA): 
 Solution A 5 ml 
 Solution B 5 ml 
 
Developer:  
 Kodak professional developer (Kodak, USA): 7.8 g 
 Distilled water 50 ml 
 
Fixer:  
 Kodak professional fixer (Kodak, USA): 9.2 g 
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 Distilled water 50 ml 
 
Stripping buffer:  
 Glycine (neoLab, Germany): 15 g 
 SDS 10% (Sigma, Germany): 1 g 
 Tween 20 (Merck, Germany): 10 ml 
 ad 1,000 ml distilled water 
 adjust to pH 2.2 with 37% HCl (Merck, Germany) 
 
3.2.12 Necropsy and pancreas preparation 
At the age of 190 days, 35 mice were exsanguinated by punction of the retroorbital 
plexus under general anaesthesia (ketamine/xylacine mixture; refer to chapter 3.2.9) 
and finally killed by cervical dislocation. Pancreata were obtained for qualitative 
histological and quantitative stereological analyses as well as for transmission 
electron microscopy. The pancreas was separated from adjacent tissues and 
weighed to the nearest 0.1 g (Mettler AE200 Electronic Analytical Balance; Mettler-
Toledo Intl. Inc., Germany). The specific weight of the pancreas (1.10 mg/mm3) was 
determined by the submersion method (Scherle 1970). A piece of 2 mm3 was cut 
from the splenic end of the pancreas and was fixed by immersion in 1 ml of            
3% glutaraldehyde in Sørensen`s phosphate buffer for transmission electron 
microscopy. The remaining pancreas was laid on a biopsy pad (Bio-optica, Italy) 
placed in a plastic tissue capsule (Engelbrecht, Germany) and fixed in 4% neutral 
buffered formaldehyde solution (SAV LP, Germany) overnight at room temperature. 
After fixation, the pancreas was embedded in agar (BactoTM Agar, Becton&Dickinson, 
USA) to alleviate its later slicing, put into a tissue capsule, routinely processed and 
embedded in paraffin (Histomaster, Bavimed, Germany). The length of the 
embedded pancreas was determined and the whole pancreas was sectioned 
perpendicular to its longitudinal axis into parallel slices of approximately 1 mm 
thickness with the first cut positioned randomly within an interval of 1 mm length at 
the splenic end of the pancreas. The slices were then positioned with the right cut 
surface facing downwards, and paraffin embedding was finished. Approximately       
5 µm thick serial sections for histology were cut with a HM 315 microtome (Microm 
GmbH, Germany), mounted on 3-aminopropyltriethoxy-silane-treated glass slides 
(Starfrost® microscope slides, Engelbrecht, Germany), and dried in a heating cabinet 
(Wagner & Munz GmbH, Germany) at 37°C for at least 12 hours. 
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3.2.13 Immunohistochemistry of the pancreas 
Immunohistochemical staining for insulin, glucagon, somatostatin, and pancreatic 
polypeptide producing cells were performed, using the indirect immunoperoxidase 
method. All incubations were carried out at room temperature in a humidity chamber. 
Normal serum and antibodies were diluted in Tris buffered saline (TBS, pH 7.4).    
TBS was used for washing if not stated differently. 
3.2.13.1 Insulin 
For qualitative histological investigations and for the determination of the volume 
density and the total volume of isolated β-cells in the pancreas, immunohistochemical 
staining for insulin was performed (see 3.2.14.2). Pancreas sections were dewaxed 
in xylene (SAV, Germany) for 20 minutes, rehydrated in a descending alcohol series 
(2 x 100%, 2 x 96%, 1 x 70% ethanol), and rinsed in distilled water. Endogenous 
peroxidase activity of tissue sections was blocked by incubation in 1% hydrogen 
peroxide (neoLab, Germany) solution for 15 minutes. After washing for 10 minutes, 
sections were pre-treated with normal rabbit serum (MP Biomedicals, USA; dilution 
1:10, 30 minutes) to reduce non-specific binding. Afterwards, a polyclonal guinea pig 
anti-swine insulin (DAKO®, Germany) antibody, diluted 1:500 in TBS, was applied for 
1 hour. After rinsing for 10 minutes in TBS, the secondary horseradish peroxidase 
conjugated rabbit anti-guinea pig IgG (DAKO®, Germany; diluted 1:50 in TBS, 
containing 5% mouse serum) was applied for 1 hour. The sections were washed for 
10 minutes in TBS before adding the chromogen substrate 3,3’-diaminobenzidine 
tetrahydrochloride dihydrate  (DAB, KEM-EN-TEC, Denmark) containing 0.1% H2O2 
to visualise immunoreactivity. Slides were rinsed in tap water for 5 minutes, 
counterstained with Mayer’s Haemalaun (Applichem, Germany) and washed under 
running tap water (5 minutes). Subsequently, the sections were dehydrated in an 
ascending alcohol series, cleared in xylene (SAV, Germany), and mounted under 
glass coverslips, using Roti® Histokitt II (Roth, Germany). 
Materials 
TBS: described above (see 3.2.11.4) 
 
Hydrogen peroxide 1% 
 30% H2O2 (neoLab, Germany) 6 ml 
 Aqua bidest 194 ml 
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DAB solution 
 DAB pellets (KEM-EN-TEC, Denmark) 1 piece 
 Aqua bidest 10 ml 
 dissolved for 1 hour (protected from light), filtered, aliquoted and stored at -20°C 
ad 1 µl 30% H2O2 (neoLab, Germany) per 1 ml DAB solution directly before 
use. 
 
3.2.13.2 Glucagon, somatostatin and pancreatic polypeptide 
The immunostaining procedure was similar to the staining of insulin                      
(see 3.2.13.1 Insulin). To reduce non-specific binding, normal swine serum (MP 
Biomedicals, USA; dilution 1:10, 30 minutes) was used. Sections were incubated with 
an antibody cocktail containing polyclonal rabbit anti-human glucagon (dilution 1:50), 
polyclonal rabbit anti-human somatostatin (dilution 1:100), and polyclonal rabbit anti-
human pancreatic polypeptide (dilution: 1:500) for 75 minutes. Horseradish 
peroxidase conjugated porcine anti-rabbit IgG (1:50, containing 5% mouse serum,    
1 hour) served as secondary antibody. All antibodies used were purchased from 
DAKO® (Germany). 
3.2.14 Quantitative stereological analyses 
Pancreata of 190-day-old mice were analysed, using state-of-the-art quantitative 
stereological methods as previously described (Herbach et al. 2007, Wanke et al. 
1994). 
3.2.14.1 Quantification of the total pancreas volume (Vpan) 
The pancreas volume, including non-pancreatic tissue (VPan0) was calculated by 
dividing the pancreas weight by its specific weight (1.10mg/mm3). To determine the 
pancreas volume corrected for non-pancreatic tissue (Vpan), it is necessary to 
substract non-pancreatic tissue from the observed volume. Therefore the complete 
cut surface of HE-stained pancreas sections was photographed (Leica DFC 320 
Digital Camera System, Leica, Germany) at a 16-times final magnification (M 400 
photomacroscope, Wild, Switzerland). For calibration, an object micrometer (Zeiss-
Kontron, Germany) was photographed at the same magnification. All photographs 
were printed under equal conditions. Point counting was performed with a point 
counting grid photocopied onto an overhead transparency. The sum of points (∑P) 
hitting pancreatic tissue (endocrine and exocrine pancreas, including connective 
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tissue of the pancreas; ∑Ppan), and the sum of points hitting the whole section 
(∑Psection, including extra pancreatic tissue) were determined separately. To calculate 
the volume fraction of pancreatic tissue in the section (Vv(pan/section)), ∑Ppan was 
divided by ∑Psection. The mean area corresponding to one point was determined using 
the Videoplan® image analysis system (Zeiss-Kontron, Germany) after calibration 
with the printed photograph of the object micrometer. The sum of cross-sectional 
areas of the pancreas (∑Apan) was obtained by multiplying ∑Ppan with the calculated 
mean area, corresponding to 1 point on the point-counting grid. To calculate the total 
pancreas volume (Vpan), Vpan0 was multiplied with the volume fraction of pancreatic 
tissue (Vv(pan/section)), in order to correct for non-pancreatic tissue.  
3.2.14.2 Determination of the relative pancreas weight 
The relative weight of the pancreas (%) was calculated by dividing the pancreas 
weight by the body weight. 
3.2.14.3 Quantitative stereological parameters 
Quantitative stereological analyses were carried out on sections immunostained for 
insulin as well as on sections simultaneously immunostained for glucagon, 
somatostatin and pancreatic polypeptide, using a Videoplan® image analysis system 
(Zeiss-Kontron, Germany) coupled to a light microscope (Orhoplan; Leitz, Germany) 
via a colour video camera (CCTV WVCD132E; Matsushita, Japan). Images were 
displayed on a colour monitor at a final magnification of x250. The sum of cross-
sectional areas of islets, β-cells and non-β-cells (∑Aislets, ∑Aβ-cells, ∑Anon-β-cells, 
respectively) were measured planimetrically by circling their outlines with a cursor on 
the digitising tablet of the image analysis system after calibration with an object 
micrometer (Zeiss, Germany). Volume fractions of the structures of interest (islets, β-
cells, non-β-cells) in the reference compartments (pancreas, islets) were calculated 
according to the principle of Delesse:  
  
 AA=Vv  
 
AA= Area fraction of a target structure in a reference compartment 
Vv= Estimated volume fraction of a target structure in a reference compartment 
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The volume density of islets in the pancreas (Vv(islets/pan)) was calculated by dividing 
∑Aislets by ∑Apan.  
The total volume of islets in the pancreas (V(islets,pan)) was attained by multiplying 
Vv(islets/pan) with Vpan.  
∑Aβ-cells was calculated from ∑Aislet - ∑Anon-β-cells. The volume density of β-cells      
(Vv(β-cells/islet)) and non-β-cells (Vv(non-β-cells/islet)) in the islets was calculated by dividing 
∑Aβ-cells and ∑Anon-β-cells, respectively, by ∑Aislet.  Moreover, the volume density of 
insulin positive cells in the islets (Vv(ins-cells/islet)) was established by dividing ∑Ains-cells 
by ∑Aislet.  
The total β-cell volume (V(β-cells, islet)) and the total non-β-cell volume (V(non-β-cells,  islet)) in 
the islets was obtained by multiplying Vv(β-cells/islet) and Vv(non-β-cells/islet), respectively, 
with V(islets, pan).  
The β-cell/non-β-cell ratio was calculated by dividing V(β-cells, islet) by V(non-β-cells,  islet). 
 
The volume density (Vv(isol.β-cells/pan)) and total volume (V(isol.β-cells, pan))of isolated β-cells 
cells in the pancreas was determined using sections immunostained for insulin. 
Isolated β-cells were defined as single β-cells or small clusters of β-cells that were 
not contained within established islets (up to four β-cell nuclear profiles) (Bonner-
Weir et al. 2008). The area of isolated β-cell profiles was determined planimetrically 
using an image analysing system, consistent of a light microscope (BX41, Olympus, 
Germany), a colour video camera (DP72, Olympus, Germany) and the software new 
CASTTM (computer assisted stereological toolbox, Visiopharm®, Denmark). The sum 
of cross-sectional areas of isolated β-cell profiles (∑Aisol.β-cells) was quantified by 
circling their outlines with the cursor of the image analysis system.  
The volume density of isolated β-cells in the pancreas (Vv(isol.β-cells/pan)) was calculated 
by dividing ∑Aisol.β-cells by ∑Apan. The total volume of isolated β-cells (V(isol.β-cells, pan)) 
was generated by multiplying (Vv(isol.β-cells/pan)) by Vpan. 
3.2.15 Transmission electron microscopy (TEM) 
Pancreatic islets of 190-day-old mice were investigated electron microscopically. A 
piece of 2 mm3 from the splenic end of the pancreas (see 3.2.12) was fixed by 
immersion in 3% glutaraldehyde in Sørensen`s phosphate buffer. After fixation for 
about 2 hours, tissue samples were washed at least 3 times in washing solution     
(0.2 M buffered saccharose solution) until no glutaraldehyde could be smelled 
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anymore. Subsequently, the pancreas was fixed for two hours at 4°C in a fixative 
solution for Epon embedding, containing 2% osmium tetroxide. After washing 3 times 
in washing solution, pancreas samples were dehydrated by an ascending acetone 
series (Roth, Germany). Pancreatic tissue was incubated in a solution containing 
equal amounts of 100% acetone and glycid ether 100 (Serva, Germany) for 1 hour at 
room temperature, followed by incubation in glycid ether 100 (2 x 30 minutes, room 
temperature). Samples were embedded in glycid ether-embedding mixture in dried 
gelatine capsules (Plano, Germany). Polymerization was carried out at 60°C for      
48 hours. 
Epon blocks were trimmed, using a Reichert-Jung TM60 milling machine (Leica, 
Germany). Semi-thin sections (0.5 µm) were produced with a Reichert-Jung 
Ultracut E microtome (Leica, Germany), and stained with toluidine blue and 
Safranin O. After identifying the islets within the semi-thin sections via light 
microscopy, and marking their positions in a drawing, the areas of the Epon blocks 
containing islets were trimmed, and ultra-thin sections (70 - 80 nm) were prepared 
(Reichert-Jung Ultracut E, Leica, Germany). The sections were mounted on coated 
copper rings, contrasted with uranyl acetate and lead citrate (Reynolds 1963), and 
examined using an EM 10 transmission electron microscope (Zeiss, Germany). 
Materials 
Sorensen`s phosphate buffer 
 Solution A:  192ml 
 Solution B: 808ml 
 
Solution A: 
 Potassium dihydrogen phosphate  
 (KH2PO4; Neolab, Germany) 4.539g 
 Distilled water 500ml 
   
Solution B: 
 Sodium phosphate dibasic dihydrate (Na2HPO4.2H2O;  
 Neolab, Germany) 11.876g 
 Distilled water 1000ml 
 
Washing solution 
 D(+)Saccharose (Neolab, Germany) 6.84g 
 Sorensen´s phosphate buffer 100ml 
 1% Merthiolat solution 0.1ml 
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Merthiolat solution 
 Ethylmercury thiosalicylic acid Na-salt (SERVA, Germany) 1g 
 Distilled water 100ml 
 
Fixative solution for Epon embedding 
 D(+)Saccharose (?) 0.45g 
 0.1m HCl (Merck, Germany) 2ml 
 Veronalacetate buffer 2ml 
 2% Osmium tetroxide solution 5ml 
 Distilled water 1ml 
  
Veronal-acetate buffer: 
 5.5-Diethylbarbituric acid Na-salt (Merck, Germany) 1.47g 
 Sodium acetate (C2H3NaO2; Merck, Germany) 0.97g 
 Distilled water 50ml 
 adjust to pH 10.3 
 
2% Osmium tetroxide solution 
 Osmium tetroxide (OsO4; Chempur®, Germany) 1g 
 Distilled water 50ml 
 
Ascending acetone series (Roth, Germany): 
 Acetone 50%: 3 x 2 minutes, 4°C 
 Acetone 70%: 2 x 10 minutes, 4°C 
 Acetone 90%: 2 x 10 minutes, 4°C 
 Acetone 100%: 2 x 20 min, 4°C 
 Acetone 100%: 1 x 20 min, room temperature) 
 
Osmium tetroxide 2% 
 Osmium tetroxide (OsO4, Merck, Germany): 1 g 
 Distilled water: 50 ml 
 
Glycid ether embedding mixture  
 Solution A: 70 ml 
 Solution B: 130 ml 
 2,4,6-tris-(dimethylaminomethyl) phenol (Serva, Germany): 3 ml 
 
Solution A:  
 glycid ether 100 (Serva, Germany): 62 ml 
 2-dodecenyl succinicacid anhydride (Serva, Germany): 100 ml 
 
Solution B:  
 glycid ether 100 (Serva, Germany): 100 ml 
 methylnadic anhydride (Serva, Germany): 89 ml 
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Staining protocol: semi-thin sections: Toluidine blue and Safranin O  
 
Toluidin blue: 
 Di-sodiumtetraborate (Borax, Merck, Germany): 1 g 
 Toluidin blue (Roth, Germany): 1 g 
 Distilled water: 100 ml 
Dissolve Borax in distilled water, add Toluidin blue and stir for 
approximately 2 hours. Filter before use. Stain sections for 45 - 60 
seconds on a heating plate (Meditel, Germany; 55°C), rinse with 
distilled water and let dry. 
 
Safranin O:  
 Di-sodium tetraborate (Borax, Merck, Germany): 1 g 
 Safranin O (Chroma, Germany): 1 g 
 Saccharose (Merck, Germany): 40 g 
 Formaldehyde 37% ( Roth, Germany): 2-3 drops 
 Distilled water: 100ml 
 
Dissolve Borax in distilled water, add Safranin O and saccharose and 
stir for approximately 2 hours. The next day, add formaldehyde. Filter 
before use. 
Stain sections for 15 seconds on a heating plate (Meditel, Germany, 
55°C), rinse with distilled water and let dry. Cover the sections with 
coverslips (Menzel GmbH & Co KG, Germany) using Histofluid 
(Superior®, Germany). 
 
Contrasting ultra-thin sections with uranyl acetate and lead citrate 
(Reynolds 1963) 
Uranyl acetate (Reynolds): 
 Uranyl acetate (Merck, Germany): 1 g 
 Redistilled water: 50 ml 
 Swing carefully, don’t stir. Filter before use. 
Stain sections for 30 minutes at room temperature. 
 
Lead acetate (Reynolds): 
 Sodium citrate 1M (Merck, Germany): 6 ml 
 Lead nitrate solution 1 M (Merck, Germany): 4 ml 
 Sodium hydrate solution 1 M (Merck, Germany): 8 ml 
 Redistilled water: 32 ml 
Mix sodium citrate with redistilled water while gently stirring. Add lead nitrate 
drop by drop, the solution gets milky (precipitation). Use sodium hydrate to clear 
the solution. Filter before use. Stain sections for 10 minutes at room 
temperature. 
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4 Results 
4.1 Clinical investigations 
4.1.1 Body weight 
From the age of 21 days onwards, the body weight of randomly fed mice was 
determined in regular intervals. At the age of 21 days (data not shown) and 30 days, 
there were no significant differences between the four groups. From 30 days after 
ovariectomy/pellet implantation (arrow) onwards, estradiol-treated ovariectomized 
mutant mice (mt-ovx-E2) weighed significantly less than mice of the three other 
groups. Non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) were 
significantly heavier than mice of all other groups at the age of 60 days (Figure 4.1). 
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Figure 4.1: Randomly fed body weights 
Figure shows body weights of randomly fed non-/placebo-treated ovariectomized mutant mice (mt-
ovx-nt/p), non-/placebo-treated sham-operated mutant mice (mt-sham-nt/p), estradiol-treated 
ovariectomized mutant mice (mt-ovx-E2) as well as non-/placebo-treated sham-operated wild-type 
mice (wt-sham-nt/p). At the age 30 days, the 4 groups were just different in genotype (mutant and 
wild-type mice) because ovariectomy/pellet implantation was accomplished at the age of 30 days 
(arrow).  
Data are means ± SEM; a-c: different superscripts show significant differences (p<0.05); 
(n): number of animals investigated 
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4.1.2 Blood glucose concentration 
4.1.2.1 Randomly fed mice 
Randomly fed blood glucose concentrations were measured in approximately 4-week 
intervals, starting with weaning at an age of 21 days. At weaning, there were no 
significant differences between the four groups. Five days after ovariectomy/pellet 
implantation mt-ovx-nt/p mice exhibited a progressive diabetic phenotype with 
increasing blood glucose levels, reaching 359 ± 126 mg/dl at 160 days of age. 
Moreover, mt-ovx-nt/p mice showed significantly higher blood glucose concentrations 
than mt-ovx-E2 as well as wild-type mice at all investigated time-points and from the 
age of 60 days onwards, also as compared to mt-sham-nt/p mice. Mt-ovx-E2 mice 
showed significantly lower blood glucose concentrations at each time point after 
ovariectomy as compared to mt-ovx-nt/p and mt-sham-nt/p mice, and almost similar 
blood glucose concentrations as wild-type mice. The blood glucose levels of mt-ovx-
E2 and wild-type mice remained stable during the investigation period, ranging from 
approximately 110 to 140mg/dl. Mt-sham-nt/p mice featured significantly higher blood 
glucose concentrations than wild-type mice from day 35 up to day 190 (Figure 4.2). 
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Figure 4.2: Randomly fed blood glucose levels between 21 and 190 days  
Non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) show a progressive diabetic 
phenotype. Blood glucose concentrations of E2-treated ovariectomized mutant mice (mt-ovx-E2) 
remain stable and there is no significant difference as compared to wild-type mice (wt-sham-nt/p).  
Data are means ± SEM; a, b, c, d, e: p<0.05: a) mt-ovx-nt/p vs. mt-sham-nt/p; b) mt-ovx-nt/p vs. wt-
sham-nt/p; c) mt-sham-nt/p vs. wt-sham-nt/p; d) mt-ovx-E2 vs. mt-ovx-nt/p; e) mt-ovx-E2 vs. mt-sham-
nt/p; ↓ ovariectomy/pellet implantation (30 days of age); (n): number of animals investigated 
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4.1.2.2 Fourteen-hours fasted mice 
Fasting blood glucose concentrations were examined approximately every 4 weeks, 
starting at the age of 50 days. Non-/placebo-treated ovariectomized mutant mice   
(mt-ovx-nt/p) exhibited a clinical manifest diabetic phenotype with increasing fasting 
blood glucose concentrations, reaching 200 ± 76 mg/dl at an age of 120 days and 
exhibited significantly higher blood glucose concentrations than all other groups 
during the complete investigation period. Non-/placebo-treated sham-operated 
mutant mice (mt-sham-nt/p) also exhibited significantly higher blood glucose 
concentrations as compared to E2-treated ovariectomized mutant (mt-ovx-E2) and 
wild-type mice (wt-sham-nt/p) from an age of 50 days up to 155 days. Mt-ovx-E2 
mice showed significantly lower blood glucose concentrations from 50 to 155 days of 
age, as compared to mt-ovx-nt/p and mt-sham-nt/p mice. From an age of 70 to     
155 days, the fasting blood glucose of E2-treated mutants was even significantly 
lower as compared to wild-type mice (Figure 4.3).  
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Figure 4.3: 14 hours fasted blood glucose levels between 50 and 180 days of age  
Non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) show higher blood glucose levels than 
the three other groups. Blood glucose concentrations of estradiol-treated ovariectomized mutant mice 
(mt-ovx-E2) are lower than those of the two other mutant groups (mt-ovx-nt/p and mt-sham-nt/p) and 
even lower than those of wild-type mice (wt-sham-nt/p). 
Data are means ± SEM; a, b, c, d, e, f: p<0.05: a) mt-ovx-nt/p vs. mt-sham-nt/p; b) mt-ovx-nt/p vs. wt-
sham-nt/p; c) mt-sham-nt/p vs. wt-sham-nt/p; d) mt-ovx-E2 vs. mt-ovx-nt/p; e) mt-ovx-E2 vs. mt-sham-
nt/p; f) mt-ovx-E2 vs. wt-sham-nt/p; (n): number of animals investigated 
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4.1.3 Oral glucose tolerance test (OGTT) 
Oral glucose tolerance tests were performed at an age of 50, 90 and 180 days of life 
(Figure 4.4, A1 – C1). Non-/placebo-treated ovariectomized mutant mice               
(mt-ovx-nt/p) featured significantly higher blood glucose concentrations as compared 
to wild-type mice (wt-sham-nt/p) as well as to E2-treated ovariectomized mutant mice 
(mt-ovx-E2) during all OGTTs (Figure 4.4, A1 – C1).  
At the age of 90 and 180 days (Figure 4.4, B1 and C1), mt-ovx-nt/p mice also 
showed significantly higher blood glucose concentrations as compared to               
mt-sham-nt/p mice. Therefore, the corresponding areas under the blood glucose 
curves (AUCblood glucose) of mt-ovx-nt/p mice were also significantly higher as 
compared to the other groups (Figure 4.4, A2 – C2). Mt-ovx-E2 mice showed lower 
blood glucose concentrations as compared to mt-sham-nt/p mice, in the second part 
of the test (starting at 20 min with 50 days, 60 min with 90 days and 90 min with     
180 days), however, the corresponding area under the glucose curve showed no 
significant difference between the two groups. In wild-type mice, blood glucose 
values already declined between 10 and 20 minutes after glucose challenge, in 
estradiol-treated mice between 20 and 30 minutes, and in the mice of the two other 
mutant groups primal between 30 and 60 minutes (90 and 180 days of life). The 
results show that ovariectomy diminishes glucose tolerance in female mutant mice 
and that estrogen-replacement therapy can restore glucose tolerance at least to the 
levels of sham-operated mutant mice (Figure 4.4). 
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Figure 4.4 (A-C): Oral glucose tolerance tests (OGTT) at 50, 90 and 180 days of age 
(A1) – (C1): Blood glucose levels during OGTT 
Non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) present significantly higher blood 
glucose levels as compared to E2-treated mice (mt-ovx-E2) at almost every time point of the test, 
irrespective of age and sampling. Blood glucose concentrations of mt-ovx-E2 mice decline later than 
those of wild-type mice (wt-sham-nt/p), but earlier than those of mt-ovx-nt/p and mt-sham-nt/p mice. 
a, b, c, d, e, f: a) mt-ovx-nt/p vs. mt-sham-nt/p; b) mt-ovx-nt/p vs. wt-sham-nt/p; c) mt-sham-nt/p vs. wt-
sham-nt/p; d) mt-ovx-E2 vs. mt-ovx-nt/p; e) mt-ovx-E2 vs. mt-sham-nt/p; f) mt-ovx-E2 vs. wt-sham-
nt/p; p<0.05 
(A2) – (C2): Area under blood glucose curve (AUCblood glucose) 
The area under blood glucose curve is significantly increased in mt-ovx-nt/p mice as compared to all 
three other groups at an age of 90 (B2) and 180 days (C2).There is no significant difference between 
the AUCblood glucose of mt-ovx-E2 and mt-sham-nt/p mice. Wild-type mice (wt-sham-nt/p) exhibit a 
significantly smaller area under their glucose curve than all three other groups, irrespective of age. 
a-c: different letters show significant differences (p<0.05);  
Data are means ± SEM; (n): number of animals investigated 
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4.1.4 Intraperitoneal insulin tolerance test (ipITT) 
IpITTs were performed at an age of 60 (A), 100 (B) and 187 (C) days of life to 
investigate insulin sensitivity of ovariectomized or sham-operated mutant and wild-
type mice that were not supplied with E2 or placebo pellets. Ten, 20, 30, 60 and        
90 minutes after intraperitoneal insulin injection, blood glucose concentration was 
determined. The percentaged decrease from basal value (T0=100%) after insulin 
injection was calculated (data not shown). The corresponding areas under these 
curves are shown in Figure 4.5. At an age of 60 and 187 days, ovariectomized 
mutant mice (mt-ovx-nt) exhibited a significantly higher AUCblood glucose than sham-
operated mutant mice (mt-sham-nt) and wild-type mice (wt-sham-nt). At an age of 
100 days, ovariectomized mutant mice showed a significantly higher area under 
blood glucose curve than wild-type mice. There existed no significant differences 
between sham-operated mutant mice and wild-type mice at all time points 
investigated. These results indicate that ovariectomy worsens insulin sensitivity in 
female mutant mice, whereas sham-operated mutant mice show similar insulin 
sensitivity as wild-type mice (Figure 4.5). 
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Figure  4.5 (A-C): Area under the curve of the percentaged blood glucose decrease 
from basal value (AUCblood glucose) of the ipITT at the age of 60 (A), 100 (B) and 187 (C) 
days 
Data are means ± SEM; a-b: different letters show significantly differences (p<0.05); 
(n): number of animals investigated 
 
4.1.5 Serum insulin concentration 
To examine basal and glucose induced insulin secretion, serum insulin 
concentrations were measured before and ten minutes after oral glucose application 
during oral glucose tolerance tests at an age of 90 and 180 days (see 4.3). At an age 
of 90 days, basal serum insulin concentrations of 14-hours fasted mice (T0) showed 
no significant differences between the 4 groups. At an age of 180 days, the basal 
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serum insulin concentrations of mt-ovx-E2 mice were significantly lower than those of 
mt-ovx-nt/p mice and mt-ovx-nt/p mice showed higher insulin levels than mt-sham-
nt/p mice. Ten minutes after glucose application (T10), all mutant mice showed 
significantly lower serum insulin concentrations as compared to wild-type mice, 
irrespective of the age at sampling (Figure 4.6). 
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Figure 4.6: Serum insulin concentrations 14 hours-fasted (T0) and 10 minutes after 
oral glucose challenge (T10) of 90 (A)- and 180 (B)-day-old mice 
The serum insulin concentrations 10 minutes after glucose challenge of the three mutant groups are 
significantly lower compared to wild-type mice at both time points investigated. 
Data are means ± SEM; a-c: different letters show significantly differences (p<0.05); (n): number of 
animals investigated 
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Figure 4.7 shows the increase of serum insulin concentrations as x–fold increase 
from basal concentrations (T0). At 90 days of life, wild-type mice showed a more than 
10-fold increase whereas all three mutant groups only demonstrated a 2- to 3-fold 
increase in insulin levels. Ninety days later, wild-type mice showed again an increase 
of about 10-fold as compared to basal values. Mt-ovx-nt/p mice showed the lowest 
increase (1.4-fold) as compared to the other groups, whereas mt-ovx-E2 mice 
demonstrated the highest increase (2.5-fold) of insulin secretion among the three 
mutant groups (Figure 4.7). 
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Figure 4.7: Increase of serum insulin concentrations 10 minutes after oral glucose 
challenge of 90- and 180-day-old mice  
The serum insulin concentrations 10 minutes after glucose challenge (T10) were divided by the insulin 
concentrations of fasted mice (T0). Wild-type mice show a significantly higher increase of insulin levels 
than mice of the three other groups at both time points. Mt-ovx-nt/p mice both times demonstrate the 
lowest increase of insulin levels. 
Data are means ± SEM; a-c: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
4.1.6 Serum estradiol concentration 
Serum estradiol concentrations have been measured at 65, 105, and 160 days of life. 
The sensitivity of the ELISA-Kit often was not high enough to detect the low estradiol 
concentrations of ovariectomized mutant mice as well as of sham-operated mutant 
mice and wild-type mice (also depending on sexual cycles of the intact sham-
operated mice) and estradiol levels ranged from 0 to 10 pg/ml (data not shown). 
Therefore, the test was used as a control for estradiol treatment. Figure 4.8 shows 
the 17βEstradiol concentration of 60-, 105- and 160-day-old estradiol-treated 
ovariectomized mutant mice. The first pellet was applied at an age of 30 days and 
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pellets were replaced at an age of 115 days (as recommended by the manufacturer). 
Thirty days after the implantation of the first estradiol pellet (60 days of life), serum 
estradiol concentrations were the highest. At an age of 105 days, 10 days before 
changing the pellets, serum estradiol levels had declined by 75 % as compared to 
those of 60-day-old E2-treated mice. Fourty-five days after replacing the pellets, 
estradiol levels lie between the latter to values (Figure 4.8). The results show that, 
although the amount of 17βEstradiol released from the pellets decreased with time, 
serum estradiol levels were at least 10-times higher in E2-treated as compared to 
non-/placebo-treated mice. 
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Figure 4.8: Serum 17βEstradiol levels of estradiol-treated ovariectomized mutant mice 
(mt-ovx-E2) at an age of 60, 105 and 160 days of life 
The serum 17βEstradiol levels are the highest at 60 days of life (30 days after first pellet implantation) 
and decrease until 85 days after first implantation (105 days of age). (n): number of animals 
investigated 
 
4.2 Beta cell function indices 
The homeostasis model assessments of baseline insulin secretion (HOMA B) and of 
insulin resistance (HOMA IR) were calculated by means of fasting blood glucose and 
serum insulin levels obtained in the course of OGTTs at 50, 90 and 180 days of age. 
Moreover, Quicki (quantitative insulin-sensitivity check index) and FGIR (fasting 
glucose-to-insulin ratio) were calculated with the obtained data. 
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4.2.1 HOMA B and HOMA IR 
The HOMA B was significantly reduced in non-/placebo-treated ovariectomized     
(mt-ovx-nt/p) and sham-operated mutant mice (mt-sham-nt/p), as compared to wild-
type mice (wt-sham-nt/p) at the age of 50, 90 and 180 days. Estradiol-treated 
ovariectomized mutant mice (mt-ovx-E2) showed a higher HOMA B as compared to 
the two non-/placebo-treated mutant mice groups (mt-ovx-nt/p and mt-sham-nt/p) at 
all examined time points, but only at the age of 90 days, the difference reached 
statistical significance (Figure 4.9). 
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Figure 4.9: Homeostasis model assessments of baseline insulin secretion (HOMA B) 
of 50-, 90- and 180-day-old mice  
Non-/placebo-treated ovariectomized (mt-ovx-nt/p) and sham-operated (mt-sham-nt/p) mutant mice 
demonstrate a lower baseline insulin secretion than estradiol-treated ovariectomized mutant mice (mt-
ovx-E2) and wild-type mice (wt-sham-nt/p) at all time points investigated. 
Data are means ± SEM; a-b: different letters show significantly differences (p<0.05); (n): number of 
animals investigated 
 
At the age of 50 days, the insulin resistance index (HOMA IR) was not significantly 
different in mice of the 4 groups. At the age of 90 and 180 days, mt-ovx-nt/p mice 
showed a higher HOMA IR as compared to mice of the 3 other groups. This 
difference was significant as compared to mt-ovx-E2 mice (3.4 fold higher) and wild-
type mice (2.4 fold higher) at the age of 90 days. Moreover, mt-ovx-E2 mice exhibited 
a significantly lower HOMA IR than mt-sham-nt/p mice (1.9 fold lower) (Figure 4.10). 
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Figure 4.10: Homeostasis model assessments of insulin resistance (HOMA IR) of 50-, 
90- and 180-day-old mice  
The HOMA IR, as an index of insulin resistance, is not different at an age of 50 days. Ninety-day-old 
non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) already show a significantly increased 
HOMA IR as compared to the two sham-operated groups (mt-sham-nt/p and wt-sham-nt/p) and at the 
age of 180 days, the difference is significant as compared to all the other groups, including wild-type 
mice. 
Data are means ± SEM; a-c: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
4.2.2 Quicki  
The quantitative insulin-sensitivity check index (Quicki) showed no significant 
difference between the four groups at an age of 50 days. At 90 and 180 days of age, 
mt-ovx-nt/p mice demonstrated a lower Quicki as compared to the three other groups 
(Figure 4.11). 
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Figure 4.11: Quantitative insulin-sensitivity check index (Quicki) of 50-, 90- and 180- 
day-old mice 
At an age of 90 and 180 days, non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) show 
the lowest Quicki within the four groups, whereas estradiol-treated ovariectomized mutant mice (mt-
ovx-E2) exhibit the highest values. 
Data are means ± SEM; a-c: different letters show significantly differences (p<0.05); (n): number of 
animals investigated 
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4.2.3 FGIR 
The fasting glucose-to-insulin ratio (FGIR) demonstrated, that non-/placebo-treated 
ovariectomized and sham-operated mutant mice exhibited a significantly higher FGIR 
as compared to wild-type mice at all time points investigated (Figure 4.12). It is 
unlikely that this parameter, which was designed to evaluate insulin-resistance/          
-sensitivity in humans (FGIR<7 considered as insulin resistant, FGIR≥7 considered 
as insulin sensitive (Silfen et al. 2001)), is transferable to mice, because our results 
are opposite to the expected data.  
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Figure 4.12: Fasting glucose-to-insulin ratio (FGIR) of 50-, 90- and 180-day-old mice  
Data are means ± SEM; a-d: different letters show significantly differences (p<0.05); (n): number of 
animals investigated 
 
4.3 Oxidative stress 
Oxidative stress leads to serum lipid peroxidation which produces thiobabituric 
reactive substances (TBARS). The amount of TBARS was determined in              
190-day-old mice and was presented in malondialdehyde (MDA) equivalents.  
Non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) showed a 
significantly higher extent of lipid peroxidation in the serum as compared to other 
mutant as well as to wild-type mice. The amount of MDA equivalents of mt-ovx-nt/p 
mice was about 2-fold higher than that of mt-sham-nt/p and wt-sham-nt/p mice and 
even 2.4-fold higher as compared to mt-ovx-E2 mice (Figure 4.13). 
 
4  Results 87 
 
0
25
50
75
100
a
b
b
b
 72
±25
30
±6
37
±7
33
±4
mt-ovx-nt/p (n=5)
mt-ovx-E2 (n=4)
mt-sham-nt/p (n=5)
wt-sham-nt/p (n=5)
M
D
A
-C
o
n
c
e
n
tr
a
ti
o
n
( µµ µµ
M
)
 
Figure 4.13: Serum lipid peroxidation expressed in malondialdehyde (MDA) 
equivalents at an age of 190 days  
The serum malondialdehyde levels of non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) 
are significantly higher than those of the three other groups.  
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
 
Blood glucose concentrations correlated with lipid peroxidation in the serum.          
Mt-ovx-nt/p mice exhibited 2.8-fold higher serum blood glucose levels as compared 
to mt-sham-nt/p mice (356 ± 193 µM vs. 129 ± 19 µM) and 3-fold higher levels as 
compared to mt-ovx-E2 and wild-type mice (356 ± 193 µM vs. 116 ± 38 µM vs.      
111 ± 14 µM) (Figure 4.14).  
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Figure 4.14: Correlation of blood glucose concentrations and lipid peroxidation 
expressed in MDA equivalents at the age of 190 days  
The serum MDA equivalents and the blood glucose concentrations correlate with r=0.98 (p<0.001) 
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4.4 Isolated pancreatic islets 
Pancreatic islets of 210-day-old mice have been isolated for the determination of ER-
stress, cell proliferation and apoptosis via Western blot analyses. 
4.4.1 ER-stress 
Primary antibodies against the ER-stress markers BiP, PeIF2α and CHOP/GADD153 
were used for the analyses. The molecular weights of the three markers were 78kDa 
for BiP, 40 kDa for PeIF2alpha and 25kDa for CHOP/GADD153. The optical density 
of the ER-stress marker bands was referred to that of β-actin (45kDa). 
4.4.1.1 BiP/β-actin 
Mt-ovx-nt/p mice showed a significantly higher optical density of BiP/actin than        
mt-sham-nt/p and wild-type mice. Mt-ovx-E2 mice also demonstrated a higher optical 
density of BIP as compared to the two sham-operated groups, but this difference was 
not statistically significant (Figure 4.15). 
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Figure 4.15: Optical density of BiP/β-actin in isolated islets at the age of 190 days  
Ovariectomized non-/placebo-treated (mt-ovx-nt/p) and E2-treated (mt-ovx-E2) mutant mice showed a 
higher optical density of BiP/β-actin than sham-operated non-/placebo-treated mutant (mt-sham-nt/p) 
and wild-type (wt-sham-nt/p) mice. 
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
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4.4.1.2 PeIF2alpha/β-actin 
The optical density of phospho-eIF2alpha/β-actin in the islets showed no significant 
difference between the four groups, although mt-ovx-nt/p and wild-type mice 
exhibited a marginally higher optical density than mt-ovx-E2 and mt-sham-nt/p mice 
(Figure 4.16). 
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Figure 4.16: Optical density of PeIF2alpha/β-actin in isolated islets at the age of 190 
days 
Mt-ovx-nt/p and wild-type mice exhibit approximately the same optical density of PeiF2alpha but a 
higher optical density than that of mt-ovx-E2 and mt-sham-nt/p mice. 
Data are means ± SEM; (n): number of animals investigated 
 
 
4.4.1.3 CHOP/β-actin 
The ER-stress marker CHOP/GADD 153 was only detectable in ovariectomized and 
sham-operated mutant and wild-type mice without E2- or placebo-treatment (mice of 
Group 1). Ovariectomized mutant mice (mt-ovx-nt) showed a significantly higher 
optical density of CHOP/β-actin than sham-operated mutant mice (mt-sham-nt). 
Moreover, mt-ovx-nt mice demonstrated a higher optical density of CHOP as 
compared to wild-type mice, although the difference was not statistically significant 
(p=0.058) (Figure 4.17). 
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Figure 4.17: Optical density of CHOP/β-actin in isolated islets at the age of 190 days 
Ovariectomized mutant mice (mt-ovx-nt) exhibit a higher optical density of CHOP/β-actin than sham-
operated mutant mice (mt-sham-nt) and sham-operated wild-type mice (wt-sham-nt). 
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
4.4.2 Apoptosis 
To identify apoptotic islet-cells, a primary antibody against caspase-3 was used. 
Intracellular cysteine proteases (caspases), especially the effector caspase-3, are 
major regulators of apoptosis. In presence of cell death stimuli, inactive pro-caspase-
3, which is usually expressed in mammalian cells, is activated by autoproteolytic 
procession from the inactive heterodimer into its active heterotetrameric form, 
consisting of a large (~20 kDa) and a small (~10 kDa) active subunit                  
(Porter and Janicke 1999, Thornberry and Lazebnik 1998). The antibody used for 
Western blot analyses detects both, the inactive and active form of caspase-3. 
Lymph node homogenate was applied as positive control for the activated subunits. 
Pro-caspase-3 was detectable in all samples. The active large subunit of caspase-3 
was only apparent in one examined sample of a placebo-treated ovariectomized 
mutant mouse as well as in lymph node homogenate (size ~19kDa), whereas no 
bands were detectable in the other islet samples examined. Only one band could be 
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detected for the active form of caspase-3 because the 17 and 19 kDa bands were not 
separated in the gel (Figure 4.18). 
 
Figure 4.18: Optical density of Caspase-3/β-actin in isolated islets at the age of 190 
days 
A: mt-ovx-p; B: mt-ovx-E2; C: mt-sham-p; P: positive control (lymph node homogenate).  
All examined samples show a pro-caspase band at 33kDa, whereas the active form of the enzyme 
(caspase-3) only appears in one sample of isolated islets from a placebo-treated ovariectomized 
mutant mouse (A) and the positive control (D). 
 
4.4.3 Cell proliferation 
To evaluate replication of islet-cells, a primary antibody against Proliferative Cell 
Nuclear Antigen (PCNA) was used. PCNA is a marker for cells in early G1- and       
S-phase of the cell cycle. It is found in the nucleus and is a cofactor of DNA 
polymerase delta. PCNA acts as a homotrimer and helps to increase the processivity 
of leading strand synthesis during DNA replication (Majka and Burgers 2004). The 
molecular weight of this marker was 25kDa.  
Mt-ovx-nt/p mice presented a significantly decreased optical density of PCNA/β-actin 
as compared to mt-sham-nt/p as well as to wild-type mice. Mt-ovx-E2 mice showed 
an optical density between mt-ovx-nt/p and mt-sham-nt/p mice (Figure 4.19). 
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Figure 4.19: Optical density of PCNA/β-actin in isolated islets at the age of 190 days 
Non-/placebo-treated ovariectomized mutant mice (mt-ovx-nt/p) exhibit a significantly lower optical 
density of PCNA/β-actin than non-/placebo-treated sham-operated mutant mice (mt-sham-nt/p) and 
wild-type mice (wt-sham-nt/p). The difference to estradiol-treated ovariectomized mutant mice (mt-ovx-
E2) is not statistically significant.  
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
 
4.5 Qualitative histological evaluations of the endocrine pancreas 
Pancreata of 190-day-old mice were evaluated using qualitative histological and 
quantitative stereological methods (see chapter 2.6). Pancreata of non-/placebo-
treated mice did not reveal any pathological changes. Two pancreata of estradiol-
treated mice showed a well demarcated abscess, located in the pancreas 
parenchyma.  
4.5.1 Insulin 
Insulin-immunostaining was performed with pancreas sections of 16 mice belonging 
to Group 1 (5 mt-ovx-nt, 5 mt-sham-nt and 6 wt-sham-nt mice) and additionally with 4 
estradiol-treated ovariectomized mutant mice (Group 2). Sham-operated wild-type 
(wt-sham-nt) mice revealed typical islet composition and distribution of insulin 
positive stained cells within the islets. Ovariectomized mutant mice (mt-ovx-nt) 
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showed less insulin positive cells than sham-operated mutants (mt-sham-nt) and 
wild-type mice. Sham-operated mutant mice (mt-sham-nt) and estradiol-treated 
ovariectomized mutant mice (mt-ovx-E2) showed almost equal amounts of insulin 
positive cells, lying in between the amounts of mt-ovx-nt and wild-type mice. Many of 
the β-cells in the islets of mt-ovx-nt mice demonstrated only a weak staining intensity, 
indicating low insulin content. Some of the insulin positive cells of mt-sham-nt mice 
showed almost as strong staining intensity as β-cells of wild-type mice, but some β-
cells were stained as weak as those of mt-ovx-nt mice, whereas the staining intensity 
from mt-ovx-E2 mice was in between that of mt-ovx-nt and mt-sham-nt mice (Figure 
4.20). 
 
 
 
Figure 4.20 (A-D): Pancreas sections with representative islet profiles of 190-day-old 
mice, immunostained for insulin  
Ovariectomized mutant mice (A) exhibit less insulin positive cells with lower staining intensity as 
compared to estradiol-treated ovariectomized mutant mice (B), sham-operated mutant mice (C) and 
wild-type mice (D). Wild-type mice show an islet profile which is predominantly composed of 
intensively stained β-cells. 
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4.5.2 Glucagon, somatostatin and pancreatic polypeptide (PP) 
Immunohistochemistry for glucagon, somatostatin and pancreatic polypeptide was 
accomplished with sections from 15 mice of Group 1 (5 mt-ovx-nt, 5 mt-sham-nt and 
5 wt-sham-nt) and 19 mice of Group 2 (5 mt-ovx-p, 5 mt-sham-p, 4 mt-ovx-E2 and    
5 wt-sham-p). Mt-ovx-nt/p and mt-ovx-E2 mice and to a lower degree also              
mt-sham-nt/p mice possessed more α-, δ- and PP-cells in islet cross sections than 
wild-type mice. The islet structure was altered in all three mutant mouse groups, with 
non-β-cells being dispersed all over the islet profile whereas wild-type mice exhibited 
a typical murine islet composition where insulin positive β-cells are located in the 
centre of the islet and are surrounded by a ring of non-β-cells (Figure 4.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 (A-D): Pancreas sections with representative islet profiles of 190-day-old 
mice, simultaneously immunostained for glucagon, somatostatin and pancreatic 
polypeptide 
Non-/placebo-treated (A) and estradiol-treated (B) ovariectomized mutant mice exhibit an increased 
number of non β-cells which are distributed all over the islet profile. In contrast, wild-type mice (D) 
demonstrate a typical islet structure, characterized by a few non-β-cells which surround a core of β-
cells. Non-/placebo-treated sham-operated mutant mice (C) show less non-β-cells as compared to the 
ovariectomized groups (A and B), but the cells are also distributed all over the islet profile. 
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4.5.3 Isolated β-cells 
Isolated β-cells were defined as single insulin positive cells and β-cell clusters of up 
to 4 nuclear profiles and are interpreted as a sign of islet neogenesis              
(Bonner-Weir et al. 2008, Inada et al. 2008). Isolated β-cells were found in all mice, 
either within the exocrine pancreas or associated to pancreatic ducts (Figure 4.22). 
 
 
 
Figure 4.22: Isolated β-cells in pancreas sections of 190-day-old mice, immunostained 
for insulin 
Isolated β-cells can be located as single cells within the exocrine pancreas (A), associated to 
pancreatic ducts (B) or as β-cell clusters up to four nuclear profiles (C). 
 
 
4.6 Quantitative stereological analyses of the endocrine pancreas 
4.6.1 Total pancreas volume 
At the age of 190 days, all three placebo-treated groups showed an approximately 
similar total pancreas volume (Vpan). Mt-ovx-E2 mice demonstrated a significantly 
lower total pancreas volume as compared to all the other groups (Figure 4.23). 
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Figure 4.23: Pancreas volume (Vpan) of 190-day-old mice  
Estradiol-treated ovariectomized mutant mice (mt-ovx-E2) demonstrate a significantly lower pancreas 
volume as compared to the 3 other groups. 
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
4.6.2 Relative pancreas weight 
The relative pancreas weight (%) was almost identical between the four groups 
(Figure 4.24). 
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Figure 4.24: Relative pancreas weight (%) of 190-day-old mice 
Mice of all 4 groups showed a similar relative pancreas weight. Data are means ± SEM  
(n): number of animals investigated 
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4.6.3 Volume density of islets in the pancreas 
The volume density of islets in the pancreas (Vv(islets/pan)) of mt-ovx-E2 mice was 
significantly lower in comparison to mt-sham-nt/p and wild-type mice (Figure 4.25). 
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Figure 4.25: Volume density of islets in the pancreas (Vv(islets/pan)) of 190-day-old mice  
Mt-ovx-E2 mice demonstrate a significantly lower Vv(islets/pan) than mt-sham-nt/p and wild-type mice. 
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated  
 
4.6.4 Total islet volume 
Mt-ovx-E2 mice possessed a significantly lower total islet volume (V(islets, pan)) than 
mice of the 3 other groups,whereas wild-type mice demonstrated the highest total 
islet volume within the four mice groups (Figure 4.26). 
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Bild 4.26: Total islet volume in the pancreas (V(islets, pan)) of 190-day-old mice  
Estradiol-treated ovariectomized mutant mice show the lowest total islet volume compared to mice of 
the 3 other groups.  
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
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4.6.5 Volume density of β-cells in the islets 
Wild-type mice exhibited a slightly but significantly higher volume density of β-cells in 
their islets (Vv(β-cells/islet)) than mice of all the 3 other groups. Mt-sham-nt/p mice 
featured a slightly higher (n.s.) Vv(β-cells/islet) as compared to the two ovariectomized 
groups (Figure 4.27). 
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Figure 4.27: Volume density of β-cells in the islets (Vv(β-cells/islet)) of 190-day-old mice 
Wild-type mice demonstrate a significantly higher Vv(β-cells/islet) as compared to mice of all the three 
other groups. Data are means ± SEM; a-b: different letters show significant differences (p<0.05);  
(n): number of animals investigated 
 
4.6.6 Total β-cell volume 
Mt-ovx-E2 mice featured a significantly lower total volume of β-cells in the islets    
(V(β-cells, islets)) than mice of the three other groups. Mt-ovx-nt/p mice demonstrated a 
lower (p=0.06) V(β-cells, islets) than mt-sham-nt/p and wild-type mice (Figure 4.28). 
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Figure 4.28: Total volume of β-cells in the islets (V(β-cells, islet)) of 190-day-old mice 
Mt-ovx-E2 mice exhibit a significantly lower total volume of β-cells in their islets as compared to mice 
of the three other groups. Data are means ± SEM; a-b: different letters show significant differences 
(p<0.05); (n): number of animals investigated 
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4.6.7 Volume density of non-β-cells in the islets 
All mutant mice showed a significantly higher volume density of non-β-cells in the 
islets (Vv(non-β-cells/islet)) than wild-type mice. Mt-sham-nt/p mice exhibited a slightly 
lower (n.s.) Vv(non-β-cells/islet) than the ovariectomized mutant mice (mt-ovx-nt/p and    
mt-ovx-E2) (Figure 4.29). 
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Figure 4.29: Volume density of non-β-cells in the islets (Vv(non-β-cells/islet)) of 190-day-old 
mice.  
Sham-operated mutant and wild-type mice (mt-sham-nt/p and wt-sham-nt/p) demonstrate a lower 
volume density of non-β-cells in the islets than ovariectomized mutant mice (mt-ovx-nt/p and mt-ovx-
E2). Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
4.6.8 Total volume of non-β-cells in the islets 
Estradiol-treated ovariectomized mutant mice showed a significantly lower total 
volume of non-β-cells in the islets (V(non-β-cells, islet)) than non-/placebo-treated 
ovariectomized and sham-operated mutant mice. Moreover, wild-type mice exhibited 
a significantly lower total volume of non-β-cells in the islets than non-/placebo-treated 
ovariectomized mutant mice and also a lower total volume than non-/placebo-treated 
sham-operated mutant mice (p=0,09) (Figure 4.30). 
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Figure 4.30: Total volume of non-β-cells in the islets (V(non-β-cells, islet)) of 190-day-old 
mice  
Mt-ovx-E2 mice and wild-type mice demonstrate a smaller total volume of non-β-cells in the islets, 
than mt-ovx-nt/p and mt-sham-nt/p mice.  
Data are means ± SEM; a-c: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
 
4.6.9 Β-cell to non-β-cell ratio 
Wild-type mice demonstrated the highest β-cell to non-β-cell ratio, whereas           
non-/placebo-treated and E2-treated ovariectomized mutants showed the lowest 
values. Non-/placebo-treated sham-operated mutant mice offered a higher β-cell to           
non-β-cell ratio as compared to the two other mutant groups, but the value is still 
lower than that of wild-type mice (Figure 4.31). 
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Figure 4.31: B-cell to non-β-cell ratio in islets of 190-day-old mice 
Non-/placebo- and E2-treated ovariectomized mutant mice demonstrated a significantly lower β-cell to 
non-β-cell ratio as compared to wild-type mice. Non-/placebo-treated sham-operated mutant mice 
showed higher ratio as compared to the two ovariectomized mutant groups, but the difference is 
statistically not significant. 
Data are means ± SEM; a-b: different letters show significant differences (p<0.05); (n): number of 
animals investigated 
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4.6.10 Volume density of isolated β-cells in the pancreas 
Wild-type mice showed a significantly higher volume density of isolated β-cells in the 
pancreas (Vv(isol. β-cells/pan)) than mice of all the three mutant groups (Figure 4.32). 
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Figure 4.32: Volume density of isolated β-cells in the pancreas (Vv(isol. β-cells/pan)) of 190-
day-old mice  
Wild-type mice demonstrate a 1.6- to 1.8-fold higher volume density of isolated β-cells in the pancreas 
(Vv(isol. β-cells/pan)) than mutant mice. Data are means ± SEM; a-b: different letters show significant 
differences (p<0.05); (n): number of animals investigated 
 
4.6.11 Total volume of isolated β-cells 
Wild-type mice showed a significantly higher total volume of isolated β-cells in the 
pancreas (V(isol. β-cells, pan)) as mice of the three mutant groups (Figure 4.33). 
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Figure 4.33: Total volume of isolated β-cells in the pancreas (V(isol. β-cells, pan)) of 190-day-
old mice   
Wild-type mice exhibit an about 1.7-fold higher total volume of isolated β-cells in the pancreas as 
compared to the two non-/placebo-treated mutant mice groups (mt-ovx-nt/p and mt-sham-nt/p) and a 
2.2-fold higher V(isol. β-cells, pan) vs. mt-ovx-E2 mice. Data are means ± SEM; a-b: different letters show 
significant differences (p<0.05); (n): number of animals investigated 
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4.7 Transmission electron microscopy 
Ultrathin pancreas sections of 190-day-old mice were examined using transmission 
electron microscopy. Concerning the amount and distribution of the distinct endocrine 
cells within the islets, electron-microscopical observations were in agreement with 
qualitative histological and immunohistochemical findings (4.5 Qualitative histological 
findings of the endocrine pancreas). Wild-type mice demonstrated a typical murine 
islet structure with basically β-cells in the centre and non-β-cells mainly located at the 
border of the islet (Figure 4.34 A). In all the three mutant mouse groups, non-β-cells 
were distributed all over the islet profile (Figure 4.34 B-D).  
 
 
Figure 4.34: Transmission electron microscopy (TEM) of islet-cell profiles of 190-day-
old mice  
Wild-type (A) mice featured a typical murine islet structure with basically β-cells (β) located in the 
centre and non-β-cells (nβ) located mainly at the border of the islet. In non-/placebo-treated (B) and 
estradiol-treated (C) ovariectomized mutant mice as well as in non-/placebo-treated sham-operated 
mutant mice (D), non-β-cells are distributed all over the islet profile. In some samples, artefacts (a), 
which maybe are a sign of beginning autolysis, can be found; in A, D: capillaries (ca); in C: exocrine 
pancreas (ex. P). 
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The cytoplasm of β-cells from wild-type mice (Figure 4.35 A) was densely packed 
with typical insulin secretory granules, characterised by an electron-dense core, 
surrounded by an electron lucent halo. In mt-ovx-nt/p mice (Figure 4.35 B), many       
β-cells exhibited very few and small secretory granules. Some of the granules 
presented a tiny core and a broadened halo as compared to wild-type mice. In mt-
ovx-E2 mice (Figure 4.35 C) and mt-sham-nt/p mice (Figure 4.35 D), β-cells with a 
granule density comparable to wild-type mice side by side with almost granule-free 
cells could be found, and the size of granule-profiles seemed to be marginally smaller 
than those of wild-type mice, but appeared bigger than those of mt-ovx-nt/p mice 
(Figure 4.35). The differences in the amount and size of secretory granules are 
mirrored by the various immunohistochemical staining intensities of β-cells described 
above (4.5 Qualitative histological findings of the endocrine pancreas). In all mutant 
mice, the rough endoplasmic reticulum (rER) seemed to be dilated as compared to 
wild-type mice (Figure 4.36 and 4.37). A few β-cells of mice from all three mutant 
groups (Figure 4.36 B - D) contained enlarged mitochondria. 
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Figure 4.35: Transmission electron microscopy (TEM) of islet-cell profiles of 190-day-
old mice 
Beta-cells of wild-type mice (A) show a high density of secretory granules.The amount of secretory 
granules in β-cells of mt-ovx-nt/p (B), mt-ovx-E2 (C) and mt-sham-nt/p (D) mice varies substantially 
within the islet. Some β-cells exhibit approximately a similar granule density as wild-type mice (e.g. β-
cell in the centre of Fig. B), but the adjacent β-cells are nearly devoid of insulin granules; mitochondria 
( M)   (A-D); Golgi lamellae ( GL) (A); rough endoplasmic reticulum ( rER) (A-D). 
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Figure 4.36: Transmission electron microscopy (TEM) of β-cell profiles of 190-day-old 
mice 
In some β-cells of mt-ovx-nt/p mice (B), the rough endoplasmic reticulum ( rER) appears dilated as 
compared to wild-type mice (A). Mt-ovx-E2 (C) and mt-sham-nt/p (D) mice in the same cell 
demonstrate ER that is almost unaltered as well as ER that appears to be slightly dilated. Mt-ovx-nt/p 
mice exhibit only few and small secretory granules ( sg); mt-ovx-E2 and mt-sham-p mice also show 
slightly fewer secretory granules compared to wild-type mice, but the size seems to be a similar; 
mitochondria ( M) (A-D); Golgi lamellae ( GL) (A, D); in C: α-cell (α) 
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Figure 4.37: Transmission electron microscopy (TEM) of β-cell profiles of 190-day-old 
mice  
Mt-ovx-nt/p (B), mt-ovx-E2 (C) and mt-sham-nt/p (D) mice exhibit a dilated rough endoplasmic 
reticulum ( rER) as compared to wild-type mice (A). 
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5 Discussion 
Heterozygous Munich Ins2C95S mutant mice exhibit a point mutation in the Ins2 gene, 
leading to the development of diabetes mellitus. It could be shown that heterozygous 
male mutant mice develop a severe progressive diabetic phenotype with severe      
β-cell dysfunction and profound loss of functional β-cell mass, whereas female 
mutants show stable and much milder diabetic symptoms and β-cell mass was not 
found to be reduced (Herbach et al. 2007). This phenomenon Is thought to result 
from antidiabetic actions of 17βEstradiol (E2) in both humans and rodents (Louet et 
al. 2004). 
The present study was performed to examine the influence of 17βEstradiol (E2) on  
β-cell survival in the pancreas of female Munich Ins2C95S mutant mice as well as its 
impact on glucose homeostasis. For this purpose, two groups of heterozygous 
female mutant mice have been ovariectomized and received either a 17βEstradiol 
replacement therapy or a placebo. Non-/placebo-treated sham-operated wild-type 
and non-/placebo-treated sham-operated mutant mice served as controls.  
5.1 Glucose homeostasis 
5.1.1 Blood glucose and insulin secretion 
Mutant and wild-type mice showed almost similar randomly fed blood glucose 
concentrations at weaning. Five days after ovariectomy/sham-operation (at 35 days 
of age), ovariectomized non-/placebo-treated mutant mice already developed 
hyperglycaemia, and showed a progressive diabetic phenotype with raising blood 
glucose concentrations up to 360 mg/dl at an age of 160 days. The progressive 
course of disease is similar to that in male heterozygous Munich Ins2C95S mutant 
mice, but males reached even higher blood glucose levels (550 mg/dl at an age of 
160 days) (Kautz 2010). Although sham-operated non-/placebo-treated mutant mice 
demonstrated blood glucose concentrations of almost 200 mg/dl at an age of 35 days 
and therefore were mildly hyperglycaemic, they showed almost constant glucose 
levels during their lifespan, never exceeding 200 mg/dl. Intact female heterozygous 
Akita mice, which also exhibit a mutation in the Ins2 gene, demonstrated almost 
stable randomly fed blood glucose concentrations from an age of 4 weeks onwards 
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as well, never reaching 330 mg/dl. The glucose levels of female Akita mice were 
higher as compared to female sham-operated Munich Ins2C95S mutant mice, but 
significantly lower as compared to male Akita mice (Yoshioka et al. 1997).  
Estradiol-treated ovariectomized Munich Ins2C95S mutant mice demonstrated almost 
similar blood glucose concentrations as wild-type mice at all time points investigated.  
In contrast to Munich Ins2C95S mutant mice and heterozygous Akita mice, single 
homozygous Ins2 and Ins1 knockout mice stay normoglycaemic, most likely due to 
compensation by increased Ins1 or Ins2 expression (Leroux et al. 2001,            
Leroux et al. 2003). Moreover, single heterozygous null-mutant mice with only one 
single Ins2 gene (NODIns1-/-,Ins2+/-) do not develop diabetes (Babaya et al. 2006), 
whereas double homozygous null mutant mice develop severe hyperglycaemia and 
die within the first 48h (Duvillie et al. 1997). Due to the fact that both heterozygous 
Munich Ins2C95S mutant mice as well as heterozygous Akita mice possess one intact 
Ins2 allele and 2 intact Ins1 alleles, the mutant insulin 2 seems to exert dominant 
negative effects on β-cell function and viability (Herbach et al. 2007,                    
Wang et al. 1999). The mutant proinsulin 2 molecules aggregate more easily than 
wild-type proinsulin and it could be shown that such aggregates also include wild-
type proinsulin due to hydrophopic interactions (Liu et al. 2007,                    
Yoshinaga et al. 2005), leading to an aggregation as well as degradation of not only 
mutant, but also wild-type proinsulin and a reduced transport of both to secretory 
granules (Wang et al. 1999). Moreover, misfolded proinsulin 2 most probably causes 
ER-stress like it is seen in heterozygous Akita mice (Wang et al. 1999,         
Yoshinaga et al. 2005), leading to the induction of β-cell apoptosis               
(Oyadomari et al. 2002).  
The progressive diabetic phenotype of non-/placebo-treated ovariectomized mutants 
can be explained by impaired insulin secretion, development of insulin resistance and 
a reduction of the total β-cell volume, similar to male Munich Ins2C95S mutant mice 
(Herbach et al. 2007). This leads to the conclusion that most likely endogenous 
estrogen produced in the ovaries from sham-operated non-/placebo-treated mutant 
mice protects them from developing a severe diabetic phenotype. Moreover, 
17βEstradiol replacement therapy could even normalise blood glucose levels of 
ovariectomized mutant mice.  
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Fasting blood glucose concentrations of ovariectomized non-/placebo-treated mutant 
mice were significantly higher as compared to sham-operated non-/placebo-treated 
mutant mice at all time points investigated, reaching the highest level of almost     
200 mg/dl at an age of 120 days. Nevertheless, the glucose levels were always lower 
as compared to male mutant mice with fasting blood glucose concentrations 
exceeding 300 mg/dl at an age of 180 days (Herbach et al. 2007). Estradiol-treated 
ovariectomized mutant mice however did not exhibit fasting hyperglycaemia and 
moreover demonstrated even lower fasting blood glucose concentrations as 
compared to wild-type mice. Sham-operated non-/placebo-treated mutant mice only 
showed a mild diabetic phenotype with mean fasting blood glucose levels always 
under 135 mg/dl. 
The mechanisms that regulate the plasma glucose concentration during the post-
absorptive state (fasting plasma glucose) are very different from those that regulate 
the plasma glucose concentration after a meal (DeFronzo 2004). Fasting plasma 
glucose (FPG) is primarily determined by the rate of hepatic glucose production 
(DeFronzo et al. 1989), whereas postprandial glucose concentration is determined by 
the rate of glucose-stimulated insulin secretion and skeletal muscle insulin sensitivity. 
Physiologically, pancreatic α-cells release glucagon during hypoglycaemia to induce 
hepatic glucose output (Gromada et al. 2007). High blood glucose concentrations 
inhibit glucagon secretion via direct effects on α-cells and most likely also in an 
indirect manner, for example via increasing insulin secretion (Dunning et al. 2005). 
Alpha-cells in chronically hyperglycaemic patients demonstrate disturbed glucose 
sensing resulting in hyperglucagonaemia which can further contribute to 
hyperglycaemia (Quesada et al. 2008, Unger et al. 1970). In male Munich Ins2C95S 
mutant mice, an increase in randomly fed glucagon levels was observed, whereas 
glucagon levels in female mutant and wild-type mice were almost similar            
(Kautz 2010). The mechanisms contributing to the α-cell pathology/dysfunction are 
still largely unknown (Quesada et al. 2008). Since fasted glucagon concentrations in 
mutant mice of both genders were similar to those of sex-matched wild-type mice 
(Kautz 2010), the fasting hyperglycaemia seen in ovariectomized placebo-treated 
mutant mice seems not to be aroused by elevated hepatic glucose synthesis due to 
hyperglucagonaemia.  
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In oral glucose tolerance tests, all three mutant groups showed higher areas under 
the blood glucose curve (AUCblood glucose) as compared to wild-type mice, irrespective 
of age at sampling. Non-/placebo-treated ovariectomized mutant mice showed 
significantly higher AUCblood glucose as compared to E2-treated ovariectomized and 
sham-operated mutants, indicating that the loss of estrogen leads to a further 
deterioration of glucose tolerance. Although estradiol-treated ovariectomized mutant 
mice demonstrated normalised fasting and randomly fed glucose levels vs.          
non-/placebo-treated mutant mice, the AUCblood glucose during OGTT was not improved 
vs. sham-operated mutant mice. The improved glucose tolerance in estrogen-treated 
vs. non-/placebo-treated ovariectomized mice is likely due to positive effects of 
estrogen on glucose stimulated insulin secretion (Ropero et al. 1999), insulin 
sensitivity in peripheral tissues (Barros et al. 2006b, Lee et al. 1999), or a 
combination of both. In estrogen receptor α knock-out mice (αERKO) an impaired 
glucose tolerance compared to wild-type mice was observed (Heine et al. 2000). 
These findings are consistent with data that ovariectomy in rodents impairs glucose 
tolerance and alters glucose-induced insulin secretion, whereas estrogen 
replacement partially or completely prevents this (Bailey and Ahmed-Sorour 1980). 
However, E2-treatment is not sufficient to restore glucose tolerance of female Munich 
Ins2C95S mutants completely. Therefore it seems likely that the effects of the mutation 
have higher negative impact on glucose tolerance than the positive effects of E2 to 
prevent them. 
The decrease of blood glucose concentrations after glucose challenge in all three 
mutant mice groups was delayed compared to wild-type mice and most likely due to 
disturbed insulin secretion 10 minutes after glucose application (Herbach et al. 2007). 
The fasted serum insulin concentrations of all mutant mice groups were almost 
similar to that of wild-type mice at an age of 90 days. At an age of 180 days E2-
treated ovariectomized mutant mice demonstrated significantly lower fasted serum 
insulin levels as compared to non-/placebo-treated ovariectomized mutants and wild-
type mice.  
Ten minutes after oral glucose application, the insulin secretion in wild-type mice 
increased about 10-fold as compared to basal values, whereas non-/placebo-treated 
ovariectomized and sham-operated mutant mice just showed a 1.4 and 1.9-fold 
increase from basal insulin levels at an age of 180 days. E2-treated ovariectomized 
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mutant mice showed with a 2.5-fold increase the highest level within the three mutant 
mice groups.  
The β-cell function indices homeostasis model assessment of baseline insulin 
secretion (HOMA B) and insulin resistance (HOMA IR (%)), were developed to 
calculate β-cell function and insulin resistance in human-beings (Lee et al. 2008, 
Wallace et al. 2004). The relationship between glucose and insulin in the basal 
(fasting) state reflects the balance between hepatic glucose output and insulin 
secretion, which is maintained by a feedback loop between the liver and β-cells 
(Turner et al. 1979). HOMA B, reflecting β-cell function, was significantly lower in 
both ovariectomized as well as sham-operated non-/placebo-treated mutant mice as 
compared to estradiol-treated ovariectomized mutant and wild-type mice.  
All these results indicate that mutant mice suffer from a disturbed glucose-stimulated 
insulin secretion (GSIS) that is fractionally ameliorated by estradiol. Nevertheless, the 
GSIS seen in E2-treated ovariectomized mutants is still exceeding low as compared 
to wild-type mice. It could be shown, that chronic hyperglycaemia can cause 
alterations in mitochondrial protein expression levels like e.g. the inner mitochondrial 
protein uncoupling protein 2 (UCP2), which has been associated with impaired GSIS 
(Nyblom et al. 2006, Wang et al. 1999). This could be one reason for the disturbed 
GSIS of placebo-treated ovariectomized and sham-operated mutant mice, but it 
could not explain the impaired GSIS in estradiol-treated ovariectomized mutant mice, 
because they did not show chronic hyperglycaemia, indicating that high blood 
glucose levels cannot be the main reason for the disturbed GSIS. It also could be 
shown that the disturbance in GSIS of female mutant mice is equal to that of male 
Munich Ins2 mutants despite a higher pancreatic insulin content of female vs. male 
mutants (Herbach et al. 2007), arguing against depletion of insulin stores as a cause 
of impaired GSIS. Isolated pancreatic islets of male Akita mice also demonstrated a 
reduced GSIS compared to wild-type mice, speaking for the point that partial 
misfolding of mutant proinsulin like in both the Munich Ins2C95S mutant mouse as well 
as the Akita mutant mouse, may lead to the disturbed insulin secretion                 
(Izumi et al. 2003, Liu et al. 2005). In the Munich Ins2C95S mutant mouse, the A6-A11 
intrachain disulfide bond is disrupted whereas the mutation existent in the Akita 
mutant mouse prevents formation of the A7-B7 interchain disulfide bond. In studies 
with HEK293 cells, expressing the mutant proinsulin from Akita mice, an increased 
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fraction of non-native proinsulin disulfide isomers was observed as well as a 
profound decrease in secretion, probably leading to intracellular degradation of non-
secreted proinsulin (Colombo et al. 2008). Izumi et al. (2003) could demonstrate that 
the early secretory pathway in β-cells of Akita mice is impaired due to the intracellular 
accumulation of misfolded proinsulin. As a consequence, secretion of both, wild-type 
and mutant proinsulin is disturbed (Izumi et al. 2003).  
Furthermore, ER-stress, caused by the misfolded proinsulin, may be involved in the 
disturbed GSIS. Energy consumption by chaperones participating in ER-stress 
mediated pathways can decrease the ATP/ADP ratio, leading to a reduced increase 
of this ratio after glucose uptake. Moreover, Ca2+ release from the ER upon           
ER-stress may elevate intracellular Ca2+ levels (Scheuner and Kaufman 2008,        
Xu et al. 2005). Likewise, chronically high glucose leads to high basal Ca2+ levels, 
reduced glucose-induced Ca2+ increase and is associated with disturbed insulin 
secretion after glucose stimulus (Bjorklund et al. 2000).  
Since estradiol-treated ovariectomized mutant mice at an age of 180 days 
demonstrated the highest increase of serum insulin 10 min after glucose stimulus as 
compared to mice of the two other mutant groups, it seems like estradiol may slightly 
improve the GSIS. This may be due to the capability of estradiol to potentiate insulin 
secretion after glucose stimulus (Ropero et al. 1999) or because of its positive effects 
related to ER-stress (Kozlov et al. 2010). Although sham-operated non-/placebo-
treated mutant mice showed a significantly higher GSIS as compared to 
ovariectomized non-/placebo-treated mutant mice, the increase of serum insulin       
10 min after glucose stimulus is slightly lower than that of estradiol-treated 
ovariectomized mutant mice. One explanation for this could be the absence of 
elevated blood glucose concentrations and therefore elimination of the negative 
impact of chronic hyperglycaemia on GSIS in estradiol-treated mutants (see above).  
 
Taken together, ovariectomy aggravates the diabetic phenotype of Munich Ins2C95S 
mutant mice, as evidenced by increased fasting and postprandial glucose levels vs. 
sham-operated mutant mice. E2-treatment rescues ovariectomized mutant females 
from developing diabetes and ameliorates disturbed glucose tolerance. However, 
disturbed GSIS is not or only slightly improved. Therefore, misfolding of mutant 
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proinsulin seems to play a major role in disturbed GSIS, whereas glucotoxicity plays 
no or only a minor role. 
5.1.2 Insulin sensitivity 
For the analysis of insulin sensitivity, intraperitoneal insulin tolerance tests (ipITT) 
were performed with mice that were not supplied with E2 or placebo pellets (non-
treated). Ovariectomized non-treated mutant mice showed a significantly higher 
AUCblood glucose during ITT as compared to sham-operated non-treated mutant and 
wild-type mice at an age of 60 and 187 days, indicating impaired insulin sensitivity in 
the absence of ovarian hormones. At the same time points, sham-operated           
non-treated mutant and wild-type mice showed almost similar areas under the blood 
glucose curve. In concordance to these findings, the HOMA IR, reflecting insulin 
resistance in both peripheral tissues and the liver, was higher in non-/placebo-treated 
ovariectomized mutant mice as compared to mice of all three other groups.            
E2-treated ovariectomized mutant mice as well as non-/placebo-treated sham-
operated mutant mice showed a similar HOMA IR. These results confirm the findings 
of the accomplished intraperitoneal insulin tolerance tests and reveal the positive 
effect of estrogen on insulin sensitivity. Due to the fact that normoglycaemic insulin-
treated male Munich Ins2C95S mutant mice showed similar insulin sensitivity 
compared to sex-matched wild-type mice, whereas placebo-treated hyperglycaemic 
male mutant mice demonstrated severely impaired insulin sensitivity (Kautz 2010), it 
seems like the development of insulin resistance is likely the consequence of 
chronically elevated blood glucose levels. It is known that long-term hyperglycaemia 
may lead to oxidative stress (Robertson 2004), which reduces insulin sensitivity, for 
example, in myocytes and adipocytes (Houstis et al. 2006, Maddux et al. 2001). 
Phloridizin, a substance that can be used to lower blood glucose concentration, was 
able to ameliorate peripheral insulin resistance in the Akita mouse (Hong et al. 2007). 
Therefore it seems likely that the impaired insulin sensitivity seen in placebo-treated 
ovariectomized mutant mice in part is a result of the chronic elevated blood glucose 
concentrations seen in these mice. On the other hand, normoglycaemic E2-treated 
ovariectomized mutant mice but also mildly hyperglycaemic non-/placebo-treated 
sham-operated mutant mice do not or only to a minor degree suffer from impaired 
insulin sensitivity due to chronic hyperglycaemia, what also would explain the lower 
HOMA IR apparent in these two groups as well as the lower AUCblood glucose during 
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ipITT in sham-operated mutant mice as compared to non-/placebo-treated 
ovariectomized mutant mice. 
Furthermore it could be shown that estradiol can improve glucose uptake in 
peripheral tissues after binding of insulin to its receptor on the target cell by inducing 
the expression of the downstream signalling molecules IRS-1 and IRS-2               
(Lee et al. 1999). In addition to this, estrogen was shown to increase β-cell function 
and mass by an increase of IRS2 and PDX-1 expression in islets of ovariectomized 
rats that indirectly leads to an enhanced IGF-1/insulin signalling cascade and results 
in an enlargement of pancreatic β-cell mass (Choi et al. 2005). Therefore it is 
possible that endogenous estrogen of sham-operated non-/placebo-treated female 
Munich Ins2C95S mutant mice as well as exogenous estradiol in E2-treated 
ovariectomized mutant mice accounts for the ameliorated peripheral insulin 
sensitivity and leads to the significantly lower insulin resistance as compared to 
estrogen lacking ovariectomized non-/placebo-treated mutant mice. It also should be 
taken into account that obesity in humans also is known to impair insulin sensitivity 
(Ahren 2005) and therefore, the mildly increased body weight of non-/placebo-treated 
ovariectomized mutant mice in comparison to mice of the other three groups could be 
another promoting factor in the development of insulin resistance.  
Taken together, the findings of the present study underline the assumption that most 
likely hyperglycaemia and additionally obesity may lead to insulin resistance that 
contributes to the progressive diabetic phenotype of non-/placebo-treated 
ovariectomized mutants. 17βEstradiol seems to improve insulin sensitivity by several 
factors such as increased glucose uptake after insulin stimulation by mainly inducing 
the expression of IRS-1 in peripheral tissues (Lee et al. 1999) and improvement of    
β-cell function and mass by inducing the expression of IRS-2 to compensate for the 
increased insulin requirement (Choi et al. 2005). Moreover estradiol is known to 
reduce body weight in rodents (see below) what might also have beneficial influence 
on insulin sensitivity. 
5.2 Body weight 
Mice of all 4 groups showed similar body weights in the time between weaning        
(21 days of life) and ovariectomy (30 days of life). Five days after ovariectomy/sham-
operation, non-/placebo-treated ovariectomized mutant mice already demonstrated 
higher body weights as compared to mice of the 3 other groups, indicating that 
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estrogen participates in the regulation of fat mass, most likely by affecting the 
expression of leptin, an important feedback controller of energy balance that acts to 
increase metabolism and depress appetite (Ahima et al. 1996). It is mainly produced 
and secreted by adipose cells and its circulating concentration normally correlates 
directly with body fat content (Considine et al. 1996). After release of leptin into the 
bloodstream it influences specific regions of the brain, such as the hypothalamus, 
where it affects the activity of the hypothalamus-pituitary axis by modulating the 
expression of several neuropeptides, such as neuropeptide Y (NPY) and 
corticotropin-releasing hormone (CRH) (Beck 2000). Estradiol is known to enhance 
the expression and secretion of leptin by adipocytes, both in vitro                  
(Kronfeld-Schor et al. 2000) and in vivo (Tanaka et al. 2001). In rats, ovariectomy 
diminished leptin gene expression in white adipose tissue and caused a decline in 
serum leptin levels while administration of E2 reversed all the effects of ovariectomy 
(Chu et al. 1999). Bilateral ovariectomy was also reported to reduce serum leptin 
levels in humans (Messinis et al. 1999). Moreover, the administration of estrogen 
increases hypothalamic expression of the long form of the leptin receptor in rats                
(Rocha et al. 2004). On the other hand, estrogen deficiency increases hypothalamic 
NPY by direct genomic modulation and causes central and/or peripheral leptin 
insensitivity (Ainslie et al. 2001). Mice lacking estrogen receptor-α (αERKO mice) or 
aromatase (ArKO mice) showed increased fat mass and hyperlipidemia             
(Heine et al. 2000, Jones et al. 2000). 
Taken together, ovariectomy may alter body weight by reducing the amount of leptin 
secreted by adipose tissue, resulting in an inappropriately low satiety signal. 
Moreover, lack of estrogen may affect body weight regulation at a central level like 
increase of NPY and decrease of CRH, which both promote hyperphagia, leading to 
mild obesity of non-/placebo-treated ovariectomized mutant mice. 
Estradiol-treated ovariectomized mutant mice demonstrated a significantly lower 
body weight as compared to all 3 other groups. The reason for this may be the 
generally known potent suppressive effect of estradiol on food intake in rodents, but 
the underlying mechanism of E2 action on appetite are still not fully understood 
(Geary 2000). Some authors suggest a taste aversive effect, but this still remains 
controversial (Flanagan-Cato et al. 2001, Ganesan 1994). Moreover, attention was 
focused on the hypothalamus as a possible site of E2 action. It was suggested that a 
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decrease in either hypothalamic NPY, or melanin-concentrating hormone (MCH) 
expression and levels may mediate anorexia (Bonavera et al. 1994,             
Mystkowski et al. 2000). In another study it could be demonstrated that 
administration of fatty acid synthase (FAS) inhibitors leads to decreased food intake 
and body weight in rodents (Loftus et al. 2000). The selective estrogen receptor 
modulator tamoxifen (TAM) can induce anorexia and thereby is associated with the 
accumulation of malonyl-CoA in the hypothalamus and inhibition of FAS expression 
(Lopez et al. 2006). All these findings indicate that the low body weight of estradiol-
treated ovariectomized mutant mice is a result of decreased food intake aroused by 
the still not completely known anorectic effects of high dose 17βEstradiol. 
5.3 Oxidative stress 
To reveal the degree of lipid peroxidation, thiobarbituric acid reactive substances 
(TBARS) are often used as a marker for oxidative stress in diabetic animal models 
and in humans (Maritim et al. 2003). At an age of 190 days, non-/placebo-treated 
ovariectomized mutant mice demonstrated about 2-fold higher serum TBARS levels 
as compared to non-/placebo-treated sham-operated mutant and wild-type mice and 
even 2.4-fold higher levels as compared to estradiol-treated ovariectomized mutant 
mice. In addition, blood glucose levels of the investigated groups correlated with lipid 
peroxidation in the serum, indicating that severe hyperglycaemia caused oxidative 
stress in non-/placebo-treated ovariectomized mutant mice. Endogenous estrogens 
in sham-operated non-/placebo-treated mutant mice as well as E2-treatment in 
ovariectomized mutants seem to prevent lipid peroxidation and probably oxidative 
stress. Significantly higher lipid peroxidation levels, owing to elevated free radicals, 
were observed in humans suffering from type 1 or type 2 diabetes mellitus 
(Griesmacher et al. 1995). Several studies accomplished on rats also demonstrated 
higher lipid peroxidation levels, for example in the serum of streptozotocin-induced 
diabetic Wistar rat (Ozansoy et al. 2001) and the Zucker diabetic fatty rat       
(Coppey et al. 2002).  
These results confirm the potential role of elevated blood glucose concentrations to 
increase lipid peroxidation. Moreover, it could be shown that estrogen may directly 
prevent oxidative stress by blocking JNK-activity (Srivastava et al. 1999) and it can 
also protect β-cells after streptozotocin exposure via extranuclear mechanisms 
through mainly ERα and additional in a GPER dependent manner. Furthermore, 
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estrogen was shown to exhibit antioxidative effects by up-regulating the expression 
of mitochondrial superoxide dismutase and glutathione peroxidase via binding to the 
estrogen receptor and activation of the MAPK pathway                  (Viña et al. 2005). 
Estrogen therefore may lead to the significantly lower lipid peroxidation in sham-
operated mutant and wild-type mice as well as in ovariectomized mutant mice 
receiving estradiol replacement therapy.  
It could be shown that oxidative stress has negative impact on insulin sensitivity of 
adipocytes and muscle cells (Houstis et al. 2006, Maddux et al. 2001). Oxidative 
stress leads to the activation of multiple serine kinase cascades                     
(Kyriakis and Avruch 1996) and potential targets of these kinases in the insulin 
signalling pathway include the insulin receptor (IR) and insulin receptor substrate 
(IRS) 1 and 2. Phosphorylation of IRS1 and IRS2 results in disturbed binding to the 
IR and impaired interaction with downstream target molecules with the consequence 
of impaired insulin action (Evans et al. 2002). Further, it was demonstrated in several 
in vitro and in vivo studies that oxidative stress reduces DNA binding activity of the 
transcription factors PDX-1 and MafA in β-cells, resulting in disturbed              
glucose-stimulated insulin secretion (GSIS) (Kaiser et al. 2003,                                  
Robertson and Harmon 2006). In addition, chronic hyperglycaemia and oxidative 
stress may reduce functional β-cell mass and lead to β-cell apoptosis                  
(Kaiser et al. 2003). 
The decreased lipid peroxidation and therefore diminished oxidative stress in       
non-/placebo-treated sham-operated as well as E2-treated ovariectomized mutant 
mice therefore may lead to an improved insulin signalling and higher insulin 
sensitivity in peripheral tissues as well as to an increased GSIS and reduced β-cell 
apoptosis. 
5.4 ER-stress 
5.4.1 Islet isolation 
The isolation of pancreatic islets was accompanied by some difficulties in             
non-/placebo-treated ovariectomized mutant mice and some estradiol-treated 
ovariectomized mutant mice. Normally, islets appear brighter than exocrine tissue 
and are round to oval shaped, with a smooth surface. Islets of ovariectomized 
mutants showed almost the same colour as exocrine tissue. To improve the optical 
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identification of islets, mice of Group 2 were perfused with neutral red before 
sacrifice, thereby producing islets that are stained red. Gray et al. (1983) reported 
that intravenous given neutral red selectively stains islets in the rat, pig and dog and 
does not appear to affect their viability as judged by insulin secretion and 
transplantation (Gray et al. 1983). However, islets of non-/placebo-treated 
ovariectomized mutant mice were very fragile, leading to deformation and 
fragmentation. The resulting irregular shape of the fragmented islets aggravated the 
differentiation from exocrine pancreas clusters even more and led to a contamination 
of islet samples with exocrine tissue. Similar difficulties were faced during islet 
isolation of Akita mice, leading to a considerable contamination of islet samples with 
non-endocrine tissue (around 30%) (Izumi et al. 2003). It is documented that 
oxidative stress due to hyperglycaemia leads to protein oxidation in serum of type 1 
diabetic patients (Ramakrishna and Jailkhani 2007) as well as in pancreata of Cohen 
diabetic rats (Ryu et al. 2008). This suggests that the reduced stability of the islets of 
hyperglycaemic non-/placebo-treated ovariectomized mutant mice may be due to 
reactive oxygen species that interact with proteins within the peri-insular capsule.   
5.4.2 ER-stress markers 
Isolated islets of 210-day-old non-/placebo-treated ovariectomized mutant mice 
demonstrated an increased abundance of BiP and CHOP as compared to            
non-/placebo-treated sham-operated mutant as well as wild-type mice. Estradiol-
treated ovariectomized mutant mice also exhibited a higher abundance of BiP as 
compared to the two sham-operated groups, but the amount was slightly less as 
compared to non-/placebo-treated ovariectomized mutant mice. Sham-operated    
non-/placebo-treated mutant and wild-type mice showed almost similar amounts of 
BiP and CHOP. All 4 groups demonstrated a similar abundance of PeIF2α. However, 
it must be taken into account that the contamination of the islet samples of 
ovariectomized mutant mice with exocrine pancreas tissue results in decreased islet-
protein content in samples, especially of non-/placebo-treated ovariectomized 
mutants. This may lead to an underestimation of ER-stress associated proteins in    
β-cells of these mice and therefore Western blot analyses have to be interpreted 
carefully. 
The three transducers of ER-stress signalling IRE1α, ATF6 and PERK together 
emanate a transcriptional and translational program, the so called unfolded protein 
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response (UPR), when unfolded proteins accumulate within the ER lumen    
(Kaufman et al. 2002, Ron and Walter 2007). They are maintained in an inactivate 
state through interaction with the protein chaperone BiP (Bertolotti et al. 2000). Upon 
accumulation of unfolded protein, BiP is released from each sensor, leading to its 
activation (Scheuner and Kaufman 2008). BiP and CHOP are both induced during 
UPR and it could be shown that both BiP and CHOP levels were significantly 
elevated in islets from type 2 diabetic patients compared to non-diabetics       
(Laybutt et al. 2007). Since BiP synthesis is induced by the accumulation of mutated 
proteins in the ER or by a number of different stress conditions that increase aberrant 
protein folding (Gething and Sambrook 1992), the accumulation of misfolded 
proinsulin 2 in β-cells of Akita mice leads to the induction of BiP and other ER-stress 
markers. It also could be shown in islets of Akita mice that high molecular weight 
forms of proinsulin existed with concomitant overexpression of BiP                    
(Wang et al. 1999). Therefore it was expected that Munich Ins2C95S mutant mice also 
show elevated BiP amounts in their islets because of accumulation of unfolded 
proinsulin 2. Due to the fact that only non-/placebo-treated and estradiol-treated 
ovariectomized mutant mice demonstrated a higher BiP abundance as compared to 
wild-type mice, it is likely that sham-operated non-/placebo-treated mutant mice were 
somehow protected from ER-stress. It is suggested that 17βEstradiol has a 
protective effect against ER-stress by decreasing XBP1(S) and CHOP mRNA levels 
(Kozlov et al. 2010), but the exact mechanisms are still unclear. Since estradiol-
treated ovariectomized mutant mice showed only slightly less BiP abundance as 
compared to non-/placebo-treated ovariectomized mutant mice, it seems like other 
ovarian hormones or gonadal factors may have protective effects against ER-stress.   
The transmembrane signalling protein PERK senses the biosynthetic protein-folding 
load on the ER and attenuates and thereby controls the rate of mRNA translation 
initiation by phosphorylation of its major physiological substrate, eukaryotic initiation 
factor 2, on the α-subunit (eIF2α) (Scheuner and Kaufman 2008). In islets of diabetic 
db/db mice, expression of various genes of the unfolded protein response (UPR) was 
increased including that of PeIF2α compared to non-diabetic controls              
(Laybutt et al. 2007). However, the abundance of PeIF2α was almost similar in all 
Munich Ins2C95S mutants and wild-type mice, speaking for the point that the mutation 
did not lead to a translational attenuation. These results are in accordance with the 
5  Discussion 120 
 
findings in Akita mice, where mutant proinsulin does not profoundly reduce protein 
synthesis (Izumi et al. 2003).  
The transcription factor CHOP (GADD153) activates downstream genes encoding 
proapoptotic functions (Scheuner and Kaufman 2008). In the Akita mouse, CHOP 
mRNA levels were much higher as compared to controls (Oyadomari et al. 2002). 
Due to the fact that non-/placebo-treated ovariectomized Munich Ins2C95S mutant 
mice showed a higher CHOP-abundance than non-/placebo-treated sham-operated 
mutant and wild-type mice, it appears that a substance produced from the ovaries 
may protect β-cells from ER-stress induced apoptosis mediated by CHOP 
(Oyadomari and Mori 2004). E2 may be such a substance, but this could not be 
analysed in this study because CHOP was not detectable in samples of mice from 
Group 2. 
Taken together, the results indicate that ovariectomy enhances ER-stress in islets of 
Munich Ins2C95S mutants. However, due to the lower purity of islet extracts of mutant 
mice vs. wild-type mice, these data have to be interpreted carefully. 
5.5 Qualitative and quantitative morphological investigations of the 
endocrine pancreas 
Pancreas sections have been immunostained for insulin (β-cells) or simultaneously 
stained for glucagon, somatostatin and pancreatic polypeptide (non-β-cells). Staining 
for non-β-cells was performed due to the fact that the insulin content in islets of 
Munich Ins2C95S mutants is low and β-cells are severely degranulated, thereby 
leading to a weak staining intensity of β-cells for insulin (Herbach et al. 2007). In 
addition, the antibody used in studies on Akita mice only detected wild-type, but not 
mutant insulin (Izumi et al. 2003, Wang et al. 1999). Therefore, β-cells might not be 
identified by insulin staining, leading to an underestimation of the β-cell proportion in 
the islets of both Akita and Munich Ins2C95S mutant mice. Furthermore, in 4-week-old 
male Akita mice, the islet area stained for insulin and glucagon was documented to 
be less than 50% that of wild-type mice (Yoshioka et al. 1997). Since it is estimated 
that δ- and PP-cells together account for less than about 10% of the islet area 
(Brissova et al. 2005, Herbach et al. 2007), it seems likely that many of the endocrine 
cells without detectable immunoreactivity for insulin nevertheless were β-cells. 
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5.5.1 Qualitative histological analyses 
Pancreas sections immunostained for insulin revealed that all mutant mice 
demonstrated less insulin-positive cells in their islet profiles as compared to wild-type 
mice, with non-treated ovariectomized mutant mice featuring fewest insulin-positive 
cells and an all-in-all weaker staining intensity as compared to wild-type mice. Non-
treated sham-operated mutant mice and E2-treated ovariectomized mutant mice 
seemed to possess almost similar amounts of insulin-positive cells within their islets, 
but exhibited more insulin positive cells than non-treated ovariectomized mutants and 
fewer than wild-type mice. Immunostaining for non-β-cells demonstrated an altered 
islet composition in all mutant groups, especially in non-treated and estradiol-treated 
ovariectomized mutant mice. While wild-type mice exhibited a typical murine islet 
composition with a core of mainly insulin-positive cells, surrounded by a small ring of 
non-β-cells, mutant mice showed an increased proportion of non-β-cells that were 
dispersed all over the islet profile. Such alterations in the islet composition were also 
observed in other diabetic mouse models like the PERK knockout mouse        
(Harding et al. 2001) and GIPRdn transgenic mice (Herbach et al. 2005), irrespective 
of the underlying genetic manipulation. Therefore, it is considered that 
hyperglycaemia plays a central role in the disturbed islet composition. Nevertheless, 
GIPRdn transgenic mice demonstrated a disturbed islet composition already before 
the onset of hyperglycaemia (Herbach et al. 2005). Further, insulin-treated 
heterozygous male Munich Ins2C95S mutant mice, which demonstrated normalised 
blood glucose concentrations compared to placebo-treated heterozygous mutants, 
also showed an about 40% reduction of the β-/non-β-cell ratio as compared to wild-
type mice (Kautz 2010).  
5.5.2 Quantitative stereological analyses 
Quantitative stereological investigations were performed using state-of-the-art 
unbiased model-independent stereological methods (Gundersen et al. 1988,     
Wanke et al. 1994). 
The volume density of β-cells in the pancreatic islets was slightly decreased in all 
mutant groups as compared to wild-type mice at an age of 190 days. Islets of wild-
type mice comprised 87% β-cells, both ovariectomized non-/placebo- and estradiol-
treated mutant mice exhibited 79% and sham-operated non-/placebo-treated mutants 
83% β-cells in their islets.  
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The total β-cell volume was significantly reduced only in E2-treated mutants as 
compared to wild-type mice. Non-/placebo-treated ovariectomized mutants showed 
an about 20% and sham-operated non-/placebo-treated mutant mice an about     
10% decreased total β-cell volume, whereas E2-treated ovariectomized mutant mice 
demonstrated a 53% decrease compared to wild-type mice, but this is most probably 
due to the significantly reduced total pancreas volume compared to all three other 
groups. Since the relative pancreas weight of all 4 groups was almost identical, the 
reduced total pancreas volume of E2-treated ovariectomized mutants most likely is a 
result of the reduced body weight. Remarkable is the fact that the total β-cell volume 
of 180-day-old male Munich Ins2C95S mutant mice was decreased by 81% compared 
with sex-matched wild-type mice whereas female mutants only showed a             
19% decrease. This resulted in a large increase of the total volume of non-β-cells in 
male mutant mice (Herbach et al. 2007). The differences in the total volume of β-cells 
between male and female mutant mice led to the assumption, that female mutant 
mice are somehow protected from changes in the islet structure and this may be due 
to beneficial effects of ovarian hormones or other substances produced in the 
ovaries. Surprisingly, ovariectomy had only a minor influence on the total volume as 
well as the volume density of β-cells in islets of Munich Ins2C95S mutants vs. wild-type 
mice and therefore it seems likely that ovarian hormones, especially 17βEstradiol, 
could not alone be responsible for the remarkable differences in the total β-cell 
volume between male and female mutants. One explanation for the only minor 
decrease in total β-cell volume in non-/placebo-treated ovariectomized mutants 
compared with sham-operated non-/placebo-treated mutants may be extraovarian 
production of ovarian hormones/substances in ovariectomized mutant mice. It is 
known that in women of reproductive age, estradiol formation takes place in a 
number of tissues such as subcutaneous fat and skin or other physiological and 
pathological sites, such as the hypothalamus or breast cancer cells                 
(Hemsell et al. 1974). The extraovarian estradiol production therefore is more 
pronounced in obese women because of increased mass of adipose tissue and skin 
(Bulun et al. 1999). Thus it may be possible that non-/placebo-treated ovariectomized 
mutant mice profit from extraovarian estradiol production, particularly due to 
increased body fat, and this may account for the almost similar volume density of     
β-cells in non-/placebo- and E2-treated ovariectomized mutants. Moreover it is 
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known that testosterone can be converted of the precursor androstenedione in 
extraovarian tissues, accounting for two thirds of testosterone production in 
reproductive-age women (Bardin and Lipsett 1967). It could be shown that 
testosterone treatment was able to reduce streptozotocin induced apoptosis of 
pancreatic β-cells in castrated male Wistar rats (Morimoto et al. 2005). If such 
beneficial effects of testosterone also play a role in female animals remains unclear. 
Another study on partial pancreatectomized ovariectomized female OLETF rats could 
demonstrate that testosterone supplementation has no positive effect on pancreatic 
β-cell mass (Zhu et al. 1998).  
The volume density of non-β-cells in the islets was about 65% increased in non-
/placebo- and E2-treated ovariectomized mutant mice and about 33% increased in 
non-/placebo-treated sham-operated mutant mice as compared to wild-type mice. 
The total volume of non-β-cells of non-/placebo-treated ovariectomized and sham-
operated mutant mice was about 50% and 35% increased as compared to wild-type 
mice, respectively. In contrast, E2-treated ovariectomized mutant mice demonstrated 
a similar total non-β-cell volume as wild-type mice but this is most likely due to the 
lower pancreas volume of E2-treated ovariectomized mutant mice compared to mice 
of the 3 other groups (see above). In male mutant mice, the total volume of           
non-β-cells was also increased, and insulin-treatment could reduce the total volume 
of non-β-cells to an amount comparable with male wild-type mice (Kautz 2010), 
indicating that chronic hyperglycaemia may lead to an increased differentiation and 
development of non-β-cells. Herbach et al. (2007) could show that most of the      
non-β-cells of both male and female Munich Ins2C95S mutant mice represented α-cells 
(Herbach et al. 2007). Investigations in several other diabetic animal models like in 
the PERK knockout mouse (Harding et al. 2001) or in the GIPRdn transgenic mouse 
(Herbach et al. 2005) affirm this observation by showing a disturbed islet 
composition, irrespective of the underlying causative mutation. Moreover, 
morphometric analyses in humans suffering from type 2 diabetes demonstrated an 
increased α-cell fraction in pancreatic islets (Yoon et al. 2003).  
Several studies could demonstrate that long-term hyperglycaemia reduces the 
concentration of PDX-1 mRNA as well as PDX-1 DNA binding activity in pancreatic 
β-cells, which is essential for β-cell development and maintenance (Melloul 2004, 
Robertson and Harmon 2006). Moreover, it was shown that inhibition of               
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Pdx-1 expression results in increased volume density of glucagon positive cells that 
are homogenously distributed all over the islet (Lottmann et al. 2001) in the same 
manner like it was seen in mutant mice in this study. It also could be shown in vitro 
that inhibition of Pdx-1 expression in insulin expressing INSrβ cells leads to 5- to    
10-fold increased levels of glucagon mRNA and largely reduced transcription of the 
insulin gene. The suppression of Pdx1 converts the insulin-producing β-cell lineage 
to an α-cell-dominated phenotype with over 90% glucagon positive cells in the whole 
cell population (Wang et al. 2001). In addition, the β-cell-specific disruption of Pdx-1 
in vivo shifted the β-/α-cell ratio from physiologically 5:1 to 1:1 (Ahlgren et al. 1998). 
All these findings lead to the assumption, that chronic hyperglycaemia may restrain 
β-cell development and may increase the differentiation of glucagon expressing       
α-cells from common progenitor cells. Moreover, it seems to be possible that α-cells 
arise from existing β-cells via trans-differentiation, leading to the altered β- to        
non-β-cell ratio as well as to the higher total volume of non-β-cells existent in islets of 
Munich Ins2C95S mutant mice. Non-/placebo-treated as well as E2-treated 
ovariectomized mutant mice demonstrated a markedly decreased β-/non-β-cell ratio 
of about 4:1 compared to sham-operated mutant mice with a ratio of about 6:1 and 
wild-type mice demonstrating a β-/non-β-cell ratio of about 7:1. Chronic 
hyperglycaemia would explain the altered islet architecture in placebo-treated 
ovariectomized mutant mice, but it is questionable why E2-treated ovariectomized 
mutant mice, which did not demonstrate hyperglycaemia, showed the same decrease 
in the β-/non-β-cell ratio as non-/placebo-treated ovariectomized mutant mice from 
over 40% as compared to wild-type mice. Therefore, chronically elevated blood 
glucose levels do not seem to be the only reason for the altered islet architecture in 
ovariectomized Munich Ins2C95S mutant mice. This assumption is in line with 
observations made in insulin-treated male heterozygous Munich Ins2C95S mutant 
mice and GIPRdn transgenic mice, where altered islet composition was also apparent 
in the absence of hyperglycaemia (Herbach et al. 2005; Kautz 2010). In Munich 
Ins2C95S mutant mice, long-term ER-stress, caused by unfolded proinsulin 2, may 
lead to reduced total β-cell volume in Munich Ins2C95S mutant mice, via programmed 
cell death (Herbach et al. 2007), thereby explaining a shift towards non-β-cells. 
Taken together, the findings suggest that 17βEstradiol has no positive effects on islet 
composition of ovariectomized Munich Ins2C95S mutants. The ovaries produce 
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several steroid hormones, including pregnenolone, progesterone,                         
17α-hydroxyprogesterone, dehydroepiandrosterone (DHEA), androstenedione, 
testosterone, estrone, and estradiol. Moreover a large number of peptides that can 
act in an intracrine, autocrine, paracrine, or endocrine fashion are produced. These 
include numerous growth factors (e.g., insulin-like growth factors (IGFs)) and 
cytokines (e.g., interleukin-1b) (Bulun and Adashi 2008).  
A direct effect of progesterone on the islets of Langerhans may be possible in intact 
female rats, as both the pancreatic α- and β-cells of these animals possess 
progesterone receptors (El Seifi et al. 1981). It could be shown that progesterone can 
increase proliferation of both α- and β-cells within the pancreatic islets of intact male 
and female Wistar rats, but not the number of single insulin- or glucagon-containing 
cells outside the pancreatic islet, suggesting that progesterone does not stimulate 
differentiation of duct cells into endocrine cells. These effects were not apparent in 
progesterone treated gonadectomized male and female rats, suggesting that the 
gonads play an essential role in the genesis of the proliferative effect of progesterone 
(Nieuwenhuizen et al. 1999). An explanation for this may be the observation that 
ovariectomy leads to the loss of progesterone binding sites within pancreatic islets 
(El Seifi et al. 1981). Therefore it is suggested that the treatment with progesterone 
has an indirect effect and is mediated by (some) gonadal factor(s) (Nieuwenhuizen et 
al. 1999). Such factors may be insulin-like growth factors-1 and -2 (IGF1 and IGF2) 
because they are known to be capable of stimulating pancreatic islet-cell proliferation 
(Hill and Hogg 1991, Nieuwenhuizen et al. 1999). 
On the other hand, Picard et al. (2002) reported that 12-week-old progesterone 
receptor knock-out mice (PR-/-) demonstrated an almost two-fold increased β-cell 
number due to a higher rate of β-cell proliferation (Picard et al. 2002). These findings 
about the effects of progesterone per se are contradictory to the effects mediated 
most likely through gonadal factors. Therefore it is not clear if progesterone is the 
causative hormone responsible for the unaltered islet architecture and β-cell mass 
observed in female mutant mice. 
 
Today there is evidence that the endocrine pancreas represents a dynamic, in adult 
life slowly renewing tissue and β-cell mass is determined by the balance between 
proliferation/neogenesis and apoptosis under physiological conditions as well as in 
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response to varying secretory demand (Ackermann and Gannon 2007,           
Bonner-Weir 2001). Beta-cell mass is increased by differentiation of new β-cells from 
progenitor cells within pancreatic ducts (neogenesis), replication of β-cells within 
existing islets (proliferation) or by increase of the size of existing β-cells 
(hypertrophy), whereas decrease in β-cell mass arises primarily through apoptosis 
and β-cell atrophy (Ackermann and Gannon 2007, Butler et al. 2003).  
Isolated β-cells in the pancreas are considered as a parameter for new islet formation 
and are defined as single, scattered insulin positive cells, endocrine cells budding 
from epithelium of pancreatic ducts and extra-islet insulin positive cell-clusters up to   
4 cells (EICs) (Bonner-Weir 2001, Kauri et al. 2007). The volume density and total 
volume of isolated β-cells was significantly decreased in all 3 mutant mice groups as 
compared to wild-type mice. These data suggest that the slightly reduced β-cell mass 
in female mutants is particularly due to impaired islet neogenesis. In contrast, it could 
be shown that insulin treatment in male Munich Ins2C95S mutant mice led to a 
significantly higher total volume of isolated β-cells as compared to non-/placebo-
treated mutant mice (Kautz 2010). Chronic severe hyperglycaemia can lead to 
reduced Pdx1 expression, resulting in reduced differentiation of progenitor cells to   
β-cells and therefore decreased total volume of isolated β-cells. It was expected that 
sham-operated non-/placebo-treated mutant mice and E2-treated ovariectomized 
mutant mice, which both showed only mild or even no hyperglycaemia, would 
demonstrate a higher total volume and volume density of isolated β-cells as 
compared to severe hyperglycaemic non-/placebo-treated ovariectomized mutant 
mice, but surprisingly all three mutant groups showed similar values. Therefore,    
ER-stress, rather than hyperglycaemia may be responsible for altered islet 
neogenesis of female Munich Ins2C95S mutant mice. 
 
The cell proliferation marker PCNA was used in Western blot analyses to detect      
β-cell replication. Non-/placebo-treated ovariectomized mutant mice showed a more 
than 50% decreased pancreatic islet abundance of PCNA as compared to wild-type 
mice whereas non-/placebo-treated sham-operated mutant mice demonstrated only a 
12% decrease. Although E2-treatment of ovariectomized mutant mice led to a       
35% higher PCNA-abundance as compared to non-/placebo-treatment, PCNA-levels 
were about 25% lower as compared to sham-operated mutants.  
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Various factors are already known to be involved in regulating β-cell mass 
(Ackermann and Gannon 2007), but since glucose and insulin are known to be 
potent stimulators of β-cell mass expansion in vitro (Guillen et al. 2008,          
Schuppin et al. 1993) as well as in vivo (Paris et al. 2003) it seems that glucose 
metabolism and insulin-signalling pathways play a central role in expansion of the 
endocrine pancreas. It could be shown that glucose infusion in mice over 4 days, 
leading to mild sustained increase in circulating blood glucose and insulin levels, 
resulted in a marked increase in β-cell replication as compared to mice infused with 
saline. The replication rate of existing β-cells increased in a dose dependent 
relationship with glucose concentration, while β-cell size and islet number remained 
unchanged and markers of neogenesis remained unaltered. It is suggested that 
cyclin D2 may be involved in postnatal glucose-induced compensatory β-cell 
expansion (Alonso et al. 2007). The mild hyperglycaemia apparent in sham-operated 
non-/placebo-treated mutant mice could therefore be a stimulus for β-cell replication 
and may explain the higher PCNA-abundance compared to the two other mutant 
mouse groups.  
In addition, long-term severe hyperglycaemia can lead to β-cell apoptosis, resulting in 
a decreased total β-cell mass most likely due to the effect of glucotoxicity         
(Donath et al. 1999). The detection of apoptosis in pancreatic islets revealed that 
only placebo-treated ovariectomized mutant mice showed apoptotic events as 
evidenced by Western blot analysis of the inactive and active form of Caspase-3. 
This could be explained by the influence of severe chronic hyperglycaemia apparent 
in these mice. However, apoptotic events could only be demonstrated in islets from 
one mouse and it is known that detection and quantification of apoptosis in β-cells is 
associated with several difficulties. Although the process of β-cell destruction is 
extended over weeks or months, only very few apoptotic β-cells are likely to be 
observable even in mouse models of severe β-cell destruction (Augstein et al. 1998, 
O'Brien et al. 1996). One reason could be the short duration of apoptotic events with 
only few minutes elapsing from initiation to complete disintegration of the cell     
(Butler et al. 2003) as well as the rapid clearance by macrophages, which makes it 
difficult to quantify programmed cell death (Izumi et al. 2003, Weir et al. 2001). 
Moreover, only one time point to detect apoptosis in β-cells may not be 
representative for the real rate of programmed cell death in the analysed tissue 
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(Donath and Halban 2004, Huerta et al. 2007). However, since β-cell mass was not 
significantly reduced in female Munich Ins2C95S mutant mice, islet-cell apoptosis may 
not be of great relevance in these mice. 
Taken together, the results reveal that 17βEstradiol alone has no protective effects 
on β-cell survival of ovariectomized female Munich Ins2C95S mutant mice. Rather it 
seems that other hormones or substances produced in the ovaries of sham-operated 
mutant mice may lead to the marginally increased total β-cell volume vs.               
non-/placebo- and E2-treated ovariectomized mutants. Nevertheless, ovarian 
substances alone could not explain the great differences concerning β-cell mass 
between male and female mutant mice.  
5.6 Electron microscopic findings in β-cells 
Electron microscopic investigations in 190-day-old mice of all 4 groups revealed that 
the different staining intensities of β-cells observed in pancreas sections 
immunostained for insulin, can be attributed to a different insulin granule density 
within the β-cells. Moreover, the altered islet structure, concerning number and 
distribution of non-β-cells was also in line with the immunohistochemical results.   
Wild-type mice showed β-cells that are densely packed with typical insulin secretory 
granules, whereas non-/placebo-treated ovariectomized mutant mice featured many 
β-cells containing very small amounts of secretory granules. Although non-/placebo-
treated sham-operated and E2-treated ovariectomized mutant mice also 
demonstrated several β-cells that were almost degranulated, they nevertheless 
seemed to exhibit more β-cells with a granule density comparable to wild-type mice. 
In contrast, insulin secretory granules were almost missing in male heterozygous 
Munich Ins2C95S mutant mice and the remaining granules appeared smaller than 
those of male wild-type mice (Herbach et al. 2007; Kautz 2010). 
The insulin granule density is influenced by several factors such as the rate of insulin 
gene transcription, insulin mRNA translation, (pro-)insulin processing as well as 
intracellular (pro-)insulin degradation. Moreover, discrepancy between insulin 
production and insulin secretion might lead to different granule density in pancreatic 
β-cells. The serum insulin levels measured 10 minutes after glucose stimulus showed 
that E2-treated ovariectomized mutant mice were able to release marginally more 
insulin into the blood stream than mice of the two other mutant groups, whereas   
non-/placebo-treated ovariectomized mutants demonstrated the lowest insulin 
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secretion. This leads to the assumption that either E2-treated mutants possess more 
insulin granules that can be secreted after glucose stimulus or the secretion of 
existing granules is more effective. The latter seems to be likely since it is known that 
estrogen can potentiate insulin secretion after glucose stimulus (see above). Due to 
the fact that non-/placebo-treated ovariectomized mutant mice demonstrated a low 
granule density in almost every β-cell and E2-treated ovariectomized mutants 
exhibited several β-cells with a high amount of secretory granules, it seems likely that 
E2-treated ovariectomized mutant mice also benefit from the higher amount of 
granules that can be secreted. Moreover, it seems likely that physiological E2 levels 
do not have the same effect on potentiating insulin secretion like high-dose            
E2-treatment, since sham-operated non-/placebo-treated mutant mice exhibited 
similar amounts of secretory granules in the β-cells as compared to E2-treated 
ovariectomized mutant mice but showed lower serum insulin levels after glucose 
stimulus.  
One reason for the reduced amount of insulin granules in non-/placebo-treated 
ovariectomized mutant mice in comparison to the two other mutant mice groups 
might be the influence of chronically high blood glucose concentrations and, 
therefore, oxidative stress that may result in reduced Ins expression due to 
decreased insulin promoter binding activity of PDX-1 and other transcription factors, 
such as MafA (Andrali et al. 2008, Melloul 2004, Melloul et al. 2002). It also could be 
shown that insulin mRNA was reduced after long-term glucose incubation of HIT-T15 
cells and this effect could be partially prevented by co-incubation with antioxidants 
(Tanaka et al. 1999). Since E2-treated ovariectomized mutant mice showed 
normoglycaemia and sham-operated non-/placebo-treated mutant mice showed only 
mild hyperglycaemia, another reason for the severe depletion of insulin granules 
within the β-cells of these two mouse groups must exist. ER-stress is known to 
reduce mRNA translation via phosphorylation of eIF2α (Sundar Rajan et al. 2007). 
The results of Western blot analyses showed no significant difference of PeIF2α 
abundance between the 4 groups, indicating that insulin mRNA translation is not 
reduced in mutant mice. In concordance with this, measurement of total insulin 
mRNA in isolated islets of 8- to 12-week-old Akita mice showed that mutant 
proinsulin 2 was transcribed to similar degree as wild-type insulin, although PeIF2α 
was not analysed (Wang et al. 1999). As a response to ER-stress, the so called ER-
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associated protein degradation (ERAD) eliminates misfolded protein to preserve the 
functionality of the endoplasmic reticulum (Scheuner and Kaufman 2008). It could be 
shown that HRD1, a component of the ERAD system, is upregulated in pancreatic 
islets of the Akita mouse and enhances intracellular degradation of misfolded and 
accumulated proinsulin (Allen et al. 2004). Therefore, it seems likely that the 
misfolded (pro)insulin 2, of Munich Ins2C95S mutants might also be degraded and 
leads, at least in part, to the reduced density of secretory granules.  
Another indicator for existing ER-stress in β-cells is the presence of dilated 
endoplasmic reticulum. This is most clearly apparent in non-/placebo-treated 
ovariectomized mutant mice, where almost every β-cell featured dilated                 
ER-structures. Although the dilatation of the ER was not as pronounced in E2-treated 
ovariectomized and sham-operated non-/placebo-treated mutant mice as compared 
to non-/placebo-treated ovariectomized mutants, it was nevertheless also existent in 
several β-cells. Male heterozygous Munich Ins2C95S mutant mice showed an even 
more pronounced disorganization of the rough endoplasmic reticulum, appearing as 
dilated cisterna, as compared to non-/placebo-treated ovariectomized female mutant 
mice (Herbach et al. 2007; Kautz 2010). Further, remarkable dilated ER was also 
seen in Akita mice (Wang et al. 1999). In general, conditions that disrupt metabolic 
homeostasis and protein-folding can cause distension of the ER cisternae, with the 
consequence that the ER is not longer able to fulfil protein-folding and -processing. 
Therefore, ER distension has become a hallmark for cells that exhibit defective 
protein-folding in the ER lumen and is observed in response to pharmacological 
induction of ER-stress, genetically impaired N-linked glycosylation, enhanced mRNA 
translation, or expression of proteins that are subject to misfolding                
(Scheuner and Kaufman 2008). The dilated structures that were apparent in all 
Munich Ins2C95S mutant mice mostly represent dilated rough ER that is found 
throughout the cytoplasm and, to a lower degree, pre-Golgi intermediates that are 
located in close association to the Golgi complex. Electron dense material, like it was 
observable in the ER lumen of male mutant mice (Kautz 2010), could also be 
identified to a lower degree in female mutants. It was shown in the Akita mouse that 
this electron dense material is composed of accumulated proinsulin                    
(Zuber et al. 2004). Therefore, the observed electron dense material observed in 
Munich Ins2C95S mutant mice most likely is a result of accumulated proinsulin 2. 
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Taken together, the lower amount of insulin granules visible in all three mutant 
mouse groups, most probably results from a combination of reduced Ins2 gene 
expression due to chronically elevated blood glucose levels and due to ER-stress 
caused by misfolded and accumulated proinsulin 2. Since in E2-treated 
ovariectomized and non-/placebo-treated sham-operated mutant mice 
hyperglycaemia is not as severe as in non-/placebo-treated ovariectomized mutant 
mice, ER-stress may probably be the main cause for the reduced granule density. 
17βEstradiol seems to exert positive effects on the total amount of insulin granules 
through several mechanisms such as decrease of blood glucose concentrations and 
the assumed protective effect in the presence of ER-stress. Due to the fact that 
sham-operated mutant mice presented a marginally higher secretory granule density 
in β-cells than E2-treated ovariectomized mutant mice, it may be possible that other 
ovarian hormones or non-steroidal substances produced and secreted from the 
ovaries may also exert positive effects on the total amount of secretory granules.  
The electron-microscopical observations also demonstrated that mice of all three 
mutant groups demonstrated several β-cells that contained enlarged mitochondria.  
In male heterozygous Munich Ins2C95S mutant mice, mitochondrial swelling was also 
observed, though to a much higher degree and additionallly mitochondria showed 
largely destroyed crests and myelin figures (Herbach et al. 2007; Kautz 2010). It is 
documented that oxidative stress and also ER-stress can increase the permeability of 
the inner mitochondrial membrane and alter its potential (Kanwar et al. 2007), leading 
to mitochondrial swelling and release of cytochrome c and as a result to the 
activation of apoptotic mitochondrial pathways (Jiang et al. 2001, Zhang et al. 2008). 
Since all mutant mice most likely suffer from ER-stress and placebo-treated 
ovariectomized mutant mice also from severe chronic hyperglycaemia, it is probably 
that the alterations in mitochondrial appearance result from activated apoptotic 
mitochondrial pathways. 
5.7 Conclusion 
The findings in this study demonstrate that ovariectomy leads to severe deterioration 
of glucose homeostasis in Munich Ins2C95S mutant mice, which can be completely 
normalised by E2 replacement therapy. Therefore, the hypothesis of beneficial 
effects of E2 on insulin secretion and insulin sensitivity was proven in Munich 
Ins2C95S mutant mice, thereby explaining the different diabetic phenotypes of male 
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and female mutant mice. In contrast, ovariectomy did not significantly alter total islet 
or β-cell volumes but severely disturbed islet composition, which could not be 
prevented by E2 replacement therapy. This shows that chronic hyperglycaemia does 
not induce severe β-cell loss in ovariectomized female mutants like it was observed 
in male mutants, leading to the assumption that other hormones or factors produced 
in the ovaries and/or the whole female body, but not 17βEstradiol, are responsible for 
preserved β-cell mass. As evidenced by electron microscopy, ovariectomy seems to 
lead to increased ER-stress in pancreatic β-cells of mutant mice vs. sham-operated 
mutant mice, which can be ameliorated by E2 supplementation. 
In the last years, several INS mutations that lead to conformational changes of the 
insulin molecule were described in humans as a new monogenic cause of permanent 
neonatal diabetes. The Munich Ins2C95S mutant mouse therefore represents an 
essential tool to further investigate the influence of INS mutations on the 
development of diabetes mellitus as well as to develop new treatment strategies. 
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6 Perspective 
Since 17βEstradiol was shown to fail to protect ovariectomized Munich Ins2C95S 
mutants from ER-stress and β-cell loss, the influence of other hormones such as 
progesterone or testosterone or of other substances produced in the ovaries,        
e.g. growth factors such as IGF1 and IGF2, on β-cell survival should be examined in 
female Munich Ins2C95S mutant mice.  
In order to get further insights into the role of ER-stress in the pathogenesis of 
diabetes mellitus and the protective effects of ovarian hormones/substances in 
female Munich Ins2C95S mutant mice, treatment of ovariectomized mutant mice with 
chemical chaperones, like 4-phenyl butyric acid or tauroursodeoxycholic acid, which 
increase ER folding capacity, would be useful. 
To examine the role of estrogen and the estrogen receptors in ER-stress and β-cell 
loss it would be helpful to cross Munich Ins2C95S mutant mice with estrogen-receptor 
knock out mice (αERKO, βERKO or αβERKO mice). Moreover it would be interesting 
to use selective estrogen receptor modulators (SERMs) such as propyl-pyrazole-triol 
(PPT) for ERα and diarylpropionitrile (DPN) for ERβ to examine the estrogenic effects 
on the appropriate receptors. 
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7 Summary 
Impact of 17βEstradiol on β-cell survival of female Munich Ins2C95S mutant mice 
Munich Ins2C95S mutant mice were generated within the Munich ENU mouse 
mutagenesis project and exhibit a point mutation in the insulin 2 gene. In recent 
years, several mutations in the INS gene were also observed in humans, leading to 
early onset of diabetes with severe hyperglycaemia.  
It could be shown that male Munich Ins2C95S mutant mice develop a severe 
progressive diabetic phenotype with profound loss of functional β-cell mass, whereas 
female mutants only showed mild glucose intolerance throughout life and no β-cell 
loss. The aim of this study was to investigate the impact of 17βEstradiol (E2) on the 
development of diabetes mellitus and β-cell survival in female Munich Ins2C95S 
mutant mice. For this purpose, female mutant mice were ovariectomized and 
received either 17βEstradiol replacement therapy via subcutaneous E2 long-term 
pellets or non-treatment/placebo pellet. Non-/placebo-treated sham-operated mutant 
and wild-type mice served as controls. Clinical parameters, such as fasted and 
randomly fed blood glucose concentration, oral glucose tolerance, insulin sensitivity, 
glucose induced insulin secretion as well as fasted serum insulin concentration were 
determined. Moreover, serum was analysed with regard to oxidative-stress and 
isolated pancreatic islets were used to determine ER-stress markers. Qualitative 
histological and quantitative stereological analyses of the pancreas were performed, 
and β-cell apoptosis as well as β-cell replication were determined.  
Ovariectomy without E2 supplementation led to the development of a severe and 
progressive diabetic phenotype. The supplementation of 17βEstradiol after 
ovariectomy normalised blood glucose concentrations of female mutant mice to the 
level of wild-type mice.  
Both, E2-treated ovariectomized and non-/placebo-treated sham-operated mutant 
mice, demonstrated an improved oral glucose tolerance, preserved insulin sensitivity 
and higher glucose induced insulin secretion as compared to non-/placebo-treated 
ovariectomized mutant mice. However, mice of all three mutant groups showed a 
severely disturbed glucose-stimulated insulin secretion as compared to wild-type 
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controls, indicating that the mutation in Ins2 and the resulting misfolding of proinsulin 
2 leads to disturbed insulin secretion.  
In addition, it could be shown that the normalised or only mildly increased blood 
glucose concentrations of E2-treated ovariectomized and non-/placebo-treated 
sham-operated mutant mice led to reduced oxidative stress, as evidenced by 
significantly reduced malondialdehyde serum levels.  
Non-/placebo- and E2-treated ovariectomized mutant mice exhibited a lower total 
volume and volume density of β-cells in the islets as well as a lower β-cell/non-β-cell 
ratio as compared to sham-operated non-/placebo-treated mutants, indicating that 
ovarian hormones/substances, other than 17βEstradiol, are responsible for the 
preserved β-cell mass of female Munich Ins2C95S mutants. Since the abundance of 
the ER-stress marker BIP was only increased in non-/placebo- and E2-treated 
mutant mice but not in sham-operated non-/placebo-treated mutant mice, ER-stress 
is likely to be responsible for reduced β-cell mass, and a substance produced in the 
ovaries other than E2 seems to protect sham-operated mutant mice from ER-stress.  
Since the volume density of isolated β-cells in the pancreas, which indicate islet 
neogenesis, was decreased in an almost identical manner in all three mutant groups 
as compared to wild-type mice, decreased islet neogenesis may explain the reduced 
β-cell mass apparent in all mutant mice.  
Ultrastructural changes in the β-cells were most prominent in placebo-treated 
ovariectomized mutant mice. Nevertheless, all mutant mice demonstrated 
accumulation of electron dense material in the dilated endoplasmic reticulum, 
suggesting that ER-stress is existent not only in ovariectomized, but also to a lower 
degree in sham-operated mutant mice. 
In conclusion, 17βEstradiol could ameliorate the diabetic phenotype by improving 
insulin secretion and insulin sensitivity but did not prevent ER-stress or loss of 
functional β-cell mass in ovariectomized Munich Ins2C95S mutant mice, suggesting 
that ovarian hormones/substances other than E2, or other substances produced in 
the whole female body, prevent female Munich Ins2C95S mutant mice from ER-stress 
and β-cell loss. 
 
8  Zusammenfassung 136 
 
8 Zusammenfassung 
Einfluss von 17βEstradiol auf das Betazellüberleben von weiblichen Munich 
Ins2C95S Mausmutanten 
Munich Ins2C95S Mausmutanten wurden innerhalb des Münchner ENU-Maus-
Mutagenese Projektes generiert und weisen eine Punktmutation im Insulin 2 Gen 
auf. In den letzten Jahren wurden verschiedene Insulingenmutationen beim 
Menschen beobachtet, welche zu einem früh einsetzenden Diabetes mellitus führen. 
Männliche heterozygote Munich Ins2C95S Mausmutanten zeigten einen hochgradigen 
Verlust funktioneller Betazellmasse und entwickelten einen schwerwiegenden, 
progressiven diabetischen Phänotyp, wohingegen weibliche Mutanten nur eine milde 
Glukose-Intoleranz aufwiesen und kein deutlicher Betazellverlust nachzuweisen war.  
In dieser Studie sollte der Einfluss von 17βEstradiol (E2) auf die Entwicklung von 
Diabetes mellitus sowie den Betazellverlust bei weiblichen Munich Ins2C95S 
Mausmutanten untersucht werden. Um die Effekte von 17βEstradiol zu analysieren 
wurden weibliche heterozygote Mutanten ovariektomiert und erhielten anschließend 
entweder eine 17βEstradiol Ersatztherapie mittels subkutaner Implantation von 
17βEstradiol Langzeit-Pellets, ein entsprechendes Placebo oder keine Therapie. 
Nicht-/Placebo-behandelte schein-ovariektomierte heterozygote Mutanten sowie 
Wildtyptiere dienten als Kontrollen. Es wurden klinische Parameter wie 
Blutglukosekonzentration, Insulinsensitivität, Glukose-stimulierte Insulinsekretion, 
sowie Nüchtern-Seruminsulinspiegel bestimmt und orale Glukosetoleranztests 
durchgeführt. Des Weiteren wurde Serum zur Ermittlung von oxidativem Stress 
untersucht sowie an isolierten pankreatischen Inseln verschiedene Marker für 
endoplasmatischen Retikulum-Stress (ER-Stress) detekiert. Die Komposition des 
endokrinen Pankreas wurde qualitativ histologisch und mittels quantitativ 
stereologischer Methoden untersucht und darüber hinaus wurden Betazell-Apoptose- 
und -Zellproliferationsraten ermittelt. 
Ovariektomie ohne E2-Supplementierung führte zur Ausbildung eines 
schwerwiegenden diabetischen Phänotyps, wohingegen eine 17βEstradiol 
Ersatztherapie die Blutglukosekonzentrationen auf das Niveau von Wildtyptieren 
senken konnte. Sowohl Schein-Ovariektomie als auch E2-Supplementierung nach 
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Ovariektomie führten zu einer verbesserten Glukosetoleranz, einer erhaltenen 
Insulinsensitivität und einer erhöhten Glukose-stimulierten Insulinsekretion im 
Vergleich zu Nicht-/Placebo-behandelten ovariektomierten Mutanten. Dennoch 
zeigten alle heterozygoten Mutanten im Vergleich zu den Wildtyptieren eine 
hochgradig gestörte Insulinsekretion nach Glukosestimulation. 
Anhand der signifikant niedrigeren Malondialdehyd-Serumwerte konnte gezeigt 
werden, dass die Normalisierung der Blutglukosekonzentrationen E2-
supplementierter ovariektomierter Mutanten sowie die nur leicht erhöhten Werte der 
schein-ovariektomierten Mutanten darüber hinaus zu einer Reduktion des oxidativen 
Stress im Vergleich zu Nicht-/Placebo-behandelten ovariektomierten Mutanten 
führten. 
Nicht-/Placebo-behandelte und E2-supplementierte Mutanten wiesen beide ein 
niedrigeres Gesamtbetazellvolumen, eine reduzierte Volumendichte von Betazellen 
in den Inseln sowie ein erniedrigtes Betazell- zu Nicht-Betazell-Verhältnis im 
Vergleich zu schein-ovariektomierten Mutanten auf, was darauf hindeutet, dass 
Ovarhormone oder andere Substanzen die in den Ovarien produziert werden, nicht 
aber 17βEstradiol, zum Schutz der Betazellen bei weiblichen Munich Ins2C95S 
Mausmutanten beitragen. Da die Abundanz des ER-Stress-Markers BiP nur bei 
Nicht-/Placebo-behandelten und E2-supplementierten ovariektomierten, nicht aber 
bei schein-ovariektomierten Mutanten erhöht war, scheint es wahrscheinlich, dass 
ER-Stress für das reduzierte Betazellvolumen verantwortlich ist und demzufolge 
andere in den Ovarien produzierte Substanzen als 17βEstradiol schein-
ovariektomierte Mutanten vor ER-Stress schützen. 
Da außerdem die Volumendichte und das Gesamtvolumen isolierter Betazellen, 
beides Indikatoren für Inselneogenese, bei allen drei Mutantengruppen in annähernd 
gleicher Weise im Vergleich zu Wildtyptieren reduziert war, könnte dies als Erklärung 
für die reduzierte Betazellmasse von hererozygoten Munich Ins2C95S Mausmutanten 
dienen. 
Ultrastrukturelle Veränderungen der Betazellen waren bei Nicht-/Placebo-
behandelten ovariektomierten Mutanten am deutlichsten ausgeprägt. Trotzdem 
zeigten Tiere aller drei Mutantengruppen eine Anreicherung elektronendichten 
Materials im dilatierten endoplasmatischen Retikulum was zu der Annahme führt, 
dass nicht nur Nicht-/Placebo-behandelte ovariektomierte Mutanten ER-Stress 
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aufweisen, sondern auch E2-supplementierte ovariektomierte und schein-
ovariektomierte Tiere zu einem geringeren Grad davon betroffen sind. 
Zusammenfassend kann gesagt werden, dass 17βEstradiol durch eine Steigerung 
der Insulinsekretion und Insulinsensitivität zwar den diabetischen Phänotyp 
verbessern kann, dennoch aber nicht in der Lage ist, vor ER-Stress zu schützen und 
den durch Ovariektomie gesteigerten Betazellverlust zu verhindern. Deshalb wird 
vermutet, dass Substanzen, die in den Ovarien oder eventuell auch im gesamten 
weiblichen Körper produziert werden, nicht aber 17βEstradiol, weibliche Munich 
Ins2C95S Mutanten vor ER-Stress und Betazellverlust schützen. 
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